SYNERGISTIC PESTICIDAL COMPOSITIONS FOR DELIVERY OF PESTICIDAL ACTIVE INGREDIENTS AND METHODS THEREFOR

Abstract

Compositions and methods for increasing the efficacy of pesticidal compositions are described herein, including synergistic pesticidal compositions comprising: benzovindiflupyr, bixafen, boscalid, cyproconazole, fenpicoxamid, fenpyrazimine, florylpicoxamid, flutriafol, fluxapyroxad, isopyrazam, isotianil, kresoxim-methyl, metrafenone, oxathiapiprolin, penflufen, penthiopyrad, picoxystrobin, prothioconazole, pydiflumetofen, revysol, sedaxane, trifloxystrobin, pyraclostrobin, azoxystrobin, chlorothalonil, cyprodinil, metalaxyl, epoxiconazole, propiconazole, difenoconazole, fludioxonil, mancozeb, tebuconazole, valifenalate, in combination with a C4-C10 saturated or unsaturated aliphatic acid and methods for delivery of pesticidal active ingredients. Some pesticidal compositions and methods as described are directed to compositions and methods for increasing the efficacy of fungicides. Some pesticidal compositions and methods as described are directed to compositions and methods for increasing the efficacy of nematicides. Some pesticidal compositions and methods as described are directed to compositions and methods for increasing the efficacy of insecticides. Methods for enhancing the activity pesticidal active ingredients in pesticidal compositions in use are also described.

Description

REFERENCE TO RELATED APPLICATIONS

This application claims priority to, and the benefit of, US provisional patent application Nos. 62/737,907 filed 27 Sep. 2018; 62/737,914 filed 27 Sep. 2018; 62/829,512 filed 4 Apr. 2019; and 62/829,525 filed 4 Apr. 2019, all entitled SYNERGISTIC PESTICIDAL COMPOSITIONS AND METHODS FOR DELIVERY OF ACTIVE INGREDIENTS, all of which are incorporated by reference herein in their entireties.

TECHNICAL FIELD

An embodiment of the present invention is related to compositions and methods for increasing the efficacy of pesticidal compositions. More particularly, some embodiments are related to synergistic pesticidal compositions and methods for delivery of pesticidal active ingredients. Some embodiments of the present invention are directed to compositions and methods for increasing the efficacy of fungicides.

Some embodiments of the present invention are directed to compositions and methods for increasing the efficacy of nematicides. Some embodiments of the present invention are directed to compositions and methods for increasing the efficacy of insecticides. Further embodiments of the present invention are directed to methods for enhancing the activity pesticidal active ingredients in pesticidal compositions.

BACKGROUND

Pesticides, including fungicides, herbicides, nematicides and insecticides, are important compositions for use in domestic, agricultural, industrial and commercial settings, such as to provide for control of unwanted pests and/or pathogens. Providing for effective pest control is of high importance in many such settings, since pests and/or other pathogens if not controlled can cause loss and or destruction of crops or other plants, or harm to animals, humans or other beneficial or desired organisms. There remains a need for environmentally safe and effective pesticides, including fungicides, nematicides and insecticides, or compounds that enhance the efficacy of pesticides, including fungicides, nematicides and insecticides, and for methods of enhancing the efficacy of pesticides including fungicides, nematicides and insecticides, so that pesticides can be used in a more environmentally safe and effective manner. In agricultural settings, for example, a variety of plant pests, such as insects, worms, nematodes, fungi, and plant pathogens such as viruses and bacteria, are known to cause significant damage to seeds and ornamental and crop plants. Chemical pesticides have generally been used, but many of these are expensive and potentially toxic to humans, animals, and/or the environment and may persist long after they are applied. Therefore it is typically beneficial to farmers, consumers and the surrounding environment to use the least amount of chemical pesticides as possible, while continuing to control pest growth in order to maximize crop yield. In a growing number of cases, chemical pesticide use has also resulted in growing resistance to certain chemical pesticides by pest organisms, leading to reduced effectiveness, requiring greater doses of pesticidal chemicals, or even failure of certain types of pesticides as viable control agents. As a result, many chemical pesticides are being phased out or otherwise restricted from use.

Natural or biologically-derived pesticidal compounds have been proposed for use in place of some chemical pesticides, in order to attempt to reduce the toxicity, health and environmental risks associated with chemical pesticide use. However, some natural or biologically-derived pesticides have proven less efficacious or consistent in their performance in comparison with competing chemical pesticides, which has limited their adoption as control agents in pesticide markets.

Therefore, there remains a need to provide improved pesticides and pesticidal compositions to allow for effective, economical and environmentally and ecologically safe control of insect, plant, fungal, nematode, mollusk, mite, viral and bacterial pests. In particular, there remains a need to provide for pesticidal compositions that desirably minimize the amount of pesticidal agents or pesticidal active ingredients required to obtain desired or acceptable levels of control of pests in use.

Accordingly, there remains a need to provide synergistic pesticidal compositions that desirably minimize the use of pesticidal agents or pesticidal active ingredients through synergistic efficacy, to provide for desired pest control performance in use. However, large-scale experimental drug combination studies in non-agricultural fields have found that synergistic combinations of drug pairs are extremely complex and rare, with only a 4-10% probability of finding synergistic drug pairs [Yin et al., PLOS 9:e93960 (2014); Cokol et al., Mol. Systems Biol. 7:544 (2011)]. In fact, a systematic screening of about 120,000 two-component drug combinations based on reference-listed drugs found fewer than 10% synergistic pairs, as well as only 5% synergistic two-component pairs for fluconazole, a triazole fungicidal compound related to certain azole agricultural fungicide compounds [Borisy et al., Proc. Natl Acad. Sci. 100:7977-7982 (2003)].

The foregoing examples of the related art and limitations related thereto are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent to those of skill in the art upon consideration of the present disclosure.

BRIEF SUMMARY

In one embodiment according to the present disclosure, a synergistic pesticidal composition is provided, comprising a pesticidal active ingredient; and a C4-C10 unsaturated aliphatic acid (including an unsaturated C6, C7, C8, C9 or C10 aliphatic acid) or an agriculturally compatible salt thereof, wherein the C4-C10 unsaturated aliphatic acid comprises at least one unsaturated C—C bond and wherein a ratio of the concentrations by weight of said pesticidal active ingredient and said C4-C10 unsaturated aliphatic acid or an agriculturally compatible salt thereof is between about 1:15,000 and 15,000:1, and more particularly between about 1:5000 and 5000:1, and further more particularly between about 1:2000 and 2000:1. In another embodiment, a synergistic pesticidal composition is provided, comprising a pesticidal active ingredient; and a C4-C10 saturated aliphatic acid (including a saturated C4, C5, C6, C7, C8, C9 or C10 aliphatic acid) or an agriculturally compatible salt thereof, wherein a ratio of the concentrations by weight of said pesticidal active ingredient and said C4-C10 saturated aliphatic acid or an agriculturally compatible salt thereof is between about 1:15,000 and 15,000:1, and more particularly between about 1:5000 and 5000:1, and further particularly between about 1:2000 and 2000:1. In yet another embodiment, a synergistic pesticidal composition is provided, comprising a pesticidal active ingredient; and a C11 unsaturated or saturated aliphatic acid or an agriculturally compatible salt thereof, wherein a ratio of the concentrations by weight of said pesticidal active ingredient and said C11 unsaturated or saturated aliphatic acid or an agriculturally compatible salt thereof is between about 1:15,000 and 15,000:1, and more particularly between about 1:2000 and 2000:1. In yet a further embodiment, a synergistic pesticidal composition is provided, comprising a pesticidal active ingredient; and a C12 unsaturated or saturated aliphatic acid or an agriculturally compatible salt thereof, wherein a ratio of the concentrations by weight of said pesticidal active ingredient and said C12 unsaturated or saturated aliphatic acid or an agriculturally compatible salt thereof is between about 1:15,000 and 15,000:1, more particularly between about 1:5000 and 5000:1, and further particularly between about 1:2000 and 2000:1. In a further embodiment, a method of synergistically enhancing the pesticidal activity of at least one pesticidal active ingredient adapted to control at least one target pest organism is provided, comprising: providing at least one pesticidal active ingredient active for said at least one target pest organism; adding a synergistically effective concentration of at least one C4-C10 unsaturated aliphatic acid comprising at least one unsaturated C—C bond, or an agriculturally acceptable salt thereof, to said pesticidal active ingredient to provide a synergistic pesticidal composition; and applying said synergistic pesticidal composition in a pesticidally effective concentration to control said at least one target pest organism. In another embodiment, instead of a C4-C10 unsaturated aliphatic acid, a C4-C10 saturated aliphatic acid or agriculturally compatible salts thereof may be provided to provide the synergistic pesticidal composition. In yet another embodiment, a C11 unsaturated or saturated aliphatic acid or agriculturally compatible salts thereof may be provided to provide the synergistic pesticidal composition. In yet a further embodiment, a C12 unsaturated or saturated aliphatic acid or agriculturally compatible salts thereof may be provided to provide the synergistic pesticidal composition. In some embodiments, the synergistic pesticidal composition may comprise a C4-C10 unsaturated or saturated aliphatic acid or a biologically compatible salt thereof, wherein said salt comprises at least one of an agriculturally, aquatic life, or mammal-compatible salt, for example. In other embodiments, a C11 unsaturated or saturated aliphatic acid or biologically compatible salt thereof, or a C12 unsaturated or saturated aliphatic acid or biologically compatible salt may be provided.

In another embodiment according to the present disclosure, a pesticidal composition is provided, comprising: one or more pesticidal agents; and one or more unsaturated C4-C10 aliphatic acids or agriculturally compatible salts thereof having at least one unsaturated C—C bond. In some other embodiments, a pesticidal composition comprising one or more pesticidal agents at one or more saturated C4-C10 aliphatic acids or agriculturally compatible salts thereof are provided. In some embodiments, the one or more saturated or unsaturated C4-C10 aliphatic acids produce a synergistic effect on the pesticidal activity of the pesticidal composition in comparison to the pesticidal activity of the pesticidal agent alone and are present in a respective synergistically active concentration ratio between about 1:15000 and 15000:1, more particularly between about 1:5000 and 5000:1, and further particularly between about 1:2000 and 2000:1. In some such embodiments, a C11 unsaturated or saturated aliphatic acid or agriculturally compatible salts thereof may be provided. In some further such embodiments, a C12 unsaturated or saturated aliphatic acid or agriculturally compatible salts thereof may be provided. In a further embodiment, a method of synergistically enhancing the pesticidal activity of at least one pesticidal active ingredient adapted to control at least one target pest organism is provided, comprising: providing at least one pesticidal active ingredient active for said at least one target pest organism; adding a synergistically effective concentration of at least one unsaturated or saturated C4-C10 aliphatic acid or an agriculturally acceptable salt thereof to provide a synergistic pesticidal composition; mixing said synergistic pesticidal composition with at least one formulation component comprising a surfactant to form a synergistic pesticidal concentrate; diluting said synergistic pesticidal concentrate with water to form a synergistic pesticidal emulsion; and applying said synergistic pesticidal emulsion at a pesticidally effective concentration and rate to control said at least one target pest organism. In some such embodiments, a C11 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof may be provided. In some further such embodiments, a C12 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof may be provided.

In some embodiments, the synergistic pesticidal composition may comprise a ratio of the concentrations by weight of said pesticidal active ingredient and said at least one saturated or unsaturated C4-C10 aliphatic acid or agriculturally compatible salts thereof is between about at least one of: 1:20,000 and 20,000:1, 1:15000 and 15000:1, 1:10,000 and 10,000:1, 1:5000 and 5000:1, 1:2500 and 2500:1, 1:2000 and 2000:1, 1:1500 and 1500:1, 1:1000 and 1000, 1:750 and 750:1, 1:500 and 500:1, 1:400 and 400:1, 1:300 and 300:1, 1:250 and 250:1, 1:200 and 200:1, 1:150 and 150:1, 1:100 and 100:1, 1:90 and 90:1, 1:80 and 80:1, 1:70 and 70:1, 1:60 and 60:1, 1:50 and 50:1, 1:40 and 40:1, 1:30 and 30:1, 1:25 and 25:1, 1:20 and 20:1, 1:15 and 15:1, 1:10 and 10:1, 1:9 and 9:1. 1:8 and 8:1, 1:7 and 7:1, 1:6 and 6:1, 1:5 and 5:1, 1:4 and 4:1, 1:3 and 3:1, 1:2 and 2:1, 1:1.5 and 1.5:1, and 1.25 and 1.25:1. In a particular such embodiment, the concentration ratios of the pesticidal active ingredient and said at least one C4-C10 saturated or unsaturated aliphatic acid or an agriculturally compatible salt thereof in the synergistic pesticidal composition are advantageously chosen so as to produce a synergistic effect against at least one target pest or pathogen. In some embodiments, the concentration ratios of the pesticidal active ingredient(s) and at least one C11 unsaturated or saturated aliphatic acid or agriculturally compatible salts thereof in the synergistic pesticidal composition may be advantageously chosen so as to produce a synergistic effect against at least one target pest or pathogen. In some further embodiments, the concentration ratios of the pesticidal active ingredient(s) and at least one C11 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof in the synergistic pesticidal composition may be advantageously chosen so as to produce a synergistic effect against at least one target pest or pathogen. In some embodiments, the synergistic pesticidal composition comprises a pesticidal active ingredient, and a C4-C10 unsaturated aliphatic acid which comprises at least one of: a trans-unsaturated C—C bond and a cis-unsaturated C—C bond. In a further such embodiment, the C4-C10 unsaturated aliphatic acid comprises at least one of: a trans-2, trans-3, trans-4, trans-5, trans-6, trans-7, trans-8, and trans-9 unsaturated bond. In yet another embodiment, a synergistic pesticidal composition is provided comprising a pesticidal active ingredient and a C4-C10 unsaturated aliphatic acid comprising at least one of: a cis-2, cis-3, cis-4, cis-5, cis-6, cis-7, cis-8, and cis-9 unsaturated bond. In some such embodiments, the pesticidal composition comprises a C11 unsaturated aliphatic acid or agriculturally compatible salt thereof, comprising at least one of: a trans-2, trans-3, trans-4, trans-5, trans-6, trans-7, trans-8, trans-9, trans-10, a cis-2, cis-3, cis-4, cis-5, cis-6, cis-7, cis-8, cis-9, and cis-10 unsaturated bond. In some further such embodiments, the pesticidal composition comprises a C12 unsaturated aliphatic acid or agriculturally compatible salt thereof, comprising at least one of: a trans-2, trans-3, trans-4, trans-5, trans-6, trans-7, trans-8, trans-9, trans-10, a cis-2, cis-3, cis-4, cis-5, cis-6, cis-7, cis-8, cis-9, and cis-10 unsaturated bond. In some embodiments, the synergistic pesticidal composition may comprise at least one C4-C10 saturated aliphatic acid, such as one or more of hexanoic, heptanoic, octanoic, nonanoic and decanoic acid, for example. In some further embodiments, the synergistic pesticidal composition may additionally comprise at least one second C4-C10 saturated or unsaturated aliphatic acid. In some further embodiments, the pesticidal composition may additionally comprise at least one second C11 or C12 unsaturated or saturated aliphatic acid, or agriculturally compatible salt thereof.

In some embodiments, the at least one C4-C10 saturated or unsaturated aliphatic acid may comprise a naturally occurring aliphatic acid, such as may be present in, or extracted, fractionated or derived from a natural plant or animal material, for example. In one such embodiment, the at least one C4-C10 saturated or unsaturated aliphatic acid may comprise one or more naturally occurring aliphatic acids provided in a plant extract or fraction thereof. In another such embodiment, the at least one C4-C10 saturated or unsaturated aliphatic acid may comprise one or more naturally occurring aliphatic acids provided in an animal extract or product, or fraction thereof. In one such embodiment, the at least one C4-C10 saturated or unsaturated alphatic acid may comprise a naturally occurring aliphatic acid comprised in a plant oil extract, such as one or more of coconut oil, palm oil, palm kernel oil, corn oil, or fractions or extracts therefrom. In another such embodiment, the at least one C4-C10 saturated or unsaturated aliphatic acid may comprise a naturally occurring aliphatic acid comprised in an animal extract or product, such as one or more of cow's milk, goat's milk, beef tallow, and/or cow or goat butter, or fractions or extracts thereof for example. In a particular embodiment, at least one C4-C10 saturated aliphatic acid may be provided in an extract or fraction of one or more plant oil extract, such as one or more of coconut oil, palm oil, palm kernel oil, corn oil, or fractions or extracts therefrom. In some further embodiments, the pesticidal composition may comprise at least one C11 or C12 saturated or unsaturated aliphatic acid provided in an extract or fraction of one or more plant or animal materials.

In some embodiments, the synergistic pesticidal composition exhibits a synergistic inhibition of growth of at least one target pest organism. In some embodiments, the synergistic pesticidal composition comprises a pesticidally effective concentration of the pesticidal active ingredient, and the one or more C4-C10 saturated or unsaturated aliphatic acid. In some further embodiments, the synergistic pesticidal composition comprises a pesticidal active ingredient, and a synergistic concentration of the one or more C4-C10 saturated or unsaturated aliphatic acid. In some embodiments, the synergistic pesticidal composition has a FIC Index (fractional inhibitory concentration index value) of less than 1 according to a growth inhibition assay for inhibition of growth of at least one target pest or pathogen organism. In some embodiments, the synergistic pesticidal composition has a FIC Index value of less than 0.75. In a further embodiment, the synergistic pesticidal composition has a FIC Index value of 0.5 or less. In some embodiments, the synergistic pesticidal composition has a synergistic efficacy factor, or Synergy Factor (comparing synergistic efficacy relative to expected additive (non-synergistic) efficacy according to the Colby Formula, or Loewe's Formula, or other accepted synergy determination method) of: at least 1.01, and more particularly at least 1.1, and further more particularly at least 1.5, and yet further more particularly at least 2, and more particularly at least 5, and yet more particularly at least 10, for example. In some such embodiments, the one or more saturated or unsaturated aliphatic acid may comprise a C11 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof. In some further such embodiments, the one or more saturated or unsaturated aliphatic acid may comprise a C12 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof.

In some embodiments, the pesticidal active ingredient may comprise at least one of a chemical pesticide and a naturally-derived pesticidal oil or extract. In a further aspect, the pesticidal active ingredient may comprise at least one of: a fungicide, nematicide, insecticide, acaricide, herbicide, and bactericide. In any such embodiments, the synergistic pesticidal composition may comprise one or more C4-C10 saturated or unsaturated aliphatic acid having at least one carboxylic group, and which may be linear or branched. In some embodiments, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise a linear monocarboxylic acid. In some embodiments, the C4-C10 unsaturated aliphatic acid may comprise one or more of cis and trans isomers. In an embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may be unsubstituted or substituted. In some embodiments, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise a substituent, such as a hydroxy, amino, carbonyl, aldehyde, acetyl, phosphate, or methyl substituent, for example. In one such embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise at least one of a 2-, 3-, 4-, 8-, or 10-substituted aliphatic acid. In one such embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise a hydroxy aliphatic acid. In one particular such embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise a 2-hydroxy, 3-hydroxy, or 4-hydroxy aliphatic acid. In one embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise an amino aliphatic acid. In one particular such embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise a 3-amino aliphatic acid. In a further embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise a methyl and/or ethyl substituted aliphatic acid. In a particular such embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise at least one of a 2-methyl, 3-methyl, 4-methyl, 2-ethyl, or 2,2-diethyl substituted aliphatic acid, for example. In some embodiments, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise an unsaturated aliphatic acid which may be mono-unsaturated or polyunsaturated, i.e. containing one, two or more unsaturated carbon-carbon (C—C) bonds respectively. In some embodiments, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise an unsaturated aliphatic acid with at least one of: a trans-unsaturated C—C bond, a cis-unsaturated C—C bond, and a plurality of conjugated unsaturated C—C bonds. In some such embodiments, the one or more saturated or unsaturated aliphatic acid may comprise a C11 unsaturated or saturated aliphatic acid. In some further such embodiments, the one or more saturated or unsaturated aliphatic acid may comprise a C12 unsaturated or saturated aliphatic acid.

In some further embodiments, the one or more C4-C10 (including C4, C5, C6, C7, C8, C9 or C10) saturated or unsaturated aliphatic acid may comprise at least one of: a trans-hexenoic acid, a cis-hexenoic acid, a hexa-dienoic acid, a hexynoic acid, a trans-heptenoic acid, a cis-heptenoic acid, a hepta-dienoic acid, a heptynoic acid, a trans-octenoic acid, a cis-octenoic acid, an octa-dienoic acid, an octynoic acid, a trans-nonenoic acid, a cis-nonenoic acid, a nona-dienoic acid, a nonynoic acid, a trans-decenoic acid, a cis-decenoic acid, a deca-dienoic acid, and a decynoic acid. In another embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may comprise at least one of: a trans-hexenoic acid, a cis-hexenoic acid, a hexa-dienoic acid other than 2,4-hexadienoic acid, a hexynoic acid, a trans-heptenoic acid, a cis-heptenoic acid, a hepta-dienoic acid, a heptynoic acid, a trans-octenoic acid, a cis-octenoic acid, an octa-dienoic acid, an octynoic acid, a trans-nonenoic acid, a cis-nonenoic acid, a nona-dienoic acid, a nonynoic acid, a trans-decenoic acid, a cis-decenoic acid, a deca-dienoic acid, and a decynoic acid. In some embodiments, the one or more unsaturated aliphatic acid may comprise at least one of a C11 or C12 unsaturated aliphatic acid, such as a cis-undecenoic, trans-undecanoic, cis-dodecenoic, trans-dodecenoic, undeca-dienoic, dodeca-dienoic, undecynoic, or dodecynoic acid, for example.

In some further embodiments, the one or more C4-C10 (including C4, C5, C6, C7, C8, C9 or C10) saturated or unsaturated aliphatic acid may comprise at least one of: hexanoic, heptanoic, octanoic, nonanoic and decanoic acid. In some embodiments, the one or more saturated or unsaturated aliphatic acid may comprise at least one of undecanoic or dodecanoic acid.

In some embodiments, the synergistic pesticidal composition may comprise one or more agriculturally compatible or acceptable salts of a one or more C4-C10 saturated or unsaturated aliphatic acid. In one such embodiment, such agriculturally compatible or acceptable salts may comprise one or more of potassium, sodium, calcium, aluminum, other suitable metal salts, ammonium, and other agriculturally acceptable salts of one or more C4-C10 saturated or unsaturated aliphatic acids, for example. In another embodiment, the synergistic pesticidal composition may comprise one or more C4-C10 saturated or unsaturated aliphatic acid or a biologically compatible salt thereof, wherein said salt comprises at least one of an agriculturally, aquatic life, or mammal-compatible salt, for example. In some embodiments, the pesticidal composition may comprise one or more agriculturally compatible or acceptable salts of one or one or more C11 or C12 saturated or unsaturated aliphatic acid.

However, in some other embodiments, the synergistic pesticidal composition may comprise a pesticidal active ingredient and a one or more C4-C10 saturated or unsaturated aliphatic acid, wherein the C4-C10 unsaturated aliphatic acid comprises at least one unsaturated C—C bond and wherein a ratio of the concentrations of said pesticidal active ingredient and said C4-C10 unsaturated aliphatic acid is between about 1:15000 and 15000:1, more particularly between about 1:5000 and 5000:1, and further particularly between about 1:2000 and 2000:1. In one such embodiment, the one or more C4-C10 saturated or unsaturated aliphatic acid may exclude agriculturally acceptable salts or other salt forms of the one or more C4-C10 saturated or unsaturated aliphatic acids. In a particular such embodiment, the synergistic pesticidal composition may exclude such salts for desired applications for which the acid forms of the one or more C4-C10 saturated or unsaturated aliphatic acids may be preferred. In one such application, it is known that accumulation of an undesirably high concentration of salts in some soils can be detrimental to the productivity or fertility of the soil, such as in particular salt sensitive soil applications, for example. Accordingly, in some embodiments, specifically excluding salt forms of the one or more C4-C10 saturated or unsaturated aliphatic acids may be particularly desirable. In some such embodiments, the pesticidal composition may comprise one or more C11 or C12 saturated or unsaturated aliphatic acid. In another embodiment, the synergistic pesticidal composition may comprise a pesticidal active ingredient and at least one C4-C10 saturated aliphatic acid, such as at least one of hexanoic, heptanoic, octanoic, nonanoic and decanoic acid, for example. In an alternative embodiment, the synergistic pesticidal composition may comprise a pesticidal active ingredient and at least one C4-C10 unsaturated aliphatic acid but explicitly excluding 2,4-hexadienoic acid. In some such embodiments, the one or more saturated or unsaturated aliphatic acid may comprise a C11 unsaturated or saturated aliphatic acid. In some further such embodiments, the one or more saturated or unsaturated aliphatic acid may comprise a C12 unsaturated or saturated aliphatic acid.

In some embodiments of the present disclosure, a synergistic pesticidal composition may comprise at least one C4-C10 saturated or unsaturated aliphatic acid and at least one pesticidal active ingredient selected from the list comprising:

• • A) Respiration inhibitors selected from:
    • inhibitors of complex III at Q_o site: azoxystrobin (II-1), coumethoxy-strobin, coumoxystrobin, dimoxystrobin (II-2), enestroburin, fenamin-strobin, fenoxystrobin/flufenoxystrobin, fluoxastrobin (II-3), kresoxim-methyl (II-4), metominostrobin, orysastrobin (II-5), picoxystrobin (II-6), pyraclostrobin (II-7), pyrame-tostrobin, pyraoxystrobin, trifloxystrobin (II-8), 2-[2-(2,5-dimethyl-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester and 2-(2-(3-(2,6-dichlorophenyl)-1-methyl-allylideneamino-oxymethyl)-phenyl)-2-methoxyimino-N-methyl-acetamide, pyribencarb, triclopyricarb/chlorodincarb, famoxadone, fenamidone;
    • Inhibitors of complex III at Q_i site: cyazofamid, amisulbrom, [(3S,6S,7R,8R)-8-benzyl-3-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)-amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl]2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[[3-(acetoxymethoxy)-4-methoxy-pyridine-2-carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[(3-isobutoxycarbony-loxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpro-panoate, [(3S,6S,7R,8R)-8-benzyl-3-[[3-(1,3-benzodioxol5-ylmethoxy)-4-methoxy-pyridine-2-carbon-yl]amino]-6-methyl-4,9-dioxol,5-dioxonan-7-yl] 2-methylpropanoate; (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenyl-methyl)-1,5-dioxonan-7-yl 2-methylpropanoate;
    • Inhibitors of complex II: benodanil, benzovindiflupyr (II-9), bixafen (II-10), boscalid (II-11), carboxin, fenfuram, fluopyram (II-12), flutolanil, fluxapyroxad (II-13), furametpyr, isofetamid, isopyrazam (II-14), mepronil, oxycarboxin, penflufen (II-15), penthiopyrad (II-16), sedaxane (II-17), tecloftalam, thifluzamide, N-(4′-trifluoromethylthiobiphenyl-2-yl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(2-(1,3,3-trimethyl-butyl)-phenyl)-1,3-dimethyl-5-fluoro-1H-pyrazole-4-carboxamide, 3-(difluorome-thyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1,5-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3,5-trimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, N-(7-fluoro-1,1,3-trimethyl-indan-4-yl)-1,3-dimethyl-pyrazole-4-carboxamide, N-[2-(2,4-dichlorophenyl)-2-methoxy-1-methyl-ethyl]-3-(difluoromethyl)-1-methyl-pyrazole-4-carboxamide;
    • Other respiration inhibitors: diflumetorim, (5,8-difluoroquinazolin-4-yl)-{2-[2-fluoro-4-(4-trifluorometh-ylpyridin-2-yloxy)-phenyl]-ethyl}-amine; binapacryl, dinobuton, dinocap, fluazinam (II-18); ferimzone; fentin salts such as fentin-acetate, fentin chloride or fentin hydroxide; ametoctradin (II-19); and silthiofam;
  • B) Sterol biosynthesis inhibitors (SBI fungicides) selected from:
    • C14 demethylase inhibitors (DMI fungicides): azaconazole, bitertanol, bromuconazole, cyproconazole (II-20), difenoconazole (II-21), diniconazole, diniconazole-M, epoxiconazole (II-22), fenbuconazole, fluquinconazole (II-23), flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole (II-24), myclobutanil, oxpoconazole, paclobutrazole, penconazole, propiconazole (II-25), prothioconazole (II-26), simeconazole, tebuconazole (II-27), tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole; imazalil, pefurazoate, prochloraz, triflumizol; fenarimol, nuarimol, pyrifenox, triforine, [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)isoxazol-4-yl]-(3-pyridyl)methanol;
    • Delta14-reductase inhibitors: aldimorph, dodemorph, dodemorphacetate, fenpropimorph, tridemorph, fenpropidin, piperalin, spiroxamine;
    • Inhibitors of 3-keto reductase: fenhexamid;
  • C) Nucleic acid synthesis inhibitors selected from:
    • phenylamides or acyl amino acid fungicides: benalaxyl, benalaxyl-M, kiralaxyl, metalaxyl, metalaxyl-M (mefenoxam) (II-38), ofurace, oxadixyl;
    • others nucleic acid inhibitors: hymexazole, octhilinone, oxolinic acid, bupirimate, 5-fluorocytosine, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine, 5-fluoro-2-(4-fluorophenylmethoxy)pyrimidin-4-amine;
  • D) Inhibitors of cell division and cytoskeleton selected from:
    • tubulin inhibitors: benomyl, carbendazim, fuberidazole, thiabendazole, thiophanate-methyl (II-39); 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine
    • other cell division inhibitors: diethofencarb, ethaboxam, pencycuron, fluopicolide, zoxamide, metrafenone (II-40), pyriofenone;
  • E) Inhibitors of amino acid and protein synthesis selected from:
    • methionine synthesis inhibitors (anilino-pyrimidines): cyprodinil, mepanipyrim, Pyrimethanil (II-41);
    • protein synthesis inhibitors: blasticidin-S, kasugamycin, kasugamycin hydrochloride-hydrate, mildiomycin, streptomycin, oxytetracyclin, polyoxine, validamycin A;
  • F) Signal transduction inhibitors selected from:
    • MAP/histidine kinase inhibitors: fluoroimid, iprodione, procymidone, vinclozolin, fenpiclonil, fludioxonil;
    • G protein inhibitors: quinoxyfen;
  • G) Lipid and membrane synthesis inhibitors selected from:
    • Phospholipid biosynthesis inhibitors: edifenphos, iprobenfos, pyrazophos, isoprothiolane; propamocarb, propamocarb-hydrochloride;
    • lipid peroxidation inhibitors: dicloran, quintozene, tecnazene, tolclofos-methyl, biphenyl, chloroneb, etridiazole;
    • phospholipid biosynthesis and cell wall deposition: dimethomorph (II-42), flumorph, mandipropamid (II-43), pyrimorph, benthiavalicarb, iprovalicarb, valifenalate, N-(1-(1-(4-cyano-phenyl)ethanesulfonyl)-but-2-yl) carbamic acid-(4-fluorophenyl) ester;
    • acid amide hydrolase inhibitors: oxathiapiprolin;
  • H) Inhibitors with Multi Site Action selected from:
    • inorganic active substances: Bordeaux mixture, copper acetate, copper hydroxide, copper oxychloride (II-44), basic copper sulfate, sulfur;
    • thio- and dithiocarbamates: ferbam, mancozeb (II-45), maneb, metam, metiram (II-46), propineb, thiram, zineb, ziram;
    • organochlorine compounds: anilazine, Chlorothalonil (II-47), captafol, captan, folpet, dichlofluanid, dichlorophen, hexachlorobenzene, pentachlorophenole and its salts, phthalide, tolylfluanid, N-(4-chloro-2-nitro-phenyl)-N-ethyl-4-methyl-benzenesulfonamide;
    • guanidines and others: guanidine, dodine, dodine free base, guazatine, guazatine-acetate, iminoctadine, iminoctadine-triacetate, iminoctadine-tris(albesilate), dithianon, 2,6-dimethyl-1H,5H-[1,4]dithii-no[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetraone (II-48);
  • I) Cell wall synthesis inhibitors selected from:
    • inhibitors of glucan synthesis: validamycin, polyoxin B;
    • melanin synthesis inhibitors: pyroquilon, tricyclazole, carpropamid, dicyclomet, fenoxanil;
  • J) Plant defence inducers selected from:
    • acibenzolar-S-methyl, probenazole, isotianil, tiadinil, prohexadione-calcium; fosetyl, fosetyl-aluminum, phosphorous acid and its salts (II-49);
  • K) Unknown mode of action selected from: bronopol, chinomethionat, cyflufenamid, cymoxanil, dazomet, debacarb, diclomezine, difenzoquat, difenzoquat-methylsulfate, diphenylamin, fenpyrazamine, flumetover, flusulfamide, flutianil, methasulfocarb, nitrapyrin, nitrothal-isopropyl, oxathiapiprolin, tolprocarb, 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, 2-[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-fluoro-6-(prop-2-yn-1-yl-oxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]-ethanone, 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, oxin-copper, proquinazid, tebufloquin, tecloftalam, triazoxide, 2-butoxy-6-iodo-3-propylchromen-4-one, N-(cyclo-propylmethoxyimino-(6-difluoro-methoxy-2,3-difluoro-phenyl)-methyl)-2-phenyl acetamide, N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethylphenyl)-N-ethyl-N-methyl formamidine, N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(2-methyl-5-trifluoromethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine, N′-(5-difluoromethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine, methoxyacetic acid 6-tert-butyl-8-fluoro-2,3-dimethyl-quinolin-4-yl ester, 3-[5-(4-meth-ylphenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine, 3-[5-(4-chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine (pyrisoxazole), N-(6-methoxy-pyridin-3-yl) cyclopropanecarboxylic acid amide, 5-chloro-1-(4,6-dimethoxy-pyrimidin-2-yl)-2-methyl-1H-benzoimidazole, 2-(4-chloro-phenyl)-N-[4-(3,4-dimethoxy-phe-nyl)-isoxazol-5-yl]-2-prop2-ynyloxy-acetamide, ethyl (Z)-3-amino-2-cyano-3-phenyl-prop-2-enoate, tertbutyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]-amino]oxymethyl]-2-pyridyl]carbamate, pentyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate, 2-[2-[(7,8-dif-luoro-2-methyl-3-quinolyl)oxy]-6-fluoro-phenyl]propan-2-ol, 2-[2-fluoro-6-[(8-fluoro-2-methyl-3-qui-nolyl)oxy]phenyl]propan-2-ol, 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline, 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline; Fenpicoxamid, florylpicoxamid;
  • L) Antifungal biopesticides selected from: Ampelomyces quisqualis, Aspergillus flavus, Aureobasidium pullulans, Bacillus pumilus (II-50), Bacillus subtilis (II-51), Bacillus subtilis var. amyloliquefaciens (II-52), Candida oleophila I-82, Candida saitoana, Clonostachys rosea f. catenulata, also named Gliocladium catenulatum, Coniothyrium minitans, Cryphonectria parasitica, Cryptococcus albidus, Metschnikowia fructicola, Microdochium dimerum, Phlebiopsis gigantea, Pseudozyma flocculosa, Pythium oligandrum DV74, Reynoutria sachlinensis, Talaromyces flavus VI 17b, Trichoderma asperellum SKT-1, T. atroviride LC52, T. harzianum T-22, T. harzianum TH 35, T. harzianum T-39; T. harzianum and T. viride, T. harzianum ICC012 and T. viride ICC080; T. polysporum and T. harzianum; T. stromaticum, T. virens GL-21, T. viride, T. viride TV1, Ulocladium oudemansii HRU3;
  • M) Growth regulators selected from: abscisic acid, amidochlor, ancymidol, 6-benzylaminopurine, brassino-lide, butralin, chlormequat (chlormequat chloride), choline chloride, cyclanilide, daminozide, dikegulac, dimethipin, 2,6-dimethylpuridine, ethephon, flumetralin, flurprimidol, fluthiacet, forchlorfenuron, gibberellic acid, inabenfide, indole-3-acetic acid, maleic hydrazide, mefluidide, mepiquat (mepiquat chloride) (II-54), naphthaleneacetic acid, N-6-benzyladenine, paclobutrazol, prohexadione (prohexadione-calcium, II-55), prohydrojasmon, thidiazuron, triapenthenol, tributyl phosphorotrithioate, 2,3,5-tri-iodobenzoic acid, trinex-apac-ethyl and uniconazole;
  • N) Herbicides selected from:
    • acetamides: acetochlor, alachlor, butachlor, dimethachlor, dimethenamid, flufenacet, mefenacet, me-tolachlor, metazachlor, napropamide, naproanilide, pethoxamid, pretilachlor, propachlor, thenylchlor;
    • amino acid derivatives: bilanafos, glyphosate, glufosinate, sulfosate;
    • aryloxyphenoxypropionates: clodinafop, cyhalofop-butyl, fenoxaprop, fluazifop, haloxyfop, metamifop, propaquizafop, quizalofop, quizalofop-P-tefuryl;
    • Bipyridyls: diquat, paraquat;
    • (thio)carbamates: asulam, butylate, carbetamide, desmedipham, dimepiperate, eptam (EPTC), esprocarb, molinate, orbencarb, phenmedipham, prosulfocarb, pyributicarb, thiobencarb, triallate;
    • cyclohexanediones: butroxydim, clethodim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, tralkoxydim;
    • dinitroanilines: benfluralin, ethalfluralin, oryzalin, pendimethalin, prodiamine, trifluralin;
      • diphenyl ethers: acifluorfen, aclonifen, bifenox, diclofop, ethoxyfen, fomesafen, lactofen, oxyfluorfen; —hydroxybenzonitriles: bomoxynil, dichlobenil, ioxynil;
      • imidazolinones: imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr;
    • phenoxy acetic acids: clomeprop, 2,4-dichlorophenoxyacetic acid (2,4-D), 2,4-DB, dichlorprop, MCPA, MCPA-thioethyl, MCPB, Mecoprop;
    • pyrazines: chloridazon, flufenpyr-ethyl, fluthiacet, norflurazon, pyridate;
    • pyridines: aminopyralid, clopyralid, diflufenican, dithiopyr, fluridone, fluroxypyr, picloram, picolinafen, thiazopyr;
    • sulfonyl ureas: amidosulfuron, azimsulfuron, bensulfuron, chlorimuronethyl, chlorsulfuron, cinosul-furon, cyclosulfamuron, ethoxysulfuron, flazasulfuron, flucetosulfuron, flupyrsulfuron, foramsulfuron, halosulfuron, imazosulfuron, iodosulfuron, mesosulfuron, metazosulfuron, metsulfuron-methyl, nico-sulfuron, oxasulfuron, primisulfuron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosul-furon, thifensulfuron, triasulfuron, tribenuron, trifloxysulfuron, triflusulfuron, tritosulfuron, 1-((2-chloro-6-propyl-imidazo[1,2-b]pyridazin-3-yl)sulfonyl)-3-(4,6-dimethoxy-pyrimidin-2-yl)urea;
    • triazines: ametryn, atrazine, cyanazine, dimethametryn, ethiozin, hexazinone, metamitron, metribuzin, prometryn, simazine, terbuthylazine, terbutryn, triaziflam;
    • ureas: chlorotoluron, daimuron, diuron, fluometuron, isoproturon, linuron, methabenzthiazuron, tebuthiuron;
    • other acetolactate synthase inhibitors: bispyribac-sodium, cloransulammethyl, diclosulam, florasulam, flucarbazone, flumetsulam, metosulam, ortho-sulfamuron, penoxsulam, propoxycarbazone, pyribam-benz-propyl, pyribenzoxim, pyriftalid, pyriminobac-methyl, pyrimisulfan, pyrithiobac, pyroxasulfone, py-roxsulam;
    • other herbicides: amicarbazone, aminotriazole, anilofos, beflubutamid, benazolin, bencarbazone, benfluresate, benzofenap, bentazone, benzobicyclon, bicyclopyrone, bromacil, bromobutide, butafenacil, butamifos, cafenstrole, carfentrazone, cinidon-ethyl, chlorthal, cinmethylin, clomazone, cumyluron, cyprosulfa-mide, dicamba, difenzoquat, diflufenzopyr, Drechslera monoceras, endothal, ethofumesate, etobenzanid, fenoxasulfone, fentrazamide, flumiclorac-pentyl, flumioxazin, flupoxam, flurochloridone, flurtamone, indanofan, isoxaben, isoxaflutole, lenacil, propanil, propyzamide, quinclorac, quinmerac, mesotrione, methyl arsonic acid, naptalam, oxadiargyl, oxadiazon, oxaziclomefone, pentoxazone, pinoxaden, pyraclonil, pyraflufen-ethyl, pyrasulfotole, pyrazoxyfen, pyrazolynate, quinoclamine, saflufenacil, sulcotrione, sulfentrazone, terbacil, tefuryltrione, tembotrione, thiencarbazone, topramezone, (3-[2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydro-2H-pyrimidin-1-yl)-phenoxy]-pyri-din-2-yloxy)-acetic acid ethyl ester, 6-amino-5-chloro-2-cyclopropyl-pyrimidine-4-carboxylic acid methyl ester, 6-chloro-3-(2-cyclopropyl-6-methyl-phenoxy)-pyridazin-4-ol, 4-amino-3-chloro-6-(4-chlorophenyl)-5-fluoro-pyridine-2-carboxylic acid, 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxy-phenyl)-pyridine-2-carboxylic acid methyl ester, and 4-amino-3-chloro-6-(4-chloro-3-dimethylamino-2-fluoro-phenyl)-pyridine-2-carboxylic acid methyl ester;
  • O) Insecticides selected from:
    • organo(thio)phosphates: acephate, azamethiphos, azinphos-methyl, chlorpyrifos, chlorpyrifos-methyl, chlorfenvinphos, diazinon, dichlorvos, dicrotophos, dimethoate, disulfoton, ethion, fenitrothion, fenthion, isoxathion, malathion, methamidophos, methidathion, methyl-parathion, mevinphos, monocrotophos, oxydemeton-methyl, paraoxon, parathion, phenthoate, phosalone, phosmet, phos-phamidon, phorate, phoxim, pirimiphos-methyl, profenofos, prothiofos, sulprophos, tetrachlorvinphos, terbufos, triazophos, trichlorfon;
    • carbamates: alanycarb, aldicarb, bendiocarb, benfuracarb, carbaryl, carbofuran, carbosulfan, fenox-ycarb, furathiocarb, methiocarb, methomyl, oxamyl, pirimicarb, propoxur, thiodicarb, triazamate;
    • pyrethroids: allethrin, bifenthrin, cyfluthrin, cyhalothrin, cyphenothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, zetacypermethrin, deltamethrin, esfenvalerate, etofenprox, fenpropathrin, fenvalerate, imiprothrin, lambda-cyhalothrin, permethrin, prallethrin, pyrethrin I and II, resmethrin, silafluofen, tau-fluvalinate, tefluthrin, tetramethrin, tralomethrin, transfluthrin, profluthrin, dimefluthrin;
    • insect growth regulators: a) chitin synthesis inhibitors: benzoylureas: chlorfluazuron, cyramazin, dif-lubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, teflubenzuron, triflumuron; buprofezin, diofenolan, hexythiazox, etoxazole, clofentazine; b) ecdysone antagonists: halofenozide, methoxyfenozide, tebufenozide, azadirachtin; c) juvenoids: pyriproxyfen, methoprene, fenoxycarb; d) lipid biosynthesis inhibitors: spirodiclofen, spiromesifen, spirotetramat;
    • nicotinic receptor agonists/antagonists compounds: clothianidin, dinotefuran, flupyradifurone, imidacloprid, thiamethoxam, nitenpyram, acetamiprid, thiacloprid, 1-2-chloro-thiazol-5-ylmethyl)-2-nitrimino-3,5-dimethyl-[1,3,5]triazinane;
    • nicotinic acetylcholine receptor disruptors or allosteric modulators (IRAC Goup 5): spinosyn (including but not limited to spinosyns A, D, B, C, E, F, G, H, J, and other spinosyn isolates from Saccharopolyspora spinosa culture), spinosad (comprising primarily spinsyns A and D), and derivatives or substituents thereof (including but not limited to tetracyclic and pentacyclic spinosyn derivatives, aziridine spinosyn derivatives, C-5,6 and/or C-13,14 substituted spinosyn derivatives); spinetoram (including but not limited to XDE-175-J, XDE-175-L or other O-ethyl substituted spinosyn derivatives); butenyl-spinosyn and derivatives or substituents thereof (such as isolates from Saccharopolyspora pogona culture);
    • bioinsecticides including but not limited to Bacillus thuriengiensis, Burkholderia spp, Beauveria bassiana, Metarhizium anisoptiae, Paecilomyces fumosoroseus, and baculoviruses (including but not limited to granuloviruses and nucleopolyhedroviruses);
    • GABA antagonist compounds: endosulfan, ethiprole, fipronil, vaniliprole, pyrafluprole, pyriprole, 5-amino-1-(2,6-dichloro-4-methyl-phenyl)-4-sulfinamoyl-1H-pyrazole-3-carbothioic acid amide;
    • mitochondrial electron transport inhibitor (METI) I acaricides: fenazaquin, pyridaben, tebufenpyrad, tolfenpyrad, flufenerim;
    • METI II and III compounds: acequinocyl, fluacyprim, hydramethylnon;
    • Uncouplers: chlorfenapyr;
    • oxidative phosphorylation inhibitors: cyhexatin, diafenthiuron, fenbutatin oxide, propargite;
    • moulting disruptor compounds: cryomazine;
    • mixed function oxidase inhibitors: piperonyl butoxide;
    • sodium channel blockers: indoxacarb, metaflumizone;
    • ryanodine receptor inhibitors: chlorantraniliprole, cyantraniliprole, fluben-diamide, N-[4,6-dichloro-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyra-zole-3-carboxamide; N-[4-chloro-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-6-methyl-phenyl]-2-(3-chloro-2-pyridyl)-5-trifluoromethyl)pyrazole-3-carboxamide; N-[4-chloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-6-methyl-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-car-boxamide; N-[4,6-dichloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; N-[4,6-dichloro-2-[(diethyl-lambda-4-sulfanyli-dene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(difluoromethyl)pyrazole-3-carboxamide; N-[4,6-di-bromo-2-[(di-2-propyl-lambda-4-sulfanyl-idene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; N-[4-chloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-6-cyano-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; N-[4,6-dibromo-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide;
    • others: benclothiaz, bifenazate, cartap, flonicamid, pyridalyl, pymetrozine, sulfur, thiocyclam, cyenopyrafen, flupyrazofos, cyflumetofen, amidoflumet, imicyafos, bistrifluron, pyrifluquinazon, 1,1′-[(3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-[[(2-cyclopropylacetyl)oxy]-methyl]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-12-hydroxy-4,6a,12b-trimethyl-11-oxo-9-(3-pyridinyl)-2H,11H-naphtho[2,1-b]pyrano[3,4-e]pyran-3,6-diyl] cyclopropaneacetic acid ester; fluensulfone, fluoroalkenyl thioethers; and
  • P) ribonucleic acid (RNA) and associated compounds including double-stranded RNA (dsRNA), microRNA (miRNA) and small interfering RNA (siRNA); bacteriophages.

In some such embodiments, the synergistic pesticidal composition may comprise one or more pesticidal active ingredient, such as selected from the list above, and one or more C11 unsaturated or saturated aliphatic acid or agriculturally acceptable salt thereof. In some further such embodiments, the synergistic pesticidal composition may comprise one or more pesticidal active ingredient, such as selected from the list above, and one or more C12 unsaturated or saturated aliphatic acid or agriculturally acceptable salt thereof.

In some embodiments, synergistic pesticidal compositions may be provided, where the pesticidal active ingredient comprises at least one pesticidal natural oil selected from: neem oil, karanja oil, clove oil, clove leaf oil, peppermint oil, spearmint oil, mint oil, cinnamon oil, thyme oil, oregano oil, rosemary oil, geranium oil, lime oil, lavender oil, anise oil, lemongrass oil, tea tree oil, apricot kernel oil, bergamot oil, carrot seed oil, cedar leaf oil, citronella oil, clove bud oil, coriander oil, coconut oil, eucalyptus oil, evening primrose oil, fennel oil, ginger oil, grapefruit oil, nootkatone(+), grapeseed oil, lavender oil, marjoram oil, pine oil, scotch pine oil, and/or garlic oil and/or components, derivatives and/or extracts of one or more pesticidal natural oil, or a combination thereof. In some further embodiments, synergistic pesticidal compositions may be provided which comprise additional active components other than the principal one or more pesticidal active ingredients, wherein such additional active components may comprise one or more additional efficacies and/or synergistic effects on the pesticidal efficacy of the composition, such as but not limited to adjuvants, synergists, agonists, activators, or combinations thereof, for example. In one such embodiment, such additional active components may optionally comprise naturally occurring compounds or extracts or derivatives thereof. In other embodiments, the pesticidal active ingredient may comprise at least one organic, certified organic, US Department of Agriculture (“USDA”) National Organic Program compliant (“NOP-compliant”) such as may be included in the US Environmental Protection Agency FIFRA 25b, list of ingredients published dated December 2015 by the US EPA entitled “Active Ingredients Eligible for Minimum Risk Pesticide Products”, the US EPA FIFRA 4a list published August 2004 entitled “List 4A—Minimal Risk Inert Ingredients” or the US EPA FIFRA 4b list published August 2004 entitled “List 4B—Other ingredients for which EPA has sufficient information”, for example, Organic Materials Review Institute listed (“OMRI-listed”) or natural pesticidal active ingredient, for example.

In some embodiments, the pesticidal active ingredient may comprise at least one of: neem oil, karanja oil and extracts or derivatives thereof. In further exemplary such embodiments, the pesticidal active ingredient may comprise at least one extract or active component of neem oil or karanja oil, such as but not limited to: azadirachtin, azadiradione, azadirone, nimbin, nimbidin, salannin, deacetylsalannin, salannol, maliantriol, gedunin, karanjin, pongamol, or derivatives thereof, for example.

BRIEF DESCRIPTION OF THE DRAWINGS

Exemplary embodiments are illustrated in referenced figures of the drawings. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.

FIG. 1 illustrates general carbonyl alkene structures (1), (2) and (3) associated with an exemplary C4-C10 unsaturated aliphatic acid, or agriculturally acceptable salt thereof, according to an embodiment of the present disclosure.

FIG. 2 illustrates an exemplary 96 well microtiter plate showing a color transition of a resazurin dye between colors indicating absence and presence of growth of a representative pest or pathogen, in accordance with a synergistic growth inhibition assay according to an embodiment of the present disclosure.

FIGS. 3-5 illustrate the observed survival rate (percent of original insects still surviving) for Trichoplusia ni (cabbage looper caterpillar) over time for in-vitro testing on a modified McMorran artificial diet to which treatments of Pylon® insecticide (containing chlorfenapyr as the pesticidal active ingredient) and exemplary unsaturated aliphatic acids (and salts) alone are shown in comparison with the corresponding survival rates for treatments with a synergistic pesticidal composition combining Pylon® insecticide with each of the exemplary unsaturated aliphatic acids (and salts) at three concentrations (shown in FIGS. 3, 4, and 5 respectively), according to an embodiment of the present invention.

DETAILED DESCRIPTION OF SEVERAL EMBODIMENTS

Throughout the following description specific details are set forth in order to provide a more thorough understanding to persons skilled in the art. However, well known elements may not have been shown or described in detail to avoid unnecessarily obscuring the disclosure. Accordingly, the description and drawings are to be regarded in an illustrative, rather than a restrictive, sense.

Definitions

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described herein.

All applications, publications, patents and other references, citations cited herein are incorporated by reference in their entirety. In case of conflict, the specification, including definitions, will control.

As used herein, the singular forms “a”, “and,” and “the” include plural referents unless the context clearly indicates otherwise.

As used herein, all numerical values or numerical ranges include integers within such ranges and fractions of the values or the integers within ranges unless the context clearly indicates otherwise. Thus, for example, reference to a range of 90-100%, includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so forth.

As used herein, “plant” embraces individual plants or plant varieties of any type of plants, in particular agricultural, silvicultural and ornamental plants.

As used herein, the terms “pest” or “pests” or grammatical equivalents thereof, are understood to refer to organisms, e.g., including pathogens, that negatively affect a host or other organism—such as a plant or an animal—by colonizing, damaging, attacking, competing with them for nutrients, infesting or infecting them, as well as undesired organisms that infest human structures, dwellings, living spaces or foodstuffs. Pests include but are not limited to fungi, weeds, nematodes, acari, and arthropods, including insects, arachnids and cockroaches. It is understood that the terms “pest” or “pests” or grammatical equivalents thereof can refer to organisms that have negative effects by infesting plants and seeds, and commodities such as stored grain.

As used herein, the terms “pesticide” or “pesticidal” or grammatical equivalents thereof, are understood to refer to any composition or substance that can be used in the control of any agricultural, natural environmental, human or other animal pathogenic, and domestic/household pests. The terms “control” or “controlling” are meant to include, but are not limited to, any killing, inhibiting, growth regulating, or pestistatic (inhibiting or otherwise interfering with the normal life cycle of the pest) activities of a composition against a given pest. These terms include for example sterilizing activities which prevent the production or normal development of seeds, ova, sperm or spores, cause death of seeds, sperm, ova or spores, or otherwise cause severe injury to the genetic material. Further activities intended to be encompassed within the scope of the terms “control” or “controlling” include preventing larvae from developing into mature progeny, modulating the emergence of pests from eggs including preventing eclosion, degrading the egg material, suffocation, interfering with mycelial growth, reducing gut motility, inhibiting the formation of chitin, disrupting mating or sexual communication, preventing feeding (antifeedant) activity, and interfering with location of hosts, mates or nutrient-sources. The term “pesticide” includes fungicides, herbicides, nematicides, insecticides and the like. The term “pesticide” encompasses, but is not limited to, naturally occurring compounds as well as so-called “synthetic chemical pesticides” having structures or formulations that are not naturally occurring, where pesticides may be obtained by various means including, but not limited to, extraction from biological sources, chemical synthesis of the compound, and chemical modification of naturally occurring compounds obtained from biological sources.

As used herein, the terms “insecticidal” and “acaridical” or “aphicidal” or grammatical equivalents thereof, are understood to refer to substances having pesticidal activity against organisms encompassed by the taxonomical classification of root term and also to refer to substances having pesticidal activity against organisms encompassed by colloquial uses of the root term, where those colloquial uses may not strictly follow taxonomical classifications. The term “insecticidal” is understood to refer to substances having pesticidal activity against organisms generally known as insects of the phylum Arthropoda, class Insecta. Further as provided herein, the term is also understood to refer to substances having pesticidal activity against other organisms that are colloquially referred to as “insects” or “bugs” encompassed by the phylum Arthropoda, although the organisms may be classified in a taxonomic class different from the class Insecta. According to this understanding, the term “insecticidal” can be used to refer to substances having activity against arachnids (class Arachnida), in particular mites (subclass Acari/Acarina), in view of the colloquial use of the term “insect.” The term “acaridical” is understood to refer to substances having pesticidal activity against mites (Acari/Acarina) of the phylum Arthropoda, class Arachnida, subclass Acari/Acarina. The term “aphicidal” is understood to refer to substances having pesticidal activity against aphids (Aphididae) of the phylum Arthopoda, class Insecta, family Aphididae. It is understood that all these terms are encompassed by the term “pesticidal” or “pesticide” or grammatical equivalents. It is understood that these terms are not necessarily mutually exclusive, such that substances known as “insecticides” can have pesticidal activity against organisms of any family of the class Insecta, including aphids, and organisms that are encompassed by other colloquial uses of the term “insect” or “bug” including arachnids and mites. It is understood that “insecticides” can also be known as acaricides if they have pesticidal activity against mites, or aphicides if they have pesticidal activity against aphids.

As used herein, the terms “control” or “controlling” or grammatical equivalents thereof, are understood to encompass any pesticidal (killing) activities or pestistatic (inhibiting, repelling, deterring, and generally interfering with pest functions to prevent the damage to the host plant) activities of a pesticidal composition against a given pest. Thus, the terms “control” or “controlling” or grammatical equivalents thereof, not only include killing, but also include such activities as repelling, deterring, inhibiting or killing egg development or hatching, inhibiting maturation or development, and chemisterilization of larvae or adults. Repellant or deterrent activities may be the result of compounds that are poisonous, mildly toxic, or non-poisonous to pests, or may act as pheromones in the environment.

As used herein, the term “pesticidally effective amount” generally means the amount of the inventive mixtures or of compositions comprising the mixtures needed to achieve an observable effect on growth, including the effects of necrosis, death, retardation, prevention, and removal, destruction, or otherwise diminishing the occurrence and activity of the target pest organism. The pesticidally effective amount can vary for the various mixtures/compositions used in the invention. A pesticidally effective amount of the mixtures/compositions will also vary according to the prevailing conditions such as desired pesticidal effect and duration, weather, target species, locus, mod+e of application, and the like. As used herein, where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value within that stated range is encompassed within embodiments of the invention. The upper and lower limits of these smaller ranges may independently define a smaller range of values, and it is to be understood that these smaller ranges are intended to be encompassed within embodiments of the invention, subject to any specifically excluded limit in the stated range.

In one embodiment according to the present disclosure, a synergistic pesticidal composition comprises a C4-C10 unsaturated aliphatic acid (or agriculturally acceptable salt thereof), the and at least one pesticidal active ingredient. In some embodiments, the effective dose of the pesticidal active ingredient when used in combination with the one or more C4-C10 saturated or unsaturated aliphatic acid is lower than the effective dose of the pesticidal active ingredient when used alone (i.e. a smaller amount of pesticidal active can still control pests when used in a synergistic composition together with the one or more C4-C10 saturated or unsaturated aliphatic acid). In some embodiments, a pesticidal active ingredient that is not effective against a particular species of pest can be made effective against that particular species when used in a synergistic composition together with one or more C4-C10 saturated or unsaturated aliphatic acid. In some such embodiments, the pesticidal composition may comprise a C11 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof. In some further such embodiments, the pesticidal composition may comprise a C12 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof.

Without being bound by any particular theory, it is believed that the one or more C4-C10 saturated or unsaturated aliphatic acids according to some embodiments of the present disclosure act as cell permeabilizing agents, and when combined with a suitable pesticidal active ingredient, may desirably facilitate the entry of the pesticidal active ingredient into the cells of a target pest or pathogen, thereby desirably providing for a synergistic activity of such a synergistic pesticidal composition. All eukaryotic cell membranes, including for example fungal cell membranes and the cell membranes of insects and nematodes are biochemically similar in that they all comprise a lipid bilayer which is comprised of phospholipids, glycolipids and sterols, as well as a large number of proteins (Cooper & Hausmann 2013). The amphipathic structure of the lipid bilayer and the polarity of membrane proteins restricts passage of extracellular compounds across the membrane and allows compartmentalization of internal organelles from the intracellular environment. Without being bound by theory, it is believed that the one or more C4-C10 saturated or unsaturated aliphatic acids according to some embodiments disclosed herein will act as cell permeabilizing agents, and when combined with a suitable pesticidal active ingredient may desirably act to enhance the entry of the active ingredient (such as but not limited to fungicidal, insecticidal, acaricidal, molluscicidal, bactericidal and nematicidal actives) into the cells and/or into the intracellular organelles or intracellular bodies of a target pest or pathogen (such as but not limited to fungi, insects, acari, mollusks, bacteria and nematodes, respectively), for example.

In a further embodiment, without being bound by theory, it is believed that the size and/or polarity of many pesticidal molecules prevents and/or limits the pesticidal active ingredient from crossing the cellular membrane, but that the addition of one or more C4-C10 saturated or unsaturated aliphatic acid in accordance with some embodiments of the present disclosure may desirably compromise or provide for the disturbance of the pest cell membrane's lipid bilayer integrity and protein organization such as to create membrane gaps, and/or increase the membrane fluidity, such as to allow the pesticidal active to more effectively enter the cell and/or intracellular organelles of the pest cells, for example. In some such embodiments, the pesticidal composition may comprise a C11 unsaturated aliphatic acid or agriculturally compatible salt thereof. In some further such embodiments, the pesticidal composition may comprise a C12 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof.

In another aspect, without being bound to any particular theory, it is believed that the one or more C4-C10 saturated or unsaturated aliphatic acids, or agriculturally acceptable salts thereof, (and in some additional embodiments, alternatively a C11 or C12 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof). In some further such embodiments, the pesticidal composition may comprise a C12 unsaturated aliphatic acid or agriculturally compatible salt thereof according to some embodiments of the present disclosure act as at least one of a potentiator, synergist, adjuvant and/or agonist when combined with a suitable pesticidal active ingredient, thereby desirably providing for a synergistic activity of such a synergistic pesticidal composition against a target pest or pathogen.

In some embodiments according to the present disclosure, a synergistic pesticidal composition accordingly to the present invention comprises one or more C4-C10 saturated or unsaturated aliphatic acid, or agriculturally acceptable salts thereof (and in some additional embodiments, alternatively a C11 or C12 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof), as an exemplary cell permeabilizing agent, in combination with a pesticide. In some embodiments, the synergistic composition comprises one or more C4-C10 saturated or unsaturated aliphatic acid (or agriculturally acceptable salt thereof), as an exemplary cell permeabilizing agent, in combination with a fungicide. In some embodiments, the synergistic composition comprises one or more C4-C10 saturated or unsaturated aliphatic acid (or agriculturally acceptable salt thereof), as an exemplary cell permeabilizing agent, in combination with a nematicide. In some embodiments, the synergistic composition comprises one or more C4-C10 saturated or unsaturated aliphatic acid (or agriculturally acceptable salt thereof), as an exemplary cell permeabilizing agent, in combination with an insecticide.

In one such embodiment, without being bound to a particular theory, it is believed that the one or more C4-C10 saturated or unsaturated aliphatic acid (and in some additional embodiments, alternatively a C11 or C12 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof) may act as a cellular membrane delivery agent, so as to improve the entry of and/or bioavailability or systemic distribution of a pesticidal active ingredient within a target pest cell and/or within a pest intracellular organelle, such by facilitating the pesticidal active ingredient in passing into the mitochondria of the pest cells, for example. In some other embodiments, without being bound by a particular theory, the one or more C4-C10 saturated or unsaturated aliphatic acid may further provide for synergistic interaction with one or more additional compounds provided as part of the pesticidal composition, such as an additional one or more C4-C10 saturated aliphatic acid, or one or more C4-C10 unsaturated aliphatic acid, or one or more additional active ingredients or adjuvants, so as to provide for synergistic enhancement of a pesticidal effect provided by the at least one pesticidal active ingredient, for example.

In another aspect, without being bound to any particular theory, it is believed that the one or more C4-C10 saturated or unsaturated aliphatic acids (or agriculturally acceptable salts thereof) according to some embodiments of the present disclosure act as at least one of a potentiator, synergist, adjuvant and/or agonist when combined with a suitable pesticidal ingredient, thereby desirably providing for a synergistic activity of such a synergistic pesticidal composition against a target pest or pathogen. In some additional embodiments, such synergistic pesticidal composition may alternatively comprise a C11 or C12 unsaturated or saturated aliphatic acid or agriculturally compatible salt thereof.

Without being bound by any particular theory, in some embodiments of the present invention, it is believed that the one or more C4-C10 saturated or unsaturated aliphatic acids act to compromise or alter the integrity of the lipid bilayer and protein organization of cellular membranes in target pest organisms. Further, it is also believed that in some embodiments one or more C4-C10 saturated or unsaturated aliphatic acids are particularly adapted for combination to form synergistic pesticidal compositions according to embodiments of the invention, which demonstrate synergistic efficacy, with pesticidal actives having a pesticidal mode of action that is dependent upon interaction with one or more components of the cellular membrane of a target pest. In some such embodiments, one or more C4-C10 saturated or unsaturated aliphatic acids may be particularly adapted for combining to form a synergistic pesticidal composition, demonstrating synergistic efficacy, with pesticidal actives which have a mode of action dependent on interaction with a cellular membrane protein. In one such embodiment, the cellular membrane protein may comprise one or more cytochrome complexes, such as a cytochrome bel complex or a cytochrome p450 complex, for example. Accordingly, in one aspect, synergistic pesticidal compositions according to some embodiments of the present invention may desirably be selected to comprise one or more C4-C10 saturated or unsaturated aliphatic acids, and one or more pesticidal active having a pesticidal mode of action that is dependent upon interaction with one or more components of the cellular membrane of a target pest, such as a cellular membrane protein, for example. In one aspect, one or more C11 or C12 saturated or unsaturated aliphatic acids is provided in combination with one or more pesticidal active having a pesticidal mode of action that is dependent upon interaction with one or more components of the cellular membrane of a target pest, such as a cellular membrane protein, for example. In a particular embodiment, one or more C4-C10 saturated or unsaturated aliphatic acids are particularly adapted for combination to form synergistic pesticidal compositions according to embodiments of the invention, which demonstrate synergistic efficacy, with pesticidal actives having a pesticidal mode of action interacting with (such as by inhibiting one or more receptor sites) the cellular membrane cytochrome be 1 complex (also known as the cytochrome complex III), such as fungicidal actives collectively referred to as Group 11 actives by the Fungicide Resistance Action Committee (FRAC), including e.g. azoxystrobin, coumoxystrobin, enoxastrobin, flufenoxystrobin, picoxystrobin, pyraoxystrobin, mandestrobin, pyraclostrobin, pyrametostrobin, triclopyricarb, kresoxim-methyl trifloxystrobin, dimoxystrobin, fenaminstrobin, metominostrobin, orysastrobin, famoxadone, fluoxastrobin, fenamidone, or pyribencar. In one such embodiment, a synergistic pesticidal composition may be selected comprising one or more C4-C10 saturated or unsaturated aliphatic acid and a pesticidal active having a pesticidal mode of action interacting with the cellular cytochrome bel complex, such as a strobilurin pesticidal active. In alternative such embodiments, the synergistic pesticidal composition comprises one or more C11 or C12 saturated or unsaturated aliphatic acids.

In another particular embodiment, one or more C4-C10 saturated or unsaturated aliphatic acids are particularly adapted for combination to form synergistic pesticidal compositions according to embodiments of the invention, which demonstrate synergistic efficacy, with pesticidal actives having a pesticidal mode of action interacting with (such as by inhibiting one or more receptor sites) the cellular membrane cytochrome p450 complex, such as to inhibit sterol biosynthesis, as is the case with exemplary fungicidal actives collectively referred to as FRAC Group 3 actives, including e.g. triforine, pyrifenox, pyrisoxazole, fenarimol, nuarimol, imazalil, oxpoconazole, pefurazoate, prochloraz, triflumizole, azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, or prothioconazole. In one such embodiment, a synergistic pesticidal composition may be selected comprising one or more C4-C10 saturated or unsaturated aliphatic acid and a pesticidal active having a pesticidal mode of action interacting with the cellular cytochrome p450 complex, such as an azole or triazole pesticidal active, for example. In alternative such embodiments, the synergistic pesticidal composition comprises one or more C11 or C12 saturated or unsaturated aliphatic acids.

In another particular embodiment, one or more C4-C10 saturated or unsaturated aliphatic acids are particularly adapted for combination to form synergistic pesticidal compositions according to embodiments of the invention, which demonstrate synergistic efficacy, with pesticidal actives having a pesticidal mode of action interacting with (such as by inhibiting one or more receptor sites) the cellular membrane, such as to uncouple oxidative phosphorylation, as is the case with exemplary insecticidal actives collectively referred to as Group 13 actives by the Insecticide Resistance Action Committee (IRAC), including e.g. quinoxyfen or proquinazid. In one such embodiment, a synergistic pesticidal composition may be selected comprising one or more C4-C10 saturated or unsaturated aliphatic acid and a pesticidal active having a pesticidal mode of action interacting with the cellular membrane, such as a pyrrole insecticidal active, an example of which is chlorfenapyr. In alternative such embodiments, the synergistic pesticidal composition comprises one or more C11 or C12 saturated or unsaturated aliphatic acids.

In another particular embodiment, one or more C4-C10 saturated or unsaturated aliphatic acids are particularly adapted for combination to form synergistic pesticidal compositions according to embodiments of the invention, which demonstrate synergistic efficacy, with pesticidal actives having a pesticidal mode of action interacting with (such as by disrupting and/or allosterically modulating one or more receptor sites) the cellular membrane, such as to disrupt one or more nicotinic acetylcholine receptor sites (such as Site 1), as is the case with exemplary insecticidal actives collectively referred to as Group 5 actives by the Insecticide Resistance Action Committee (IRAC). Such IRAC Group 5 actives include, for example: spinosyn (including but not limited to spinosyns A, D, B, C, E, F, G, H, J, and other spinosyn isolates from Saccharopolyspora spinosa culture), spinosad (comprising primarily spinsyns A and D), and derivatives or substituents thereof (including but not limited to tetracyclic and pentacyclic spinosyn derivatives, aziridine spinosyn derivatives, C-5,6 and/or C-13,14 substituted spinosyn derivatives); spinetoram (including but not limited to XDE-175-J, XDE-175-L or other O-ethyl substituted spinosyn derivatives); butenyl-spinosyn and derivatives or substituents thereof (such as isolates from Saccharopolyspora pogona culture). In one such embodiment, a synergistic pesticidal composition may be selected comprising one or more C4-C10 saturated or unsaturated aliphatic acid and a pesticidal active having a pesticidal mode of action interacting with the cellular membrane, such as a spinosyn or spinosyn derivative insecticidal active, examples of which may include Spinosad and spinetoram. In alternative such embodiments, the synergistic pesticidal composition may comprise one or more C11 or C12 saturated or unsaturated aliphatic acids, substituents, or salts thereof.

Without being bound by any particular theory, in some further embodiments of the present invention, it is believed that one or more C4-C10 saturated or unsaturated aliphatic acids act to compromise or alter the integrity of the lipid bilayer and protein organization of cellular membranes in target pest organisms, and by so doing are effective to increase at least one of the fluidity and permeability of a cellular membrane of a target pest organism, which may desirably increase permeability and/or transport of a pesticidal active through the cellular membrane, for example. Further, it is also believed that in some embodiments one or more C4-C10 saturated or unsaturated aliphatic acids are particularly adapted for combination to form synergistic pesticidal compositions according to embodiments of the invention, which demonstrate synergistic efficacy, with pesticidal actives having a pesticidal mode of action that is dependent upon transport across one or more cellular membrane of a target pest, such as to interact with a target site inside a cell or an intracellular organelle of the target pest. In some such embodiments, a synergistic pesticidal composition according to an embodiment of the present invention, demonstrating synergistic efficacy, may comprise one or more C4-C10 saturated or unsaturated aliphatic acid, and one or more pesticidal active having a mode of action dependent on transport across a cellular membrane. Accordingly, in one aspect, synergistic pesticidal compositions according to some embodiments of the present invention may desirably be selected to comprise one or more C4-C10 saturated or unsaturated aliphatic acids, and one or more pesticidal active having a pesticidal mode of action that is dependent upon interaction with a target site within a cell or intracellular organelle of a target pest, such as a cellular membrane protein, for example. In alternative such embodiments, the synergistic pesticidal composition comprises one or more C11 or C12 saturated or unsaturated aliphatic acids.

In a particular embodiment, one or more C4-C10 saturated or unsaturated aliphatic acids are particularly adapted for combination to form synergistic pesticidal compositions according to embodiments of the invention, which demonstrate synergistic efficacy, with pesticidal actives having a pesticidal mode of action interacting with (such as by inhibiting one or more receptors) at a target site across a cellular membrane of a target pest, such as fungicidal actives collectively referred to as FRAC Group 9 and Group 12 actives, for example, including e.g. cyprodinil, mepanipyrim, pyrimethanil, fenpiclonil or fludioxonil. In one such embodiment, a synergistic pesticidal composition may be selected comprising one or more C4-C10 saturated or unsaturated aliphatic acid and a pesticidal active having a pesticidal mode of action interacting with a target site within a cellular membrane of a target pest, such as one or more of an anilinopyrimidine such as cyprodinil, and a phenylpyrrole such as fludioxonil, for example. In alternative such embodiments, the synergistic pesticidal composition comprises one or more C11 or C12 saturated or unsaturated aliphatic acids.

Without being bound by any particular theory, in some yet further embodiments of the present invention, it is believed that one or more C4-C10 saturated or unsaturated aliphatic acids act to compromise or alter the integrity of the lipid bilayer and protein organization of cellular membranes in target pest organisms, and by so doing are effective to increase at least one of the fluidity and permeability of a cellular membrane of a target pest organism, which may desirably increase permeability and/or transport of a pesticidal active through the cellular membrane, for example. Further, it is also believed that in some alternative embodiments one or more C4-C10 unsaturated aliphatic acids having unsaturated C—C bonds at one or more of the second (2-), third (3-) and terminal ((n−1)-) locations in the aliphatic acid carbon chain may be desirably adapted for combination to form synergistic pesticidal compositions according to embodiments of the invention, which demonstrate synergistic efficacy, with pesticidal actives. In some particular such embodiments, one or more C4-C10 aliphatic acids comprising an unsaturated C—C bond at one or more of the 2-,3- and (n−1)-locations (wherin n is the number of carbons in the unsaturated aliphatic acid) may desirably be adapted for forming synergistic pesticidal compositions in combination with one or more pesticidal active having a pesticidal mode of action that is dependent upon interaction with a cellular membrane component of a target pest, or dependent upon transport across one or more cellular membrane of a target pest (such as to interact with a target site inside a cell or an intracellular organelle of the target pest). In some such embodiments, a synergistic pesticidal composition according to an embodiment of the present invention, demonstrating synergistic efficacy, may comprise one or more C4-C10 unsaturated aliphatic acid having an unsaturated C—C bond at one or more of the 2-, 3- and terminal ((n−1)-) locations in the aliphatic acid carbon chain, and one or more pesticidal active having a mode of action dependent on interaction with a target pest cellular membrane component, or on transport across a target pest cellular membrane. In alternative such embodiments, the synergistic pesticidal composition comprises one or more C11 or C12 unsaturated aliphatic acids having an unsaturated C—C bond at one or more of the 2-, 3- and terminal ((n−1)-).

In some embodiments, the one or more C4-C10 saturated or unsaturated aliphatic acid (or agriculturally acceptable salt thereof) comprises an aliphatic carbonyl alkene. In some embodiments, the one or more C4-C10 saturated or unsaturated aliphatic acid (or agriculturally acceptable salt thereof) comprises at least one C4-C10 unsaturated aliphatic acid having at least one carboxylic group and at least one unsaturated C—C bond. In another embodiment, the C4-C10 unsaturated aliphatic acid (or agriculturally acceptable salt thereof) comprises at least two C4-C10 unsaturated aliphatic acids having at least one carboxylic group and at least one unsaturated C—C bond. In yet another embodiment, the C4-C10 unsaturated aliphatic acid (or agriculturally acceptable salt thereof) comprises at least one carboxylic acid group and at least one of a double or triple C—C bond. In a further embodiment, a synergistic pesticidal composition is provided comprising at least one pesticidal active ingredient, and at least one C4-C10 unsaturated aliphatic acid (or agriculturally acceptable salt thereof) having at least one carboxylic acid group and at least one unsaturated C—C bond, in combination with at least one C4-C10 saturated aliphatic acid (or agriculturally acceptable salt thereof). In yet another embodiment, the C4-C10 saturated or unsaturated aliphatic acid may be provided as a plant extract or oil, or fraction thereof, containing the at least one C4-C10 saturated or unsaturated aliphatic acid, for example, or in further embodiments, containing the one or more C11 or C12 saturated or unsaturated aliphatic acid.

In some embodiments, the one or more C4-C10 saturated or unsaturated aliphatic acid (or agriculturally acceptable salt thereof) comprises an aliphatic carbonyl alkene having one of the general structures (1), (2) or (3), as shown in FIG. 1. In further embodiments, the one or more C4-C10 saturated or unsaturated aliphatic acid may additionally comprise a C11 or C12 saturated or unsaturated aliphatic acid, and may comprise an aliphatic carbonyl alkene having one of the general structures (1), (2) or (3) as shown in FIG. 1. In some embodiments, the C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid may additionally comprise at least one substituent selected from the list comprising: hydroxy, alkyl and amino substituents. In some exemplary embodiments, the at least one substituent may comprise at least one of: 2-hydroxy, 3-hydroxy, 4-hydroxy, 8-hydroxy, 10-hydroxy, 12-hydroxy, 2-methyl, 3-methyl, 4-methyl, 2-ethyl, 3-ethyl, 4-ethyl, 2,2-diethyl, 2-amino, 3-amino, and 4-amino substituents, for example. In some embodiments, the C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid may comprise an agriculturally acceptable salt form of any of the above-mentioned aliphatic acids. In some embodiments, the composition comprises one or more C4-C10 saturated or unsaturated aliphatic acid (or agriculturally acceptable salt thereof) and a fungicidal active ingredient. In some embodiments, the effective dose of the fungicidal active ingredient when used in combination with the one or more C4-C10 saturated or unsaturated aliphatic acid is lower than the effective dose of the fungicidal active ingredient when used alone (i.e. a smaller amount of fungicidal active can still control fungi when used in a composition together with the one or more C4-C10 saturated or unsaturated aliphatic acid). In some embodiments, a fungicidal active ingredient that is not effective against a particular species of fungi (such as at a particular concentration that is below a lower limit of efficacy for a particular fungi, or for a particular species of fungi which may be at least partially resistant or tolerant to the particular fungicidal active ingredient when applied alone) can be made effective against that particular species when used in a composition together with one or more C4-C10 saturated or unsaturated aliphatic acid, or in further embodiments, with one or more C11 or C12 saturated or unsaturated aliphatic acid.

In some embodiments, the composition comprises one or more C4-C10 saturated or unsaturated aliphatic acid (or agriculturally acceptable salt thereof) and a nematicidal active ingredient. In some embodiments, the effective dose of the nematicidal active ingredient when used in combination with the one or more C4-C10 saturated or unsaturated aliphatic acid is lower than the effective dose of the nematicidal active ingredient when used alone (i.e. a smaller amount of nematicidal active can still control nematodes when used in a composition together with the one or more C4-C10 saturated or unsaturated aliphatic acid). In some embodiments, a nematicidal active ingredient that is not effective against a particular species of nematode (such as at a particular concentration that is below a lower limit of efficacy for a particular nematode, or for a particular species of nematode which may be at least partially resistant or tolerant to the particular nematicidal active ingredient when applied alone) can be made effective against that particular species when used in a composition together with one or more C4-C10 saturated or unsaturated aliphatic acid, or in further embodiments, with one or more C11 or C12 saturated or unsaturated aliphatic acid.

In some embodiments, the composition comprises one or more C4-C10 saturated or unsaturated aliphatic acid (or agriculturally acceptable salt thereof) and an insecticidal active ingredient. In some embodiments, the effective dose of the insecticidal active ingredient when used in combination with the one or more C4-C10 saturated or unsaturated aliphatic acid is lower than the effective dose of the insecticidal active ingredient when used alone (i.e. a smaller amount of insecticidal active can still control insects, to an exemplary desired degree of control, when used in a composition together with the one or more C4-C10 saturated or unsaturated aliphatic acid). In some embodiments, the aliphatic acid may further comprise one or more C11 or C12 saturated or unsaturated aliphatic acid. In some embodiments, an insecticidal active ingredient that is not effective against a particular species of insect (such as at a particular concentration that is below a lower limit of efficacy for a particular insect, or for a particular species of insect which may be at least partially resistant or tolerant to the particular insecticidal active ingredient when applied alone) can be made effective against that particular species when used in a composition together with one or more C4-C10 saturated or unsaturated aliphatic acid, or in further embodiments, with one or more C11 or C12 saturated or unsaturated aliphatic acid. In further embodiments, the one or more C4-C10 saturated or unsaturated aliphatic acid (or in further embodiments, with one or more C11 or C12 saturated or unsaturated aliphatic acid) may desirably provide for a synergistic increased efficacy of at least one of an acaricidal, molluscicidal, bactericidal or virucidal active ingredient such that the composition is pesticidally effective against one or more of an acari, mollusk, bacterial or viral pest, for example.

In some embodiments, a pesticidal composition is provided comprising at least one C4-C10 saturated or unsaturated aliphatic acid (or in some further embodiments at least one C11 or C12 saturated or unsaturated apliphatic acid) and an insecticidal pesticidal active ingredient, comprising at least one nicotinic acetylcholine receptor disruptors. In one such embodiment, the insecticidal active ingredient may comprise at least one or more of: a spinosyn (including but not limited to spinosyns A, D, B, C, E, F, G, H, J, and other spinosyn isolates from Saccharopolyspora spinosa culture), spinosad (comprising primarily spinsyns A and D), and derivatives or substituents thereof (including but not limited to tetracyclic and pentacyclic spinosyn derivatives, aziridine spinosyn derivatives, C-5,6 and/or C-13,14 substituted spinosyn derivatives); a spinetoram (including but not limited to XDE-175-J and XDE-175-L); and a butenyl-spinosyn and derivatives or substituents thereof (such as isolates from Saccharopolyspora pogona culture). In a particular such embodiment, a pesticidal composition is provided, comprising at least one C4-C10 saturated or unsaturated aliphatic acid (or in some further embodiments at least one C11 or C12 saturated or unsaturated apliphatic acid) and at least one of spinosyn A and spinosyn D. In a further such embodiment, the at least one spinosyn comprises spinosad. In some embodiments, the pesticidal composition comprises a synergistic pesticidal composition. In some particular embodiments, the synergistic pesticidal composition desirably provides a synergistic efficacy to control at least one insect pest.

In some further embodiments, a method of reducing a risk of resistance of at least one target pest to at least one pesticidal active ingredient is provided, the method comprising:

• • selecting at least one C4-C10 saturated or unsaturated aliphatic acid, or suitable salt thereof, which when applied to said at least one target pest as a pesticidal composition comprising said at least one pesticidal active ingredient and said at least one C4-C10 saturated or unsaturated aliphatic acid, or suitable salt thereof, is effective to provide a synergistic efficacy against said at least one target pest, relative to the application of said at least one pesticidal active ingredient alone; and applying said at least one pesticidal composition to a locus proximate to said at least one target pest.

In some embodiments, the at least one C4-C10 saturated or unsaturated aliphatic acid, or in further embodiments, with one or more C11 or C12 saturated or unsaturated aliphatic acid, may comprise a naturally occurring aliphatic acid, such as may be present in, or extracted, fractionated or derived from a natural plant or animal material, for example. In one such embodiment, the at least one C4-C10 saturated or unsaturated aliphatic acid may comprise one or more naturally occurring aliphatic acids provided in a plant extract or fraction thereof. In another such embodiment, the at least one C4-C10 saturated or unsaturated aliphatic acid may comprise one or more naturally occurring aliphatic acids provided in an animal extract or product, or fraction thereof. In one such embodiment, the at least one C4-C10 saturated or unsaturated alphatic acid may comprise a naturally occurring aliphatic acid comprised in a plant oil extract, such as one or more of coconut oil, palm oil, palm kernel oil, corn oil, or fractions or extracts therefrom. In another such embodiment, the at least one C4-C10 saturated or unsaturated alphatic acid may comprise a naturally occurring aliphatic acid comprised in an animal extract or product, such as one or more of cow's milk, goat's milk, beef tallow, and/or cow or goat butter, or fractions or extracts thereof for example. In a particular embodiment, at least one C4-C10 saturated or unsaturated aliphatic acid may be provided as a component of one or more natural plant or animal material, or extract or fraction thereof. In a particular such embodiment, at least one C4-C10 saturated aliphatic acid may be provided in an extract or fraction of one or more plant oil extract, such as one or more of coconut oil, palm oil, palm kernel oil, corn oil, or fractions or extracts therefrom.

In some embodiments, an emulsifier or other surfactant may used in preparing pesticidal compositions according to aspects of the present disclosure. Suitable surfactants can be selected by one skilled in the art. Examples of surfactants that can be used in some embodiments of the present disclosure include, but are not limited to sodium lauryl sulfate, saponin, ethoxylated alcohols, ethoxylated fatty esters, alkoxylated glycols, ethoxylated fatty acids, ethoxylated castor oil, glyceryl oleates, carboxylated alcohols, carboxylic acids, ethoxylated alkylphenols, fatty esters, sodium dodecylsulfide, other natural or synthetic surfactants, and combinations thereof. In some embodiments, the surfactant(s) are non-ionic surfactants. In some embodiments, the surfactant(s) are cationic or anionic surfactants. In some embodiments, a surfactant may comprise two or more surface active agents used in combination. The selection of an appropriate surfactant depends upon the relevant applications and conditions of use, and selection of appropriate surfactants are known to those skilled in the art.

In one aspect, a pesticidal composition according to some embodiments of the present disclosure comprises one or more suitable carrier or diluent component. A suitable carrier or diluent component can be selected by one skilled in the art, depending on the particular application desired and the conditions of use of the composition. Commonly used carriers and diluents may include ethanol, isopropanol, isopropyl myristate, other alcohols, water and other inert carriers, such as but not limited to those listed by the EPA as a Minimal Risk Inert Pesticide Ingredients (4A) (the list of ingredients published dated December 2015 by the US EPA FIFRA 4a list published August 2004 entitled “List 4A—Minimal Risk Inert Ingredients”) or, for example, Inert Pesticide Ingredients (4B) (the US EPA FIFRA 4b list published August 2004 entitled “List 4B—Other ingredients for which EPA has sufficient information”) or under EPA regulation 40 CFR 180.950 dated May 24, 2002, each of which is hereby incorporated herein in its entirety for all purposes including for example, citric acid, lactic acid, glycerol, castor oil, benzoic acid, carbonic acid, ethoxylated alcohols, ethoxylated amides, glycerides, benzene, butanol, 1-propanol, hexanol, other alcohols, dimethyl ether, and polyethylene glycol.

In one embodiment according to the present disclosure, a method of enhancing the efficacy of a pesticide is provided. In one aspect, a method of enhancing the efficacy of a fungicide is provided. In another aspect, a method of enhancing the efficacy of a nematicide is provided. In a further aspect, a method of enhancing the efficacy of an insecticide is provided.

In one such embodiment, the method comprises providing a synergistic pesticidal composition comprising a pesticidal active ingredient and at least one C4-C10 saturated or unsaturated aliphatic acid (or in further embodiments, with one or more C11 or C12 saturated or unsaturated aliphatic acid) and exposing a pest to the resulting synergistic composition. In a particular exemplary embodiment, without being bound by any particular theory, the at least one C4-C10 saturated or unsaturated aliphatic acid may desirably be functional as a cell permeabilizing or cell membrane disturbing agent. In one aspect, the method comprises providing a fungicidal composition comprising a fungicidal active ingredient and at least one C4-C10 saturated or unsaturated aliphatic acid and exposing a fungus to the resulting synergistic composition. In another aspect, the method comprises providing a nematicidal composition comprising a nematicidal active ingredient and at least one C4-C10 saturated or unsaturated aliphatic acid and exposing a nematode to the resulting synergistic composition. In a further aspect, the method comprises providing an insecticidal composition comprising an insecticidal active ingredient and at least one C4-C10 saturated or unsaturated aliphatic acid and exposing an insect to the resulting synergistic composition.

In one embodiment according to the present disclosure, the at least one C4-C10 saturated or unsaturated aliphatic acid (or in further embodiments, with one or more C11 or C12 saturated or unsaturated aliphatic acid) provided in a pesticidal composition comprises an unsaturated aliphatic carbonyl alkene. In a particular such embodiment, without being bound by any particular theory, the at least one C4-C10 unsaturated aliphatic acid may desirably be functional as a cell permeabilizing or cell membrane disturbing agent. In one such embodiment, the cell permeabilizing agent comprises a carbonyl alkene having the general structure (1), (2) or (3), as shown in FIG. 1. In a further embodiment, the cell permeabilizing agent comprises at least one unsaturated aliphatic acid comprising at least one carboxylic group and having at least one unsaturated C—C bond.

In one exemplary embodiment, a method comprises providing a synergistic pesticidal composition comprising a pesticidal active ingredient and at least one C4-C10 saturated or unsaturated aliphatic acid (or in further embodiments, with one or more C11 or C12 saturated or unsaturated aliphatic acid) which is functional as a cell permeabilizing agent, and exposing a pest to the synergistic pesticidal composition to increase the amount of the pesticidal active ingredient that enters cells of the pest. In some such embodiments, the pesticidal active is a fungicide and the pest is a fungus, and without being bound by a particular theory, the at least one C4-C10 saturated or unsaturated aliphatic acid cell permeabilizing agent allows the fungicide to pass more easily through the fungal cell walls and membranes, and/or intracellular membranes. In some such embodiments, the pesticide is a nematicide and the pest is a nematode, and without being bound by a particular theory, the at least one C4-C10 saturated or unsaturated aliphatic acid cell permeabilizing agent allows the nematicide to pass more easily through the nematode cell and intracellular membranes. In some such embodiments, the pesticide is an insecticide, and without being bound by a particular theory, the at least one C4-C10 saturated or unsaturated aliphatic acid cell permeabilizing agent allows the insecticide to pass more easily through insect cuticle, chitin membrane, or cell or intracellular membranes.

In some embodiments, in addition to the actual synergistic action with respect to pesticidal activity, certain synergistic pesticidal compositions according to embodiments of the present disclosure can also desirably have further surprising advantageous properties. Examples of such additional advantageous properties may comprise one or more of: more advantageous degradability in the environment; improved toxicological and/or ecotoxicological behaviour such as reduced aquatic toxicity or toxicity to beneficial insects, for example.

In a further aspect, for any of the embodiments described above or below providing for a synergistic pesticidal composition comprising at least one pesticidal active and one or more C4-C10 saturated or unsaturated aliphatic acid or salt thereof, in an alternative embodiment, the synergistic pesticidal composition may alternatively comprise at least one pesticidal active and one or more C11 saturated or unsaturated aliphatic acid or salt thereof. In another aspect, for any of the embodiments described above providing for a synergistic pesticidal composition comprising at least one pesticidal active and one or more C4-C10 saturated or unsaturated aliphatic acid or salt thereof, in an alternative embodiment, the synergistic pesticidal composition may alternatively comprise at least one pesticidal active and one or more C12 saturated or unsaturated aliphatic acid or salt thereof.

EXPERIMENTAL METHODS

In accordance with an embodiment of the present disclosure, the combination of at least one C4-C10 saturated or unsaturated aliphatic acid (and in some embodiments alternatively at least one C11 or C12 saturated or unsaturated aliphatic acid) and a pesticidal active ingredient produces a synergistic pesticidal composition demonstrating a synergistic pesticidal effect. In some embodiments, the synergistic action between the pesticidal active ingredient, and the at least one C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid components of the pesticidal compositions according to embodiments of the present disclosure was tested using a Synergistic Growth Inhibition Assay, which is derived from and related to a checkerboard assay as is known in the art for testing of combinations of antimicrobial agents. In the Synergistic Growth Inhibition Assay used in accordance with some embodiments of the present disclosure, multiple dilutions of combinations of pesticidal active ingredient and at least one C4-C10 saturated or unsaturated aliphatic acid agents are tested in individual cells for inhibitory activity against a target pest or pathogenic organism. In one such embodiment, the combinations of pesticidal active ingredient and C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agents may preferably be tested in decreasing concentrations. In a further such embodiment, the combinations of pesticidal active ingredient and C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agents may be tested in increasing concentrations. These multiple combinations of the pesticidal active ingredient and at least one C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agents may be prepared in 96-well microtiter plates. In one such embodiment, the Synergistic Growth Inhibition Assay then comprises rows which each contain progressively decreasing concentrations of the pesticidal active ingredient and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agents to test for the MIC of the agents in combination at which growth of the target pest or pathogen is inhibited. Thus, each well of the microtiter plate is a unique combination of the two agents, at which inhibitory efficacy of the combination against the target pest or pathogen can be determined.

A method of determining and quantifying synergistic efficacy is by calculation of the “Fractional Inhibitory Concentration Index” or FIC index, as is known in the art for determining synergy between two antibiotic agents (see for example M. J. Hall et al., “The fractional inhibitory concentration (FIC) index as a measure of synergy”, J Antimicrob Chem., 11 (5):427-433, 1983, for example). In one embodiment according to the present disclosure, for each row of microtiter cells in the Synergistic Growth Inhibition Assay, the FIC index is calculated from the lowest concentration of the pesticidal active ingredient and one or more C4-C10 saturated or unsaturated aliphatic acid agents necessary to inhibit growth of a target pest or pathogen. The FIC of each component is derived by dividing the concentration of the agent present in that well of the microtiter plate by the minimal inhibitory concentration (MIC) needed of that agent alone to inhibit growth of the target pest or pathogen. The FIC index is then the sum of these values for both agents in that well of the microtiter plate. The FIC index is calculated for each row as follows:

FIC_index=MIC_a/MIC_A+MIC_b/MIC_B

where MIC_a, MIC_b are the minimal inhibitory concentration (MIC) of compounds A and B, respectively, when combined in the mixture of the composition, and MIC_A, MIC_B are the MIC of compounds A and B, respectively, when used alone. Fractional inhibitory concentration indices may then used as measure of synergy. When the lowest FIC index obtained in a microtiter plate in this way is less than 1 (FIC_index<1), the combination of the pesticidal active ingredient and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agents exhibits synergism, and indicates a synergistic pesticidal composition. When the FIC index is equal to 1, the combination is additive. FIC index values of greater than 4 are considered to exhibit antagonism.

In a particular embodiment, when the FIC index is equal or less than 0.5, the combination of the pesticidal active ingredient and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agents exhibits strong synergism. For example, in one embodiment, an FIC index of 0.5 may correspond to a synergistic pesticidal composition comprising a pesticidal agent at ¼ of its individual MIC, and one or more (or alternatively C11 or C12) C4-C10 saturated or unsaturated aliphatic acid agent at ¼ of its individual MIC.

In some embodiments of the present disclosure, the exemplary Synergistic Growth Inhibition Assay was conducted starting with an initial composition comprising a pesticidal active ingredient agent (compound A) at its individual MIC and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agent (compound B) at its individual MIC in the first well of a row on a 96 well microtiter plate. Then, serial dilutions of these initial compositions in successive wells in the row of the microtiter plate were used to assay the pesticidal composition under the same conditions to determine the concentration of the composition combining the two agents corresponding to the microtiter well in which growth inhibition of the target pest or organism ceases. The minimal inhibitory concentrations of each individual pesticidal active ingredient agent (compound A) and each of the one or more C4-C10 saturated or unsaturated aliphatic acid agent (as compound B) were determined in parallel with the compositions combining the two agents.

In some embodiments, Fusarium oxysporum was used as a representative pest organism or pathogen to determine synergy in pesticidal compositions comprising a pesticidal active ingredient agent (compound A) and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agent (compound B). Resazurin dye (also known as Alamar blue dye) was used as an indicator to determine the presence of growth or inhibition of growth of Fusarium oxysporum in the wells of the 96 well microtiter plates used in the exemplary Synergistic Growth Inhibition Assay. In addition to the color change of the resazurin dye in the presence of growth of the Fusarium oxysporum, an optical or visual examination of the microtiter well may also be made to additionally determine the presence of growth or inhibition of growth of the Fusarium oxysporum.

In other embodiments, Botrytis cinerea was used as a representative pest organism or pathogen to determine synergy in pesticidal compositions comprising a pesticidal active ingredient (compound A) and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agent (compound B). Similarly to as described above, Resazurin was used as an indicator of growth or inhibition of growth of Botrytis cinerea in the exemplary Synergistic Growth Inhibition Assay. In addition to the color change of the resazurin, an optical or visual examination of the microtiter well may also be made to additionally determine the presence of growth or inhibition of growth of the Botrytis cinerea.

In further embodiments, Sclerotinia sclerotiorum was used as a representative pest organism or pathogen to determine synergy in pesticidal compositions comprising a pesticidal active ingredient (compound A) and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agent (compound B). Similarly to as described above, Resazurin was used as an indicator of growth or inhibition of growth of Sclerotinia sclerotiorum in the exemplary Synergistic Growth Inhibition Assay. In addition to the color change of the resazurin, an optical or visual examination of the microtiter well may also be made to additionally determine the presence of growth or inhibition of growth of the Sclerotinia sclerotiorum.

Alternatively, other suitable representative pest or pathogen organisms may be used to determine synergy of combinations of pesticidal active ingredient agents and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agents in accordance with embodiments of the present disclosure. For example, other representative fungal pathogens may be used, such as but not limited to Leptosphaeria maculans, Sclerotinia spp. and Verticillium spp. In yet other examples, suitable non-fungal representative pests or pathogens may be used, such as insect, acari, nematode, bacterial, viral, mollusc or other pests or pathogens suitable for use in an MIC growth inhibition assay test method. All examples detailed below were tested according to the exemplary Synergistic Growth Inhibition Assay described above, using routine techniques for MIC determination known to those of skill in the art. Stock solutions of the pesticidal active ingredient agents and the one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agents were initially prepared in 100% dimethylsulfoxide (“DMSO”), and diluted to 10% DMSO using sterile potato dextrose broth (PDB) before further serial dilution to obtain the test solution concentrations for use in the microtiter plate wells, with exceptions in particular experimental examples noted in detail below. Accordingly, the maximum concentration of DMSO in the test solutions was limited to 10% DMSO or less, which was separately determined to be non-inhibitory to the growth of the representative fungal pests used in the test.

A culture of the representative fungal pathogen, namely Fusarium oxysporum, Botrytis cinerea, or Sclerotinia sclerotiorum, for example, is grown to exponential phase in potato dextrose broth (PDB). A 20 uL aliquot of homogenized mycelium from the culture is transferred to a well of a 96 well microtiter plate, and incubated for a period between 1 day and 7 days (depending on the pathogen and the particular assay reagents, as noted in the example descriptions below) with 180 uL of the test solution comprising the pesticidal and aliphatic acid agents in combination at a range of dilutions, to allow the mycelium to grow. Following the incubation period, 10 uL of resazurin dye is added to each well and the color in the solution is observed and compared to the color of the test solution at the same concentrations in wells without mycelial culture innoculum to control for effects of the test solution alone. The resazurin dye appears blue for wells with only the initial 20 uL culture where growth has been inhibited, and appears pink for wells where mycelial growth has occurred, as shown in FIG. 2, where the transition from blue to pink color can be clearly seen in each of the uppermost 4 rows of microtiter wells (labelled as 1-4 in FIG. 2) as the concentration of the pesticidal and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agents in the test solution decreases from left to right. In addition to the color change of the resazurin dye, growth or absence of growth of the mycelial culture is also observed visually or optically.

In accordance with this assay method, the Minimum Inhibitory Concentration is the lowest concentration at which growth is inhibited, and corresponds to the microtiter well in which the dye color is the same as for the control without culture and without growth, and/or in which a visual and/or optical inspection confirm that growth is inhibited.

EXPERIMENTAL EXAMPLES

Example 1: Growth Inhibition of Fusarium oxysporum by Pyraclostrobin in Combination with Several Exemplary C4-C10 Unsaturated Aliphatic Acids (or Agriculturally Acceptable Salts Thereof)

Sample Preparation:

10 mg of pyraclostrobin (available from Santa Cruz Biotechnology of Dallas, Tex. as stock #229020) was dissolved in 10 mL dimethylsulfoxide (DMSO) and the resulting solution was diluted 2-fold in DMSO to give a concentration of 0.5 mg/mL. This solution was diluted 10-fold in potato dextrose broth (PDB) to give a concentration of 0.05 mg/mL in 10% DMSO/90% PDB. The solubility of pyraclostrobin in 10% DMSO/90% PDB was determined to be 0.0154 mg/mL using high performance liquid chromatography (HPLC).

A solution of (2E,4E)-2,4-hexadienoic acid, potassium salt, was prepared by dissolving 2 g of (2E,4E)-2,4-hexadienoic acid, potassium salt, in 20 mL of PDB which was diluted further by serial dilution in PDB. A solution of (2E,4E)-2,4-hexadienoic acid (available from Sigma-Aldrich as stock #W342904) was prepared by dissolving 20 mg of (2E,4E)-2,4-hexadienoic acid in 1 mL DMSO and adding 0.1 mL to 0.9 mL PDB resulting in a 2 mg/mL solution of (2E,4E)-2,4-hexadienoic acid in 10% DMSO/90% PDB which was diluted further by serial dilution in PDB.

A solution of trans-2-hexenoic acid (available from Sigma-Aldrich as stock #W316903) was prepared by dissolving 100 mg trans-2-hexenoic acid in 1 mL DMSO and adding 0.1 mL to 0.9 mL PDB resulting in a 10 mg/mL solution in 10% DMSO/90% PDB which was diluted further by serial dilution in PDB. A solution of trans-3-hexenoic acid (available from Sigma-Aldrich as stock #W317004) was prepared by adding 20 uL trans-3-hexenoic acid to 1980 uL PDB and the resulting solution was serially diluted in PDB. The density of trans-3-hexenoic acid was assumed to be 0.963 g/mL.

Combinations of pyraclostrobin and one or more exemplary C4-C10 saturated or unsaturated aliphatic acids (and agriculturally acceptable salts thereof) were prepared by adding 0.5 mL of 0.0308 mg/mL pyraclostrobin to 0.5 mL of 1.25 mg/mL (2E,4E)-2,4-hexadienoic acid, potassium salt, (combination 1), 0.5 mL of 0.25 mg/mL (2E,4E)-2,4-hexadienoic acid (combination 2), 0.5 mL of 0.625 mg/mL (2E,4E)-2,4-hexadienoic acid (combination 3), 0.5 mL of 1.25 mg/mL of trans-2-hexenoic acid (combination 4), or 0.5 mL of 0.6019 mg/mL trans-3-hexenoic acid (combination 5). Each combination was tested over a range of 2-fold dilutions in the Synergistic Growth Inhibition Assay detailed above, observed following a 24 hour incubation period, and the FIC Index for each combination calculated, as shown below in Table 1.

TABLE 1
Growth inhibition of Fusarium oxysporum by pyraclostrobin in combination with several
exemplary unsaturated aliphatic acids (or agriculturally acceptable salts thereof).
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0154
		(2E,4E)-2,4-hexadienoic		0.625
		acid, potassium salt
		(2E,4E)-2,4-hexadienoic		0.125
		acid
		Trans-2-hexenoic acid		0.3125
		Trans-3-hexenoic acid		0.3125
1	Pyraclostrobin	(2E,4E)-2,4-hexadienoic	0.00385	0.1563	40	0.50
		acid, potassium salt
2	Pyraclostrobin	(2E,4E)-2,4-hexadienoic	0.00385	0.03125	20	0.50
		acid
3	Pyraclostrobin	(2E,4E)-2,4-hexadienoic	0.001925	0.03906	8	0.44
		acid
4	Pyraclostrobin	Trans-2-hexenoic acid	0.00385	0.1563	40	0.75
5	Pyraclostrobin	Trans-3-hexenoic acid	0.00385	0.07813	20	0.50

Example 2: Growth Inhibition of Fusarium oxysporum by Fludioxonil in Combination with Several Exemplary Unsaturated Aliphatic Acids (or Agriculturally Acceptable Salts Thereof)

Sample Preparation:

20 mg of fludioxonil (available from Shanghai Terppon Chemical Co. Ltd., of Shanghai, China) was dissolved in 10 mL dimethylsulfoxide (DMSO) and the resulting solution was diluted 2-fold in DMSO to give a concentration of 1 mg/mL. This solution was diluted 10-fold in potato dextrose broth (PDB) to give a concentration of 0.1 mg/mL in 10% DMSO/90% PDB. The solubility of fludioxonil in 10% DMSO/90% PDB was determined to be 0.0154 mg/mL using HPLC.

A solution of (2E,4E)-2,4-hexadienoic acid, potassium salt, was prepared by dissolving 2 g of (2E,4E)-2,4-hexadienoic acid, potassium salt, in 20 mL of PDB which was diluted further by serial dilution in PDB. A solution of (2E,4E)-2,4-hexadienoic acid (available from Sigma-Aldrich as #W342904) was prepared by dissolving 20 mg of (2E,4E)-2,4-hexadienoic acid in 1 mL DMSO and adding 0.1 mL to 0.9 mL PDB resulting in a 2 mg/mL solution of (2E,4E)-2,4-hexadienoic acid in 10% DMSO/90% PDB which was diluted further by serial dilution in PDB.

A solution of trans-2-hexenoic acid (available from Sigma-Aldrich as stock #W316903) was prepared by dissolving 100 mg trans-2-hexenoic acid in 1 mL DMSO and adding 0.1 mL to 0.9 mL PDB resulting in a 10 mg/mL solution in 10% DMSO/90% PDB which was diluted further by serial dilution in PDB. A solution of trans-3-hexenoic acid (available from Sigma-Aldrich as stock #W317004) was prepared by adding 20 uL trans-3-hexenoic acid to 1980 uL PDB and the resulting solution was serially diluted in PDB. The density of trans-3-hexenoic acid was assumed to be 0.963 g/mL.

Combinations of compounds A and B as shown below in Table 2 were prepared by adding 0.5 mL of 9.63×10−4 mg/mL fludioxonil to each of 0.5 mL of 0.625 mg/mL (2E,4E)-2,4-hexadienoic acid, potassium salt, (combination 1), 0.5 mL of 0.25 mg/mL (2E,4E)-2,4-hexadienoic acid (combination 2), 0.5 mL of 0.625 mg/mL of trans-2-hexenoic acid (combination 3), and 0.5 mL of 0.6019 mg/mL trans-3-hexenoic acid (combination 4). Each combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following a 24 hour incubation period, and the FIC Index for each combination calculated, as shown below in Table 2.

TABLE 2
Growth inhibition of Fusarium oxysporum by fludioxonil in combination with several
exemplary unsaturated aliphatic acids (or agriculturally acceptable salts thereof).
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Fludioxonil		4.8125 × 10−4
		(2E,4E)-2,4-hexadienoic		0.625
		acid, potassium salt
		(2E,4E)-2,4-hexadienoic		0.125
		acid
		Trans-2-hexenoic acid		0.3125
		Trans-3-hexenoic acid		0.3125
1	Fludioxonil	(2E,4E)-2,4-hexadienoic	6.0188 × 10−5	0.03906	649	0.19
		acid, potassium salt
2	Fludioxonil	(2E,4E)-2,4-hexadienoic	6.0188 × 10−5	0.01563	260	0.25
		acid
3	Fludioxonil	Trans-2-hexenoic acid	1.2038 × 10−4	0.07813	649	0.5
4	Fludioxonil	Trans-3-hexenoic acid	1.2038 × 10−4	0.07813	649	0.5

Example 3: Growth Inhibition of Fusarium oxysporum by Fludioxonil in Combination with Several Exemplary Unsaturated Aliphatic Acids

Sample Preparation:

20 mg fludioxonil (available from Shanghai Terppon Chemical Co. Ltd., of Shanghai, China) was dissolved in 10 mL dimethylsulfoxide (DMSO) and the resulting solution was diluted 2-fold in DMSO to give a concentration of 1 mg/mL. This solution was diluted 10-fold in potato dextrose broth (PDB) to give a concentration of 0.1 mg/mL in 10% DMSO/90% PDB. The solubility of fludioxonil in 10% DMSO/90% PDB was determined to be 0.0154 mg/mL using HPLC.

Stock solutions of several exemplary C4-C10 unsaturated aliphatic acids as Compound B for testing individual MICs were prepared at 25 uL/mL in DMSO by adding 25 uL of each Compound B to 975 uL DMSO, followed by 10-fold dilution in PDB, for each of 3-octenoic acid (available from Sigma-Aldrich as stock #CDS000466), trans-2-octenoic acid (available from Sigma-Aldrich), 9-decenoic acid (available from Sigma-Aldrich as #W366005), 3-decenoic acid (available from Sigma-Aldrich as stock #CDS000299), and trans-2-decenoic acid (available from TCI America as stock #D0098).

For testing in combination with fludioxonil, solutions of 3-octenoic acid, trans-2-octenoic acid, and 9-decenoic acid were prepared at 0.78 uL/mL in DMSO by adding 3.125 uL of each Compound B to 2 mL of DMSO, followed by 2-fold dilution in DMSO to give 0.78 uL/mL. Solutions of 3-decenoic acid and trans-2-decenoic acid were prepared similarly, but applying a further 2-fold dilution in DMSO to give a concentration of 0.39 uL/mL in DMSO.

Each of these resulting stock solutions were then diluted 10-fold in PDB to give solutions of 0.078 uL/mL for each of 3-octenoic acid, trans-2-octenoic acid, and 9-decenoic acid, and to give solutions of 0.039 uL/mL for each of 3-decenoic acid and trans-2-decenoic acid, all in 10% DMSO/90% PDB. Combinations of the exemplary Compound B components with fludioxonil were prepared by adding 0.5 mL of 0.078 uL/mL of each of 3-octenoic acid, trans-2-octenoic acid, and 9-decenoic acid or 0.039 uL/mL of each of 3-decenoic acid and trans-2-decenoic acid, to 0.5 mL of 4.813×10⁻⁴ mg/mL fludioxonil obtained from serial dilution of 0.0154 mg/mL of fludioxonil in 10% DMSO/90% PDB, as prepared above, with PDB. The density of 3-octenoic acid was assumed to be 0.938 g/mL. The density of trans-2-octenoic acid was assumed to be 0.955 g/mL. The density of 3-decenoic acid was assumed to be 0.939 g/mL. The density of trans-2-decenoic acid was assumed to be 0.928 g/mL. The density of 9-decenoic acid was assumed to be 0.918 g/mL.

Each combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following a 24 hour incubation period, and the FIC Index for each combination calculated, as shown below in Table 3.

TABLE 3
Growth inhibition of Fusarium oxysporum by fludioxonil in combination
with several exemplary unsaturated aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Fludioxonil		2.4063 × 10−4
		3-Octenoic acid		0.1466
		Trans-2-octenoic acid		0.1492
		3-Decenoic acid		0.07336
		Trans-2-decenoic acid		0.03625
		9-Decenoic acid		0.07172
1	Fludioxonil	3-Octenoic acid	1.2031 × 10−4	0.01832	152	0.63
2	Fludioxonil	Trans-2-octenoic acid	1.2031 × 10−4	0.01865	155	0.63
3	Fludioxonil	3-Decenoic acid	1.2031 × 10−4	0.00917	76	0.63
4	Fludioxonil	Trans-2-decenoic acid	1.2031 × 10−4	0.00906	75	0.75
5	Fludioxonil	9-Decenoic acid	1.2031 × 10−4	0.01793	149	0.75

Example 4: Growth Inhibition of Fusarium oxysporum by Thyme Oil in Combination in Combination with Several Exemplary Unsaturated Aliphatic Acids

Sample Preparation:

12.5 mg of thyme oil (available from Sigma-Aldrich as stock #W306509) was dissolved in 1 g dimethylsulfoxide (DMSO) and the resulting solution was diluted 10-fold in PDB to give a concentration of 1.25 mg/mL 10% DMSO/90% PDB.

Stock solutions of several exemplary C4-C10 unsaturated aliphatic acids as Compound B for testing individual MICs were prepared at 25 μL/mL by adding 25 μL of each of 3-octenoic acid (available from Sigma-Aldrich as stock #CDS000466), trans-2-octenoic acid (available from Sigma-Aldrich as stock #CDS000466), 9-decenoic acid (available from Sigma-Aldrich as stock #W366005), 3-decenoic acid (available from Sigma-Aldrich as stock #CDS000299), and trans-2-decenoic acid (available from TCI America as stock #D0098), to 975 μL DMSO followed by 10-fold dilution in PDB.

Stock solutions of the exemplary C4-C10 unsaturated aliphatic acids as Compound B for testing in combination with thyme oil were prepared by adding 3.125 μL of each of 3-octenoic acid, trans-2-octenoic acid, and 9-decenoic acid, to 2 mL of DMSO followed by 2-fold dilution in DMSO to give a 0.78 L/mL concentration stock solution. Solutions of 3-decenoic acid and trans-2-decenoic acid were prepared similarly, but applying a further 2-fold dilution in DMSO to give a concentration of 0.39 μL/mL. Each of these resulting stock solutions were then diluted 10-fold dilution in PDB to give solutions of 0.078 μL/mL (for each of 3-octenoic acid, trans-2-octenoic acid, and 9-decenoic acid) and 0.039 L/mL (for 3-decenoic acid and trans-2-decenoic acid) in 10% DMSO/90% PDB.

Combinations of the exemplary Compound B components with thyme oil were prepared by adding 0.5 mL of 0.078 i/mL of each of 3-octenoic acid, trans-2-octenoic acid, and 9-decenoic acid or 0.039 μL/mL of each of 3-decenoic acid and trans-2-decenoic acid, to 0.5 mL of 1.25 mg/mL thyme oil in 10% DMSO/90% PDB. The density of 3-octenoic acid was assumed to be 0.938 g/mL. The density of trans-2-octenoic acid was assumed to be 0.955 g/mL. The density of 3-decenoic acid was assumed to be 0.939 g/mL. The density of trans-2-decenoic acid was assumed to be 0.928 g/mL. The density of 9-decenoic acid was assumed to be 0.918 g/mL

Each combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following a 24 hour incubation period, and the FIC Index for each combination calculated, as shown below in Table 4.

TABLE 4
Growth inhibition of Fusarium oxysporum by thyme oil in combination
in combination with several exemplary unsaturated aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Thyme oil		1.25
		3-Octenoic acid		0.14656
		Trans-2-octenoic acid		0.14922
		3-Decenoic acid		0.07336
		Trans-2-decenoic acid		0.03625
		9-Decenoic acid		0.07172
1	Thyme oil	3-Octenoic acid	0.3125	0.01832	0.059	0.38
2	Thyme oil	Trans-2-octenoic acid	0.3125	0.01865	0.060	0.38
3	Thyme oil	3-Decenoic acid	0.3125	0.00917	0.029	0.38
4	Thyme oil	Trans-2-decenoic acid	0.3125	0.00906	0.029	0.50
5	Thyme oil	9-Decenoic acid	0.3125	0.01793	0.057	0.50

Example 5: Growth Inhibition of Botrytis cinerea by Neem Oil Limonoid Extract (Extracted from Cold-Pressed Neem Oil) and Fortune Aza Technical (Azadirachtin Extract) in Combination with Various Exemplary Unsaturated Aliphatic Acids

Sample Preparation:

An extract of limonoids was prepared from cold-pressed neem oil using solvent extraction with hexane and methanol to prepare a neem oil limonoid extract. Fortune Aza Technical pesticide containing 14% azadirachtin (extracted from neem seed/kernel source) was obtained from Fortune Biotech Ltd. of Secunderabad, India.

Solutions of neem oil limonoid extract and Fortune Aza Technical were prepared at 5 mg/mL in DMSO followed by ten-fold dilution in PDB to give a concentration of 0.5 mg/mL in 10% DMSO/90% PDB.

Stock solutions of 3-octenoic acid and trans-2-octenoic acid as Compound B for testing of individual MICs were prepared at 25 μL/mL by adding 25 μL of each Compound B to 975 μL DMSO followed by 10-fold dilution in PDB.

For testing in combination with neem oil limonoid extract and Fortune Aza Technical, stock solutions of 3-octenoic acid and trans-2-octenoic acid were prepared at 6.25 L/mL by adding 62.5 μL of the respective compound to 937.5 μL of DMSO followed by 10-fold dilution in PDB (ratio 11.7). Stock solutions of 3-octenoic acid and trans-2-octenoic acid were prepared at 3.125 L/mL for testing in combination by adding 31.25 μL of the respective compound to 968.75 μL of DMSO followed by 10-fold dilution in PDB (ratio 6.0 or 5.9). Stock solutions of 3-octenoic acid and trans-2-octenoic acid at 0.625 L/mL for testing in combination were prepared by adding 6.25 μL of the respective compound to 993.75 μL of DMSO followed by 10-fold dilution in PDB (ratio 1.2). The density of 3-octenoic acid was assumed to be 0.938 g/mL. The density of trans-2-octenoic acid was assumed to be 0.955 g/mL. Combinations were prepared by adding 0.5 mL of 6.25 μL/mL, 3.125 μL/mL, or 0.625 μL/mL 3-octenoic acid ortrans-2-octenoic acid, as prepared above (as Compound B), to 0.5 mL neem oil limonoid extract or Fortune Aza Technical at 0.5 mg/mL in acid DMSO/90% PDB (as Compound A) for testing in the synergistic growth inhibition assay. Each combination was observed following a 24 hour incubation period, and the FIC Index for each combination calculated, as shown below in Tables 5 and 6.

TABLE 5
Growth inhibition of Botrytis cinerea by limonoid extract from cold-pressed
neem oil in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Neem oil		0.25
	limonoid extract
		3-octenoic acid		0.14656
		Trans-2-octenoic acid		0.07461
1	Neem oil	3-octenoic acid	0.0078125	0.09160	11.7	0.66
	limonoid extract
2	Neem oil	3-octenoic acid	0.015625	0.09160	5.9	0.69
	limonoid extract
3	Neem oil	3-octenoic acid	0.0625	0.07656	1.2	0.75
	limonoid extract
4	Neem oil	Trans-2-octenoic acid	0.0078125	0.04663	6.0	0.66
	limonoid extract
5	Neem oil	Trans-2-octenoic acid	0.03125	0.03730	1.2	0.63
	limonoid extract

TABLE 6
Growth inhibition of Botrytis cinerea by Fortune Aza Technical
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Fortune Aza		0.25
	Tech.
		3-octenoic acid		0.14656
		Trans-2-octenoic acid		0.07461
1	Fortune Aza	3-octenoic acid	0.0078125	0.09160	11.7	0.66
	Tech.
2	Fortune Aza	3-octenoic acid	0.015625	0.09160	5.9	0.69
	Tech.
3	Fortune Aza	3-octenoic acid	0.0625	0.07656	1.2	0.75
	Tech.
4	Fortune Aza	Trans-2-octenoic acid	0.0078125	0.04663	6.0	0.66
	Tech.
5	Fortune Aza	Trans-2-octenoic acid	0.03125	0.03730	1.2	0.63
	Tech.

Example 6: Growth Inhibition of Fusarium oxysporum by Fludioxonil in Combination with Various Exemplary Saturated Aliphatic Acids

Sample Preparation:

20 mg fludioxonil was dissolved in 10 mL dimethylsulfoxide (DMSO) and the resulting solution was diluted 2-fold in DMSO to give a concentration of 1 mg/mL. This solution was diluted 10-fold in potato dextrose broth (PDB) to give a concentration of 0.1 mg/mL in 10% DMSO/90% PDB. The solubility of fludioxonil in 10% DMSO/90% PDB was determined to be 0.0154 mg/mL using high performance liquid chromatography. A solution of 0.000963 mg/mL fludioxonil was prepared by adding 625 μL of 0.0154 mg/mL fludioxonil to 9375 μL of PDB.

For testing individual MICs, stock solutions of hexanoic acid or octanoic acid as Component B were prepared by adding 100 μL hexanoic acid (93 mg) or octanoic acid (91 mg) to 900 μL PDB resulting in concentrations of 9.3 mg/mL and 9.1 mg/mL, respectively. A stock solution of decanoic acid was prepared at 10 mg/mL in DMSO followed by 10-fold dilution in PDB producing a concentration of 1 mg/mL in 10% DMSO/90% PDB. The stock solution of decanoic acid, potassium salt, was prepared by adding 100 mg to 10 mL of PDB resulting in a concentration of 10 mg/mL. A stock solution of dodecanoic acid was prepared at 1 mg/mL in DMSO followed by 10-fold dilution in PDB producing a concentration of 0.1 mg/mL in 10% DMSO/90% PDB.

For testing MICs of combinations, a solution of hexanoic acid at 0.29 mg/mL was prepared by adding 156 μL of the 9.3 mg/mL stock solution to 4844 μL PDB. Similarly, a solution of octanoic acid at 1.14 mg/mL was prepared diluting the 9.1 mg/mL stock solution in PDB. A solution of decanoic acid at 0.5 mg/mL was prepared by 2-fold dilution of the 1 mg/mL stock solution. A solution of decanoic acid, potassium salt, at 0.156 mg/mL was prepared by adding 78 μL of the 10 mg/mL stock solution to 4922 μL PDB. A solution of dodecanoic acid at 0.2 mg/mL was prepared by dissolving 2 mg in 1 mL DMSO followed by 10-fold dilution in PDB at 40° C.

Combinations for results shown in Table 7 were prepared by adding 0.5 mL of 0.0154 mg/mL fludioxonil to 0.5 mL of each of the stock solutions. Each combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following a 24 hour incubation period, and the FIC Index for each combination calculated, as shown below in Table 7.

TABLE 7
Growth inhibition of Fusarium oxysporum by fludioxonil in combination
with various exemplary saturated aliphatic acids (and salts thereof).
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Fludioxonil		4.8125 × 10−4
		Hexanoic acid		0.14531
		Octanoic acid		0.56875
		Decanoic acid		0.25
		Decanoic acid,		0.078125
		potassium salt
		Dodecanoic acid		0.1
1	Fludioxonil	Hexanoic acid	1.20375 × 10−4	0.00114	10	0.26
2	Fludioxonil	Octanoic acid	1.20375 × 10−4	0.00444	37	0.26
3	Fludioxonil	Decanoic acid	1.20375 × 10−4	0.00195	16	0.26
4	Fludioxonil	Decanoic acid,	1.20375 × 10−4	0.00061	5	0.26
		potassium salt
5	Fludioxonil	Dodecanoic acid	1.20375 × 10−4	0.00078	7	0.26

Combinations for results shown in Table 8 were prepared by adding 0.5 mL of 0.000963 mg/mL fludioxonil to 0.5 mL of each of the stock solutions.

TABLE 8
Growth inhibition of Fusarium oxysporum by fludioxonil in
combination with various exemplary saturated aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Fludioxonil		4.8125 × 10−4
		Hexanoic acid		0.29
		Octanoic acid		1.14
		Decanoic acid		0.25
		Decanoic acid,		0.078125
		potassium salt
		Dodecanoic acid		0.1
1	Fludioxonil	Hexanoic acid	1.20375 × 10−4	0.03633	309	0.38
2	Fludioxonil	Octanoic acid	1.20375 × 10−4	0.14219	1181	0.38
3	Fludioxonil	Decanoic acid	1.20375 × 10−4	0.0625	519	0.5
4	Fludioxonil	Decanoic acid,	1.20375 × 10−4	0.01953	162	0.5
		potassium salt
5	Fludioxonil	Dodecanoic acid	1.20375 × 10−4	0.025	208	0.5

Example 7: Growth Inhibition of Fusarium oxysporum by Limonoid Extract from Cold-Pressed Neem Oil and Fortune Aza Technical (Azadirachtin Extract) in Combination with Various Exemplary Saturated Aliphatic Acids

Sample Preparation:

An extract of limonoids was prepared from cold-pressed neem oil using solvent extraction with hexane and methanol to prepare a neem oil limonoid extract. Fortune Aza Technical pesticide containing 14% azadirachtin (extracted from neem seed/kernel source) was obtained from Fortune Biotech Ltd. of Secunderabad, India (also referred to as “Azatech”). Solutions of neem oil limonoid extract and Fortune Aza Technical were prepared at 5 mg/mL in DMSO followed by ten-fold dilution in PDB to give a concentration of 0.5 mg/mL in 10% DMSO/90% PDB. These solutions were used for testing the individual MICs.

For testing the individual MIC of octanoic acid, a solution was prepared by adding 100 uL octanoic acid (91 mg) to 900 uL PDB resulting in concentrations of 9.1 mg/mL. A stock solution of decanoic acid was prepared at 10 mg/mL in DMSO followed by 10-fold dilution in PDB producing a concentration of 1 mg/mL in 10% DMSO/90% PDB.

Combinations with octanoic acid were prepared by dissolving 5 mg neem oil limonoid extract or Fortune Aza Technical in 1 mL of DMSO and adding 6.25 uL octanoic acid (d=0.91 g/mL) followed by 10-fold dilution in PDB. This produced a solution containing 0.5 mg/mL neem oil limonoid extract or Fortune Aza Technical and 0.56875 mg/mL octanoic acid. Combinations with decanoic acid were prepared by dissolving 5 mg neem oil limonoid extract or Fortune Aza Technical in 1 mL of DMSO and adding 2.5 mg of decanoic acid followed by 10-fold dilution in PDB. This produced a solution containing 0.5 mg/mL neem oil limonoid extract or Fortune Aza Technical and 0.25 mg/mL decanoic acid.

Each combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following a 24 hour incubation period, and the FIC Index for each combination calculated, as shown below in Table 9.

TABLE 9
Growth inhibition of Fusarium oxysporum by neem oil limonoid extract or Fortune Aza
Technical (Azatech) in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Neem oil		0.5
	limonoid extract
	Azatech		0.5
		Octanoic acid		0.56875
		Decanoic acid		0.25
1	Neem oil	Octanoic acid	0.0625	0.07109	1.14	0.25
	limonoid extract
2	Neem oil	Decanoic acid	0.125	0.0625	0.5	0.5
	limonoid extract
3	Fortune	Octanoic acid	0.0625	0.07109	1.14	0.25
	Aza Tech.
4	Fortune	Decanoic acid	0.125	0.0625	0.5	0.5
	Aza Tech.

Sample Preparation for Examples 8-34

For each of experimental Examples 8-34 described below, concentrated stock solutions, and diluted working solutions were prepared for each of the exemplary pesticidal active ingredients as Component A, and each of the exemplary unsaturated and saturated aliphatic acids as Component B, in accordance with the following descriptions:

Compound A Pesticidal Active Ingredients:

Concentrated stock solutions were prepared by dissolving pesticidal active ingredient in 100% dimethylsulfoxide (DMSO), which were then diluted 10-fold in potato dextrose broth (PDB) to give a working stock solution, as described below:

Pyraclostrobin (available from Santa Cruz Biotech, Dallas, Tex., USA, as stock 4 SC-229020): A 0.5 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.05 mg/mL working stock solution, for which an effective solubilized concentration of 0.015 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.015 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Azoxystrobin (available from Sigma-Aldrich, St. Louis, Mo., USA, as stock #31697): A 1.75 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.175 mg/mL working stock solution, for which an effective solubilized concentration of 0.15 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.15 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Chlorothalonil (available from Chem Service Inc., West Chester, Pa., USA, as stock #N-11454): A 0.5 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.05 mg/mL working stock solution, for which an effective solubilized concentration of 0.002 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.002 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Fludioxonil (available from Shanghai Terppon Chemical Co. Ltd., of Shanghai, China): A 1.05 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.105 mg/mL working stock solution, for which an effective solubilized concentration of 0.021 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.021 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Cyprodinil (available from Shanghai Terppon Chemical Co. Ltd., of Shanghai, China): A 1.37 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.137 mg/mL working stock solution, for which an effective solubilized concentration of 0.009 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.009 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Metalaxyl: A 3.32 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.332 mg/mL working stock solution, for which an effective solubilized concentration of 0.316 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.316 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Difenoconazole (available from Santa Cruz Biotech, Dallas, Tex., USA, as stock no. SC-204721): A 1.3 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.13 mg/mL working stock solution, for which an effective solubilized concentration of 0.051 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.051 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Propiconazole (available from Shanghai Terppon Chemical Co. Ltd., of Shanghai, China): A 1.0 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.10 mg/mL working stock solution, for which an effective solubilized concentration of 0.089 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.089 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Epoxiconazole (available from Shanghai Terppon Chemical Co. Ltd., of Shanghai, China): A 2.5 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.25 mg/mL working stock solution, for which an effective solubilized concentration of 0.03 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.025 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Tebuconazole (available from Shanghai Terppon Chemical Co. Ltd., of Shanghai, China): A 5.0 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.50 mg/mL working stock solution, for which an effective solubilized concentration of 0.45 mg/mL was verified using high performance liquid chromatography (HPLC). This 0.45 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in Tables the tables below.

Picoxystrobin (available from Sigma Aldrich, #33658): A 5.0 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.50 mg/mL working picoxystrobin stock solution, which was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Isopyrazam (available from Sigma Aldrich, #32532): A 5.0 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.50 mg/mL working isopyrazam stock solution, which was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Penthiopyrad (available from aksci.com, #X5975): A 5.0 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.50 mg/mL working penthiopyrad stock solution, which was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Oxathiapiprolin (available from carbosynth.com, #FO159014): A 5.0 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.50 mg/mL working oxathiapiprolin stock solution, which was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Prothioconazole (available from Sigma Aldrich, #34232): A 5.0 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.50 mg/mL working prothioconazole stock solution, which was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Trifloxystrobin (available from Sigma Aldrich, #46447): A 5.0 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.50 mg/mL working trifloxystrobin stock solution, which was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Mancozeb (available from Sigma Aldrich, #45553): A 5.0 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a nominal 0.50 mg/mL working penthiopyrad stock solution, which was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Thyme oil (available from Sigma-Aldrich, St. Louis, Mo., USA as stock #W306509), garlic oil (available from New Directions Aromatics, Missisauga, ON, Canada), lemongrass oil (available from Xenex Labs, Coquitlam, BC, Canada as stock #OL123), wintergreen oil (available from Xenex Labs, Coquitlam, BC, Canada as stock #OW134), peppermint oil (available from Xenex Labs, Coquitlam, BC, Canada as stock #OP1531), spearmint oil (available from Xenex Labs, Coquitlam, BC, Canada as stock #AS132), clove leaf oil (available from New Directions Aromatics, Missisauga, ON, Canada), cinnamon leaf oil (available from Xenex Labs, Coquitlam, BC, Canada as stock #OC2131), tea tree oil (available from Newco Natural Technology, Calgary, AB, Canada), geranium oil (available from Xenex Labs, Coquitlam, BC, Canada as stock #OW134), peppermint oil (available from Xenex Labs, Coquitlam, BC, Canada as stock #OG1042), rosemary oil (available from Xenex Labs of Coquitlam, BC, Canada as stock #OR131), and oregano oil (available from New Directions Aromatics, Missisauga, ON, Canada): A 100 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 10 mg/mL concentration. This 10 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below. Nootkatone(+) (available from Alfa Aesar, Ward Hill, Mass., USA as stock #A19166): A 10 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 1.0 mg/mL concentration. This 1.0 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in Tables 10-111 below.

Neem oil limonoid extract: An extract of limonoids was prepared from cold-pressed neem oil using solvent extraction with hexane and methanol to prepare a neem oil limonoid extract. A 5 mg/mL stock solution of neem oil limonoid extract in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 0.5 mg/mL concentration. This 0.5 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Fortune Aza Technical: Fortune Aza Technical™ pesticide containing 14% azadirachtin (extracted from neem seed/kernel source) was obtained from Fortune Biotech Ltd. of Secunderabad, India. A 5 mg/mL stock solution of Fortune Aza Technical in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 0.5 mg/mL concentration. This 0.5 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Karanja oil flavonoid extract: An extract of flavonoids was prepared from cold-pressed karanja oil by solvent extraction. A 5 mg/mL stock solution of karanja oil flavonoid extract in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 0.5 mg/mL concentration. This 0.5 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Salannin: Salannin was extracted and purified from cold-pressed neem oil by solvent extraction. A 1 mg/mL stock solution of salannin in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 0.1 mg/mL concentration. This 0.1 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Compound B Unsaturated Aliphatic Acids:

Concentrated stock solutions were prepared by dissolving each exemplary unsaturated aliphatic acid in 100% dimethylsulfoxide (DMSO), which were then diluted 10-fold in potato dextrose broth (PDB) to give a working stock solution, as described below:

Trans-2-hexenoic acid, trans-3-hexenoic acid, cis-3-hexenoic acid, 5-hexenoic acid, 3-heptenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, 3-octenoic acid, 7-octenoic acid, 3-decenoic acid, cis-3-decenoic acid, 9-decenoic acid, trans-2-nonenoic acid, 3-nonenoic acid, (9Z)-octadecenoic acid (oleic acid) (all available from Sigma-Aldrich, St. Louis, Mo., USA), trans-2-decenoic acid (available from TCI America, Portland, Oreg., USA as stock #D0098), cis-2-decenoic acid (available from BOC Sciences, Sirley, N.Y., USA), and trans-2-undecenoic acid (available from Alfa Aesar, Ward Hill, Mass., USA as stock #L-11579): A 50 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 5 mg/mL concentration. This 5 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

(2E,4E)-2,4-hexadienoic acid (available from Sigma-Aldrich, St. Louis, Mo., USA): A 20 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 2 mg/mL concentration. This 2 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in the tables below.

Compound B Saturated Aliphatic Acids:

Concentrated stock solutions were prepared by dissolving each exemplary saturated aliphatic acid in 100% dimethylsulfoxide (DMSO), which were then diluted 10-fold in potato dextrose broth (PDB) to give a working stock solution, as described below:

Hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid (all available from Sigma-Aldrich, St. Louis, Mo., USA): A 50 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 5 mg/mL concentration. This 5 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in data Tables below.

Decenoic acid (available from Sigma-Aldrich, St. Louis, Mo., USA): A 10 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 1 mg/mL concentration. This 1 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in data Tables below.

Dodecenoic acid (available from Sigma-Aldrich, St. Louis, Mo., USA): A 1 mg/mL stock solution in 100% DMSO was diluted 10-fold in PDB to provide a working stock solution of 0.1 mg/mL concentration. This 0.1 mg/mL effective concentration working stock solution was used for further serial dilution in PDB to the required individual concentrations as specified in data Tables below.

Exemplary Hydroxy-substituted aliphatic acids: 2- and 3-hydroxybutyric acid, 2-hydroxyhexanoic acid, 12-hydroxydodecanoic acid (all available from Sigma-Aldrich, St. Louis, Mo., USA); 3-hydroxydecanoic acid, 3-hydroxyhexanoic acid (both available from Shanghai Terppon Chemical, Shanghai, China); 3-, 8-, 10-hydroxyoctanoic acid (all available from AA Blocks LLC, San Diego, Calif., USA), 2-hydroxyoctanoic acid (available from Alfa Aesar, Ward Hill, Mass., USA): a stock solution was prepared for each by dissolving each acid in 100% DMSO, which was then diluted in PDB to 10% DMSO concentration, before further serial dilution in PDB to the required individual concentrations as specified in the data Tables below.

Exemplary alkyl-substituted aliphatic acids: 2-ethylhexanoic acid, 2-methyloctanoic acid, 3-methylnonanoic acid, 3-methylbutyric acid (all available from Sigma-Aldrich, St. Louis, Mo., USA); 2,2-diethylbutyric acid, 2- and 4-methylhexanoic acid, 2-methyldecanoic acid (all available from AA Blocks LLC, San Diego, Calif., USA); 3-methylhexanoic acid (available from 1 ClickChemistry Inc., Kendall Park, N.J., USA): a stock solution was prepared for each by dissolving each acid in 100% DMSO, which was then diluted in PDB to 10% DMSO concentration, before further serial dilution in PDB to the required individual concentrations as specified in the data Tables below.

Exemplary amino-substituted aliphatic acid: 3-aminobutyric acid (available from AK Scientific Inc., Union City, Calif., USA): a stock solution was prepared by dissolving each acid in 100% DMSO, which was then diluted in PDB to 10% DMSO concentration, before further serial dilution in PDB to the required individual concentrations as specified in the data Tables below.

The working stock solutions for each Compound A and Compound B component were then serially diluted to test the individual MIC of each pesticidal active ingredient (as Compound A), each unsaturated or saturated aliphatic acid (as Compound B), and the combined MIC of each combination of Compound A and Compound B, according to the synergistic growth inhibition assay described above.

Example 8: Growth Inhibition of Fusarium oxysporum by Pyraclostrobin, Azoxystrobin, Chlorothalonil, Fluidioxonil, Cyprodinil, Difenoconazole, and Tebuconazole, in Combination with Various Exemplary Saturated Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, chlorothalonil, fluidioxonil, cyprodinil, difenoconazole, and tebuconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 10-15 below. Working solutions of hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, and decanoic acid, (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 10-15 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 48 hours, and the FIC Index for each combination calculated, as shown in Tables 10-15 below.

TABLE 10
Growth inhibition of Fusarium oxysporum by pyraclostrobin,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.015
		Hexanoic acid		0.15625
		Heptanoic acid		0.15625
		Octanoic acid		0.15625
		Nonanoic acid		0.15625
		Decanoic acid		0.125
		Dodecanoic acid		0.1
		3-Hydroxybutyric acid		10
		3-Hydroxydecanoic acid		0.25
1	Pyraclostrobin	Hexanoic acid	0.00187	0.019531	10	0.25
2	Pyraclostrobin	Heptanoic acid	0.00375	0.039062	10	0.50
3	Pyraclostrobin	Octanoic acid	0.00187	0.039062	21	0.38
4	Pyraclostrobin	Nonanoic acid	0.00375	0.039062	10	0.50
5	Pyraclostrobin	Decanoic acid	0.00375	0.015625	4	0.38
6	Pyraclostrobin	Dodecanoic acid	0.00375	0.025	7	0.50
7	Pyraclostrobin	3-Hydroxybutyric acid	0.00375	2.5	667	0.50
8	Pyraclostrobin	3-Hydroxydecanoic acid	0.00187	0.015625	8	0.25

TABLE 11
Growth inhibition of Fusarium oxysporum by azoxystrobin, in
combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Azoxystrobin		0.075
		Hexanoic acid		0.15625
		Heptanoic acid		0.15625
		Octanoic acid		0.15625
		Nonanoic acid		0.07812
		Dodecanoic acid		0.1
1	Azoxystrobin	Hexanoic acid	0.01875	0.039062	2	0.50
2	Azoxystrobin	Heptanoic acid	0.01875	0.039062	2	0.50
3	Azoxystrobin	Octanoic acid	0.01875	0.039062	2	0.50
4	Azoxystrobin	Nonanoic acid	0.01875	0.019531	1	0.50
5	Azoxystrobin	Dodecanoic acid	0.01875	0.025	1.3	0.50

TABLE 12
Growth inhibition of Fusarium oxysporum by chlorothalonil,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Chlorothalonil		0.000125
		Heptanoic acid		0.15625
		Octanoic acid		0.3125
		Nonanoic acid		0.3125
		Dodecanoic acid		0.1
		3-Hydroxydecanoic		0.25
		acid
1	Chlorothalonil	Heptanoic acid	6.25 × 10−5	0.039062	625	0.75
2	Chlorothalonil	Octanoic acid	6.25 × 10−5	0.039062	625	0.63
3	Chlorothalonil	Nonanoic acid	6.25 × 10−5	0.019531	313	0.56
4	Chlorothalonil	Dodecanoic acid	6.25 × 10−5	0.025	400	0.75
5	Chlorothalonil	3-Hydroxydecanoic	1.9531 × 10−6	0.003125	16000	0.19
		acid

TABLE 13
Growth inhibition of Fusarium oxysporum by fludioxonil and cyprodinil,
in combination with an exemplary saturated aliphatic acid
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Fludioxonil		0.021
	Cyprodinil		0.009
		Dodecanoic acid		0.1
		3-Hydroxydecanoic acid		0.25
1	Fludioxonil	Dodecanoic acid	0.00525	0.025	5	0.50
2	Fludioxonil	3-Hydroxydecanoic acid	0.00131	0.03125	24	0.19
3	Cyprodinil	3-Hydroxydecanoic acid	0.00225	0.03125	14	0.50

TABLE 14
Growth inhibition of Fusarium oxysporum by difenoconazole,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Difenoconazole		0.051
		Heptanoic acid		0.15625
		Octanoic acid		0.3125
1	Difenoconazole	Heptanoic acid	0.01275	0.039062	3	0.50
2	Difenoconazole	Octanoic acid	0.01275	0.078125	6	0.50

TABLE 15A
Growth inhibition of Fusarium oxysporum by tebuconazole, in
combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Tebuconazole		0.255
		Heptanoic acid		0.15625
		Octanoic acid		0.15625
		Nonanoic acid		0.15625
		Decanoic acid		0.03125
		Dodecanoic acid		0.1
1	Tebuconazole	Heptanoic acid	0.05625	0.039062	0.7	0.50
2	Tebuconazole	Octanoic acid	0.05625	0.039062	0.7	0.50
3	Tebuconazole	Nonanoic acid	0.05625	0.039062	0.7	0.50
4	Tebuconazole	Decanoic acid	0.05625	0.007812	0.14	0.50
5	Tebuconazole	Dodecanoic acid	0.05625	0.0025	0.4	0.50

TABLE 15B
Growth inhibition of Fusarium oxysporum by various synthetic fungicides
in combination with saturated 3-hydroxy aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.015
	Azoxystrobin		0.15
	Fludioxonil		0.021
	Difenoconazole		0.051
	Tebuconazole		0.225
		3-Hydroxybuturic acid		10
		3-Hydroxyhexanoic acid		2.5
		3-Hydroxydecanoic acid		0.25
1	Pyraclostrobin	3-Hydroxybuturic acid	0.001875	2.5	1333	0.38
2	Azoxystrobin	3-Hydroxybuturic acid	0.0375	2.5	67	0.50
3	Azoxystrobin	3-Hydroxyhexanoic acid	0.0375	0.625	17	0.50
4	Fludioxonil	3-Hydroxybuturic acid	0.00525	2.5	476	0.50
5	Difenoconazole	3-Hydroxybuturic acid	0.01275	2.5	196	0.50
6	Tebuconazole	3-Hydroxybuturic acid	0.05625	2.5	44	0.50
7	Tebuconazole	3-Hydroxydecanoic acid	0.05625	0.0625	1.1	0.50

Example 9: Growth Inhibition of Sclerotinta Sclerotiorum by Pyraclostrobin, Azoxystrobin, Propiconazole, Epiconazole, Tebuconazole, and Difenoconazole, in Combination with Various Exemplary Saturated Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, propiconazole, epiconazole, tebuconazole, and difenoconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 16-20 below. Working solutions of hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, and dodecanoic acid, (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 16-20 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 7 days, and the FIC Index for each combination calculated, as shown in Tables 16-20 below.

TABLE 16
Growth inhibition of Sclerotinia sclerotiorum by pyraclostrobin,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0075
		Hexanoic acid		0.039062
		Heptanoic acid		0.039062
		Octanoic acid		0.019531
		Nonanoic acid		0.019531
		Decanoic acid		0.15625
		Dodecanoic acid		0.05
1	Pyraclostrobin	Hexanoic acid	9.375 × 10−4	0.009765	10	0.38
2	Pyraclostrobin	Heptanoic acid	4.688 × 10−4	0.004883	10	0.19
3	Pyraclostrobin	Octanoic acid	9.375 × 10−4	0.004883	5	0.38
4	Pyraclostrobin	Nonanoic acid	4.688 × 10−4	0.004883	10	0.31
5	Pyraclostrobin	Decanoic acid	9.375 × 10−4	0.001953	2	0.14
6	Pyraclostrobin	Dodecanoic acid	9.375 × 10−4	0.00625	7	0.25

TABLE 17
Growth inhibition of Sclerotinia sclerotiorum by azoxystrobin,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Azoxystrobin		0.15
		Hexanoic acid		0.039062
		Heptanoic acid		0.039062
		Octanoic acid		0.039062
		Nonanoic acid		0.078125
		Decanoic acid		0.078125
		Dodecanoic acid		0.05
1	Azoxystrobin	Hexanoic acid	0.0375	0.019531	0.52	0.75
2	Azoxystrobin	Heptanoic acid	0.0375	0.009766	0.26	0.50
3	Azoxystrobin	Octanoic acid	0.01875	0.004883	0.26	0.25
4	Azoxystrobin	Nonanoic acid	0.01875	0.004883	0.26	0.19
5	Azoxystrobin	Decanoic acid	0.0375	0.003906	0.10	0.75
6	Azoxystrobin	Dodecanoic acid	0.009375	0.003125	0.33	0.13

TABLE 18
Growth inhibition of Sclerotinia sclerotiorum by propiconazole,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Propiconazole		0.089
		Decanoic acid		0.078125
		Dodecanoic acid		0.05
1	Propiconazole	Decanoic acid	0.0445	0.0078125	0.18	0.60
2	Propiconazole	Dodecanoic acid	0.0223	0.0125	0.56	0.50

TABLE 19
Growth inhibition of Sclerotinia sclerotiorum by epiconzaole and tebuconazole,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Epoxiconazole		0.03
	Tebuconazole		0.225
		Hexanoic acid		0.078125
		Heptanoic acid		0.0390625
		Octanoic acid		0.078125
		Nonanoic acid		0.078125
		Decanoic acid		0.03125
		Dodecanoic acid		0.1
1	Epoxiconazole	Heptanoic acid	0.0075	0.009765	1.3	0.50
2	Epoxiconazole	Octanoic acid	0.00375	0.004883	1.3	0.19
3	Epoxiconazole	Decanoic acid	0.0075	0.003906	0.5	0.38
4	Epoxiconazole	Dodecanoic acid	0.00375	0.00625	1.7	0.19
5	Tebuconazole	Hexanoic acid	0.028125	0.009765	0.35	0.25
6	Tebuconazole	Heptanoic acid	0.028125	0.004883	0.17	0.25
7	Tebuconazole	Octanoic acid	0.0028125	0.004883	0.17	0.19
8	Tebuconazole	Nonanoic acid	0.028125	0.004883	0.17	0.19
9	Tebuconazole	Decanoic acid	0.05625	0.003906	0.07	0.38
10	Tebuconazole	Dodecanoic acid	0.028125	0.00625	0.22	0.19

TABLE 20A
Growth inhibition of Sclerotinia sclerotiorum by difenoconazole,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Difenoconazole		0.01275
		Nonanoic acid		0.039062
		Decanoic acid		0.015615
		Dodecanoic acid		0.025
1	Difenoconazole	Nonanoic acid	0.006375	0.009766	1.5	0.75
2	Difenoconazole	Decanoic acid	0.006375	0.003906	0.6	0.75
4	Difenoconazole	Dodecanoic acid	0.003188	0.00625	2.0	0.50

TABLE 20B
Growth inhibition of Sclerotinia sclerotiorum by various fungicides,
in combination with various exemplary saturated hydroxy aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.00375
	Azoxyst robin		0.075
	Chlorothalonil		3.125 × 10−5
	Cyprodinil		0.009
	Metalaxyl		1.261
	Difenoconazole		0.0255
	Propiconazole		0.089
	Epoxiconazole		0.03
	Tebuconazole		0.05625
		3-Hydroxybuturic acid		5.0
		3-Hydroxyhexanoic acid		2.5
		3-Hydroxydecanoic acid		0.0625
1	Pyraclostrobin	3-Hydroxybuturic acid	0.0009375	1.25	1333	0.50
2	Pyraclostrobin	3-Hydroxyhexanoic acid	0.0009375	0.625	667	0.50
3	Pyraclostrobin	3-Hydroxydecanoic acid	0.0009375	0.015625	17	0.50
4	Azoxystrobin	3-Hydroxyhexanoic acid	0.01875	0.625	33	0.50
5	Chlorothalonil	3-Hydroxyhexanoic acid	7.813 × 10−6	1.25	160000	0.75
6	Cyprodinil	3-Hydroxyhexanoic acid	0.00225	1.25	556	0.75
7	Metalaxyl	3-Hydroxyhexanoic acid	0.31525	1.25	4	0.75
8	Difenoconazole	3-Hydroxybuturic acid	0.006375	2.5	392	0.75
9	Difenoconazole	3-Hydroxyhexanoic acid	0.006375	1.25	196	0.75
10	Propiconazole	3-Hydroxybuturic acid	0.02225	2.5	112	0.75
11	Propiconazole	3-Hydroxyhexanoic acid	0.02225	1.25	56	0.75
12	Epoxiconazole	3-Hydroxybuturic acid	0.001875	0.625	333	0.19
13	Epoxiconazole	3-Hydroxyhexanoic acid	0.00375	0.625	167	0.38
14	Tebuconazole	3-Hydroxybuturic acid	0.014062	1.25	89	0.50
15	Tebuconazole	3-Hydroxyhexanoic acid	0.014062	0.625	44	0.50

Example 10: Growth Inhibition of Botrytis cinerea by Pyraclostrobin, Azoxystrobin, Cyprodinil, Metalaxyl, Epiconazole, Tebuconazole, Propiconazole, and Difenoconazole, in Combination with Various Exemplary Saturated Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, cyprodiil, metalaxyl, epiconazole, tebuconazole, propiconazole, and difenoconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 21-26 below. Working solutions of hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, and dodecanoic acid, (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 21-26 below. Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 48 hours, and the FIC Index for each combination calculated, as shown in Tables 21-26 below.

TABLE 21
Growth inhibition of Botrytis cinerea by pyraclostrobin, in
combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0019
		Hexanoic acid		0.078125
		Heptanoic acid		0.078125
		Octanoic acid		0.078125
		Nonanoic acid		0.078125
		Decanoic acid		0.03125
		Dodecanoic acid		0.025
1	Pyraclostrobin	Hexanoic acid	9.375 × 10−4	0.009766	10	0.63
2	Pyraclostrobin	Heptanoic acid	9.375 × 10−4	0.004883	5	0.56
3	Pyraclostrobin	Octanoic acid	4.688 × 10−4	0.002441	5	0.28
4	Pyraclostrobin	Nonanoic acid	4.688 × 10−4	0.002441	5	0.28
5	Pyraclostrobin	Decanoic acid	2.344 × 10−4	0.001953	8	0.19
6	Pyraclostrobin	Dodecanoic acid	9.375 × 10−4	0.003125	3	0.63

TABLE 22
Growth inhibition of Botrytis cinerea by azoxystrobin, in
combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Azoxystrobin		0.0375
		Hexanoic acid		0.078125
		Heptanoic acid		0.078125
		Octanoic acid		0.078125
		Nonanoic acid		0.078125
		Decanoic acid		0.078125
1	Azoxystrobin	Hexanoic acid	0.01875	0.019531	1	0.75
2	Azoxystrobin	Heptanoic acid	0.01875	0.009765	0.5	0.63
3	Azoxystrobin	Octanoic acid	0.01875	0.009765	0.5	0.63
4	Azoxystrobin	Nonanoic acid	0.01875	0.009765	0.5	0.63
5	Azoxystrobin	Decanoic acid	0.009375	0.078125	0.8	0.35

TABLE 23
Growth inhibition of Botrytis cinerea by pyraclostrobin, cyprodinil,
metalaxyl, azoxystrobin, epoxiconazole, and tebuconazole, in combination
with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.00375
	Cyprodinil		0.0045
	Metalaxyl		0.316
	Azoxystrobin		0.075
	Epoxiconazole		0.03
	Tebuconazole		0.1125
		Decanoic acid	0.03125
1	Pyraclostrobin	Decanoic acid	2.344 × 10−4	0.001953	8	0.13
3	Cyprodinil	Decanoic acid	5.625 × 10−4	0.03125	28	0.63
4	Metalaxyl	Decanoic acid	0.0395	0.015625	0.4	0.63
5	Azoxystrobin	Decanoic acid	0.009375	0.0078125	0.8	0.38
6	Epoxiconazole	Decanoic acid	0.00375	0.015625	4	0.63
7	Tebuconazole	Decanoic acid	0.014062	0.0078125	0.6	0.38

TABLE 24
Growth inhibition of Botrytis cinerea by difenoconazole and propiconazole,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Difenoconazole		0.051
	Propiconazole		0.089
		Hexanoic acid		0.15625
		Heptanoic acid		0.15625
		Octanoic acid		0.15625
		Nonanoic acid		0.15625
		Decanoic acid		0.3125
		Dodecanoic acid		0.05
1	Difenoconazole	Hexanoic acid	0.01275	0.039062	3.1	0.50
2	Difenoconazole	Heptanoic acid	0.01275	0.019531	1.5	0.38
3	Difenoconazole	Octanoic acid	0.01275	0.019531	1.5	0.38
4	Difenoconazole	Nonanoic acid	0.01275	0.019531	1.5	0.38
5	Difenoconazole	Decanoic acid	0.006275	0.015625	2.5	0.18
6	Difenoconazole	Dodecanoic acid	0.01275	0.0125	1.0	0.50
7	Propiconazole	Decanoic acid	0.011125	0.015625	1.4	0.18
8	Propiconazole	Dodecanoic acid	0.02225	0.0125	0.6	0.50

TABLE 25
Growth inhibition of Botrytis cinerea by tebuconazole, in
combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Tebuconazole		0.1125
		Hexanoic acid		0.078125
		Heptanoic acid		0.078125
		Octanoic acid		0.078125
		Nonanoic acid		0.078125
		Decanoic acid		0.015625
		Dodecanoic acid		0.05
1	Tebuconazole	Hexanoic acid	0.014062	0.009766	0.7	0.25
2	Tebuconazole	Heptanoic acid	0.014062	0.004883	0.3	0.19
3	Tebuconazole	Octanoic acid	0.014062	0.004883	0.3	0.19
4	Tebuconazole	Nonanoic acid	0.014062	0.004883	0.3	0.19
5	Tebuconazole	Decanoic acid	0.007031	0.003906	0.6	0.31
6	Tebuconazole	Dodecanoic acid	0.014062	0.003125	0.2	0.19

TABLE 26
Growth inhibition of Botrytis cinerea by cyprodinil and metalaxyl,
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Cyprodinil		0.0045
	Metalaxyl		0.316
		Octanoic acid		0.078125
		Decanoic acid		0.078125
		Dodecanoic acid		0.05
1	Cyprodinil	Decanoic acid	0.001125	0.03125	28	0.65
2	Metalaxyl	Octanoic acid	0.01975	0.004883	0.25	0.13
3	Metalaxyl	Decanoic acid	0.0395	0.015625	0.4	0.33
4	Metalaxyl	Dodecanoic acid	0.079	0.0125	0.16	0.50

Example 11: Growth Inhibition of Fusarium oxysporum by Pyraclostrobin, Azoxystrobin, Fludioxonil, Cyprodinil, Difenoconazole, Epoxiconazole, and Tebuconazole, in Combination with Various Exemplary Unsaturated Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, fludioxonil, cyprodinil, difenoconazole, epoxiconazole, and tebuconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 27-32 below. Working solutions of (2E,4E)-2,4-hexadienoic acid, trans-3-hexenoic acid, 4-hexenoic acid, 5-hexenoic acid, 3-heptenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, 7-octenoic acid, 3-decenoic acid, 9-decenoic acid, trans-2-nonenoic acid, 3-nonenoic acid, trans-2-decenoic acid, and trans-2-undecenoic acid, (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 27-32 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 48 hours, and the FIC Index for each combination calculated, as shown in Tables 27-32 below.

TABLE 27
Growth inhibition of Fusarium oxysporum by pyraclostrobin, in
combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.015
		(2E,4E)-2,4-hexadienoic		0.025
		acid
		Trans-3-hexenoic acid		0.3125
		4-Hexenoic acid		0.3125
		5-Hexenoic acid		0.3125
		3-Heptenoic acid		0.15625
		Trans-2-octenoic acid		0.3125
		Trans-3-octenoic acid		0.15625
		7-Octenoic acid		0.3125
		3-Decenoic acid		0.3125
		9-Decenoic acid		0.3125
1	Pyraclostrobin	(2E,4E)-2,4-hexadienoic	0.00375	0.0625	17	0.50
		acid
2	Pyraclostrobin	Trans-3-hexenoic acid	0.001875	0.078125	42	0.38
3	Pyraclostrobin	4-Hexenoic acid	0.00375	0.15625	42	0.75
4	Pyraclostrobin	5-Hexenoic acid	0.00375	0.039062	10	0.38
5	Pyraclostrobin	3-Heptenoic acid	0.001875	0.078125	42	0.63
6	Pyraclostrobin	Trans-2-octenoic acid	0.001875	0.019531	10	0.19
7	Pyraclostrobin	Trans-3-octenoic acid	0.001875	0.019531	10	0.25
8	Pyraclostrobin	7-Octenoic acid	0.001875	0.019531	10	0.19
9	Pyraclostrobin	3-Decenoic acid	0.00375	0.078125	21	0.50
10	Pyraclostrobin	9-Decenoic acid	0.00375	0.039062	10	0.38

TABLE 28
Growth inhibition of Fusarium oxysporum by azoxystrobin, in
combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Azoxystrobin		0.15
		Trans-3-hexenoic acid		0.3125
		3-Heptenoic acid		0.15625
		Trans-2-nonenoic acid		0.15625
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.3125
1	Azoxystrobin	Trans-3-hexenoic acid	0.0375	0.078125	2	0.50
2	Azoxystrobin	3-Heptenoic acid	0.001875	0.019531	1	0.25
3	Azoxystrobin	Trans-2-nonenoic acid	0.0375	0.039062	1	0.50
4	Azoxystrobin	3-Decenoic acid	0.001875	0.019531	1	0.38
5	Azoxystrobin	9-Decenoic acid	0.00375	0.039062	1	0.50

TABLE 29
Growth inhibition of Fusarium oxysporum by fludioxonil and cyprodinil,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Fludioxonil		0.021
	Cyprodinil		0.009
		3-Heptenoic acid		0.15625
		3-Decenoic acid		0.15625
1	Fludioxonil	3-Heptenoic acid	0.00525	0.03906	7	0.50
2	Fludioxonil	3-Decenoic acid	0.00525	0.03906	7	0.50
3	Cyprodinil	3-Decenoic acid	0.00225	0.019531	9	0.38

TABLE 30
Growth inhibition of Fusarium oxysporum by difenoconazole, in
combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Difenoconazole		0.051
		Trans-3-hexenoic acid		0.3125
		4-Hexenoic acid		0.3125
		3-Heptenoic acid		0.15625
		Trans-2-octenoic acid		0.15625
		3-Octenoic acid		0.15625
		Trans-3-octenoic acid		0.15625
		7-Octenoic acid		0.3125
		Trans-2-nonenoic acid		0.3125
		Trans-2-decenoic acid		0.078125
		9-Decenoic acid		0.15625
1	Difenoconazole	Trans-3-hexenoic acid	0.006375	0.078125	12	0.38
2	Difenoconazole	4-Hexenoic acid	0.01275	0.15625	12	0.75
3	Difenoconazole	3-Heptenoic acid	0.006375	0.078125	12	0.63
4	Difenoconazole	Trans-2-octenoic acid	0.01275	0.039062	3	0.50
5	Difenoconazole	3-Octenoic acid	0.01275	0.019531	1.5	0.38
6	Difenoconazole	Trans-3-octenoic acid	0.01275	0.039062	3	0.50
7	Difenoconazole	7-Octenoic acid	0.01275	0.039062	3	0.50
8	Difenoconazole	Trans-2-nonenoic acid	0.01275	0.039062	3	0.38
9	Difenoconazole	Trans-2-decenoic acid	0.01275	0.019531	1.5	0.50
10	Difenoconazole	9-Decenoic acid	0.01275	0.039062	3	0.50

TABLE 31
Growth inhibition of Fusarium oxysporum by epoxiconazole, in
combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Epoxiconazole		0.03
		Trans-3-hexenoic acid		0.15625
		3-Heptenoic acid		0.15625
		Trans-2-octenoic acid		0.15625
		3-Octenoic acid		0.15625
		3-Decenoic acid		0.078125
1	Epoxiconazole	Trans-3-hexenoic acid	0.0075	0.078125	10	0.75
2	Epoxiconazole	3-Heptenoic acid	0.0075	0.039062	5	0.50
3	Epoxiconazole	Trans-2-octenoic acid	0.0075	0.039062	5	0.50
4	Epoxiconazole	3-Octenoic acid	0.0075	0.039062	5	0.50
5	Epoxiconazole	3-Decenoic acid	0.0075	0.039062	5	0.75

TABLE 32
Growth inhibition of Fusarium oxysporum by tebuconazole, in
combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Tebuconazole		0.225
		Trans-2-octenoic acid		0.3125
		3-Octenoic acid		0.15625
		Trans-3-octenoic acid		0.15625
		7-Octenoic acid		0.15625
		Trans-2-nonenoic acid		0.3125
		3-Nonenoic acid		0.15625
		Trans-2-decenoic acid		0.15625
		9-Decenoic acid		0.078125
		Trans-2-undecenoic acid		0.15625
1	Tebuconazole	Trans-2-octenoic acid	0.05625	0.039062	0.7	0.38
2	Tebuconazole	3-Octenoic acid	0.05625	0.019531	0.3	0.38
3	Tebuconazole	Trans-3-octenoic acid	0.05625	0.039062	0.7	0.50
4	Tebuconazole	7-Octenoic acid	0.05625	0.039062	0.7	0.50
5	Tebuconazole	Trans-2-nonenoic acid	0.028125	0.019531	0.7	0.19
6	Tebuconazole	3-Nonenoic acid	0.05625	0.019531	0.3	0.38
7	Tebuconazole	Trans-2-decenoic acid	0.05625	0.019531	0.3	0.38
8	Tebuconazole	9-Decenoic acid	0.05625	0.039062	0.7	0.75
9	Tebuconazole	Trans-2-undecenoic acid	0.05625	0.019531	0.3	0.38

Example 12: Growth Inhibition of Sclerotinia sclerotiorum by Pyraclostrobin, Azoxystrobin, Chlorothalonil, Fludioxonil, Difenoconazole, Propiconazole, Epoxiconazole, and Tebuconazole, in Combination with Various Exemplary Unsaturated Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, chlorothalonil, fludioxonil, difenoconazole, propiconazole, epoxiconazole, and tebuconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 33-42 below. Working solutions of (2E,4E)-2,4-hexadienoic acid, trans-2-hexenoic acid, trans-3-hexenoic acid, 5-hexenoic acid, 3-heptenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, 3-octenoic acid, 7-octenoic acid, 3-decenoic acid, cis-3-hexenoic acid, 9-decenoic acid, trans-2-nonenoic acid, 3-nonenoic acid, (9Z)-octadecenoic acid, trans-2-decenoic acid, cis-2-decenoic acid, and trans-2-undecenoic acid (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 33-42 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 7 days, and the FIC Index for each combination calculated, as shown in Tables 33-42 below.

TABLE 33
Growth inhibition of Sclerotinia sclerotiorum by pyraclostrobin,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0075
		(2E,4E)-2,4-hexadienoic acid		0.125
		Trans-2-hexenoic acid		0.15625
		Trans-3-hexenoic acid		0.15625
		5-Hexenoic acid		0.15625
		3-Heptenoic acid		0.078125
		Trans-2-octenoic acid		0.039062
		3-Octenoic acid		0.078125
		Trans-3-octenoic acid		0.039062
		7-Octenoic acid		0.039062
		Trans-2-nonenoic acid		0.019531
		3-Nonenoic acid		0.019531
		Trans-2-decenoic acid		0.019531
		3-Decenoic acid		0.039062
		9-Decenoic acid		0.039062
		Trans-2-undecenoic acid		0.019531
		(9Z)-octadecenoic acid		5.0
1	Pyraclostrobin	(2E,4E)-2,4-hexadienoic acid	0.001875	0.015625	8	0.38
2	Pyraclostrobin	Trans-2-hexenoic acid	0.000937	0.009765	10	0.19
3	Pyraclostrobin	Trans-3-hexenoic acid	0.000937	0.019531	21	0.25
4	Pyraclostrobin	5-Hexenoic acid	0.000937	0.019531	21	0.25
5	Pyraclostrobin	3-Heptenoic acid	0.000937	0.009766	10	0.25
6	Pyraclostrobin	Trans-2-octenoic acid	0.000469	0.004882	10	0.19
7	Pyraclostrobin	3-Octenoic acid	0.000469	0.004882	10	0.13
8	Pyraclostrobin	Trans-3-octenoic acid	0.000469	0.004882	10	0.19
9	Pyraclostrobin	7-Octenoic acid	0.000469	0.004882	10	0.19
10	Pyraclostrobin	Trans-2-nonenoic acid	0.000469	0.004882	10	0.31
11	Pyraclostrobin	3-Nonenoic acid	0.000469	0.004882	10	0.31
12	Pyraclostrobin	Trans-2-decenoic acid	0.000937	0.002441	3	0.25
13	Pyraclostrobin	3-Decenoic acid	0.000234	0.002441	10	0.09
14	Pyraclostrobin	9-Decenoic acid	0.000469	0.004882	10	0.19
15	Pyraclostrobin	Trans-2-undecenoic acid	0.000469	0.004882	10	0.31
16	Pyraclostrobin	(9Z)-octadecenoic acid	0.00375	2.5	667	1.00

TABLE 34
Growth inhibition of Sclerotinia sclerotiorum by pyraclostrobin,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.00375
		Trans-3-hexenoic acid		0.15625
		Cis-3-hexenoic acid		0.15625
		Trans-2-decenoic acid		0.019531
		Cis-2-decenoic acid		0.019531
1	Pyraclostrobin	Trans-3-hexenoic acid	0.001875	0.039062	21	0.75
2	Pyraclostrobin	Cis-3-hexenoic acid	0.001875	0.039062	21	0.75
3	Pyraclostrobin	Trans-2-decenoic acid	0.0009375	0.002441	3	0.38
4	Pyraclostrobin	Cis-2-decenoic acid	0.0009375	0.002441	3	0.38

TABLE 35
Growth inhibition of Sclerotinia sclerotiorum by azoxystrobin,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Azoxystrobin		0.15
		Trans-3-hexenoic acid		0.15625
		5-Hexenoic acid		0.15625
		3-Heptenoic acid		0.078125
		3-Octenoic acid		0.039062
		Trans-3-octenoic acid		0.039062
		3-Nonenoic acid		0.039062
		Trans-2-decenoic acid		0.009766
		3-Decenoic acid		0.039062
		9-Decenoic acid		0.039062
1	Azoxystrobin	Trans-3-hexenoic acid	0.0375	0.039062	1	0.50
2	Azoxystrobin	5-Hexenoic acid	0.0375	0.039062	1	0.50
3	Azoxystrobin	3-Heptenoic acid	0.0375	0.019531	0.5	0.50
4	Azoxystrobin	3-Octenoic acid	0.0375	0.019531	0.5	0.75
5	Azoxystrobin	Trans-3-octenoic acid	0.01875	0.009766	0.5	0.38
6	Azoxystrobin	3-Nonenoic acid	0.0375	0.019531	0.5	0.75
7	Azoxystrobin	Trans-2-decenoic acid	0.0375	0.004882	0.1	0.75
8	Azoxystrobin	3-Decenoic acid	0.01875	0.009766	0.5	0.38
9	Azoxystrobin	9-Decenoic acid	0.01875	0.009766	0.5	0.38

TABLE 36
Growth inhibition of Sclerotinia sclerotiorum by chlorothalonil,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Chlorothalonil		3.125 × 10−5
		Trans-2-nonenoic acid		0.039062
		3-Nonenoic acid		0.039062
		9-Decenoic acid		0.039062
1	Chlorothalonil	Trans-2-nonenoic acid	3.906 × 10−6	0.009766	2500	0.38
2	Chlorothalonil	3-Nonenoic acid	7.813 × 10−6	0.019531	2500	0.75
3	Chlorothalonil	9-Decenoic acid	7.813 × 10−6	0.019531	2500	0.75

TABLE 37
Growth inhibition of Sclerotinia sclerotiorum by fludioxonil,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Fludioxonil		0.000164
		Trans-2-octenoic acid		0.078125
		3-Octenoic acid		0.078125
		Trans-2-nonenoic acid		0.078125
		3-Nonenoic acid		0.078125
		Trans-2-decenoic acid		0.039062
		9-Decenoic acid		0.15625
1	Fludioxonil	Trans-2-octenoic acid	8.203 × 10−5	0.019531	238	0.75
2	Fludioxonil	3-Octenoic acid	8.203 × 10−5	0.019531	238	0.75
3	Fludioxonil	Trans-2-nonenoic acid	8.203 × 10−5	0.009766	119	0.63
4	Fludioxonil	3-Nonenoic acid	8.203 × 10−5	0.009766	119	0.63
5	Fludioxonil	Trans-2-decenoic acid	8.203 × 10−5	0.009766	119	0.75
6	Fludioxonil	9-Decenoic acid	8.203 × 10−5	0.019531	238	0.63

TABLE 38
Growth inhibition of Sclerotinia sclerotiorum by difenoconazole,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Difenoconazole		0.0255
		Trans-2-octenoic acid		0.078125
		Trans-2-nonenoic acid		0.039062
		3-Nonenoic acid		0.078125
		Trans-2-decenoic acid		0.019531
		3-decenoic acid		0.039062
		9-Decenoic acid		0.078125
		Trans-2-undecenoic acid		0.039062
1	Difenoconazole	Trans-2-octenoic acid	0.006375	0.019531	3.1	0.50
2	Difenoconazole	Trans-2-nonenoic acid	0.006375	0.009766	1.5	0.50
3	Difenoconazole	3-Nonenoic acid	0.006375	0.009766	1.5	0.38
4	Difenoconazole	Trans-2-decenoic acid	0.006375	0.009766	1.5	0.75
5	Difenoconazole	3-Decenoic acid	0.006375	0.019531	3.1	0.75
6	Difenoconazole	9-Decenoic acid	0.006375	0.019531	3.1	0.50
7	Difenoconazole	Trans-2-undecenoic acid	0.006375	0.009766	1.5	0.50

TABLE 39
Growth inhibition of Sclerotinia sclerotiorum by propiconazole,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Propiconazole		0.089
		3-Heptenoic acid		0.078125
		Trans-2-nonenoic acid		0.019531
		Trans-2-decenoic acid		0.019531
		9-Decenoic acid		0.039062
		Trans-2-undecenoic acid		0.039062
1	Propiconazole	3-Heptenoic acid	0.02225	0.019531	0.9	0.50
2	Propiconazole	Trans-2-nonenoic acid	0.02225	0.009766	0.4	0.75
3	Propiconazole	Trans-2-decenoic acid	0.02225	0.009766	0.4	0.75
4	Propiconazole	9-Decenoic acid	0.02225	0.009766	0.9	0.38
5	Propiconazole	Trans-2-undecenoic acid	0.02225	0.009766	0.4	0.75

TABLE 40
Growth inhibition of Sclerotinia sclerotiorum by epoxiconazole,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Epoxiconazole		0.03
		Trans-2-nonenoic acid		0.019531
		Trans-2-decenoic acid		0.019531
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.078125
1	Epoxiconazole	Trans-2-nonenoic acid	0.0075	0.009766	1.3	0.75
2	Epoxiconazole	Trans-2-decenoic acid	0.0075	0.009766	1.3	0.75
3	Epoxiconazole	3-Decenoic acid	0.0075	0.019531	2.6	0.50
4	Epoxiconazole	9-Decenoic acid	0.0075	0.019531	2.6	0.50

TABLE 41
Growth inhibition of Sclerotinia sclerotiorum by tebuconazole,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Tebuconazole		0.1125
		Trans-3-hexenoic acid		0.15625
		3-Heptenoic acid		0.078125
		Trans-2-nonenoic acid		0.039062
		3-Nonenoic acid		0.039062
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.078125
		Trans-2-undecenoic acid		0.039062
1	Tebuconazole	Trans-3-hexenoic acid	0.05625	0.039062	0.7	0.75
2	Tebuconazole	3-Heptenoic acid	0.05625	0.019531	0.3	0.75
3	Tebuconazole	Trans-2-nonenoic acid	0.028125	0.004882	0.2	0.38
4	Tebuconazole	3-Nonenoic acid	0.05625	0.009766	0.2	0.75
5	Tebuconazole	3-Decenoic acid	0.028125	0.009766	0.3	0.38
6	Tebuconazole	9-Decenoic acid	0.028125	0.009766	0.3	0.38
7	Tebuconazole	Trans-2-undecenoic acid	0.05625	0.009766	0.2	0.75

TABLE 42
Growth inhibition of Sclerotinia sclerotiorum by tebuconazole,
in combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Tebuconazole		0.1125
		Trans-3-octanoic acid		0.039062
		Trans-2-decenoic acid		0.019531
1	Tebuconazole	Trans-3-octanoic acid	0.028125	0.019531	0.7	0.75
2	Tebuconazole	Trans-2-decenoic acid	0.028125	0.004882	0.2	0.50

Example 13: Growth Inhibition of Botrytis cinerea by Pyraclostrobin, Azoxystrobin, Chlorothalonil, Cyprodinil, Metalaxyl, Epoxiconazole, and Tebuconazole, in Combination with Various Exemplary Unsaturated Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, chlorothalonil, cyprodinil, metalaxyl, epoxiconazole, and tebuconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 43-50 below. Working solutions of (2E,4E)-2,4-hexadienoic acid, trans-2-hexenoic acid, trans-3-hexenoic acid, 5-hexenoic acid, 3-heptenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, 3-octenoic acid, 7-octenoic acid, 3-decenoic acid, 9-decenoic acid, trans-2-nonenoic acid, 3-nonenoic acid, (9Z)-octadecenoic acid, trans-2-decenoic acid, and trans-2-undecenoic acid (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 43-50 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 48 hours, and the FIC Index for each combination calculated, as shown in Tables 43-50 below.

TABLE 43
Growth inhibition of Botrytis cinerea by pyraclostrobin, in
combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.001875
		(2E,4E)-2,4-hexadienoic		0.0625
		acid
		Trans-2-hexenoic acid		0.078125
		Trans-3-hexenoic acid		0.15625
		4-Hexenoic acid		0.3125
		5-Hexenoic acid		0.15625
		3-Heptenoic acid		0.078125
		Trans-2-octenoic acid		0.039062
		3-Octenoic acid		0.078125
		Trans-3-octenoic acid		0.078125
		7-Octenoic acid		0.078125
		Trans-2-nonenoic acid		0.078125
		3-Nonenoic acid		0.078125
		Trans-2-decenoic acid		0.019531
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.15625
		Trans-2-undecenoic acid		0.15625
1	Pyraclostrobin	(2E,4E)-2,4-hexadienoic	0.000469	0.007812	17	0.38
		acid
2	Pyraclostrobin	Trans-2-hexenoic acid	0.000937	0.009766	10	0.63
3	Pyraclostrobin	Trans-3-hexenoic acid	0.000469	0.009766	21	0.31
4	Pyraclostrobin	4-Hexenoic acid	0.000937	0.019531	21	0.56
5	Pyraclostrobin	5-Hexenoic acid	0.000469	0.009766	21	0.31
6	Pyraclostrobin	3-Heptenoic acid	0.000469	0.004882	10	0.31
7	Pyraclostrobin	Trans-2-octenoic acid	0.000234	0.002441	10	0.19
8	Pyraclostrobin	3-Octenoic acid	0.000234	0.002441	10	0.16
9	Pyraclostrobin	Trans-3-octenoic acid	0.000469	0.004882	10	0.31
10	Pyraclostrobin	7-Octenoic acid	0.000469	0.004882	10	0.31
11	Pyraclostrobin	Trans-2-nonenoic acid	0.000469	0.004882	10	0.31
12	Pyraclostrobin	3-Nonenoic acid	0.000469	0.004882	10	0.31
13	Pyraclostrobin	Trans-2-decenoic acid	0.000469	0.004882	10	0.50
14	Pyraclostrobin	3-Decenoic acid	0.000234	0.004882	21	0.19
15	Pyraclostrobin	9-Decenoic acid	0.000234	0.002441	10	0.14
16	Pyraclostrobin	Trans-2-undecenoic acid	0.000937	0.009766	10	0.56

TABLE 44
Growth inhibition of Botrytis cinerea by pyraclostrobin, in
combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.001875
		(2E,4E)-2,4-hexadienoic		0.0625
		acid
		Trans-2-hexenoic acid		0.039062
		Trans-3-hexenoic acid		0.15625
		5-Hexenoic acid		0.078125
		3-Heptenoic acid		0.078125
		Trans-2-octenoic acid		0.039062
		3-Octenoic acid		0.078125
		7-Octenoic acid		0.039062
		Trans-2-nonenoic acid		0.039062
		3-Nonenoic acid		0.078125
		Trans-2-decenoic acid		0.078125
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.078125
		Trans-2-undecenoic acid		0.078125
1	Pyraclostrobin	(2E,4E)-2,4-hexadienoic	0.000234	0.003906	17	0.19
		acid
2	Pyraclostrobin	Trans-2-hexenoic acid	0.000234	0.002441	10	0.19
3	Pyraclostrobin	Trans-3-hexenoic acid	0.000469	0.009766	21	0.31
4	Pyraclostrobin	5-Hexenoic acid	0.000469	0.009766	21	0.38
5	Pyraclostrobin	3-Heptenoic acid	0.000469	0.004882	10	0.19
6	Pyraclostrobin	Trans-2-octenoic acid	0.000234	0.002441	10	0.19
7	Pyraclostrobin	3-Octenoic acid	0.000469	0.004882	10	0.31
8	Pyraclostrobin	7-Octenoic acid	0.000234	0.002441	10	0.19
9	Pyraclostrobin	Trans-2-nonenoic acid	0.000234	0.002441	10	0.19
10	Pyraclostrobin	3-Nonenoic acid	0.000469	0.004882	10	0.31
11	Pyraclostrobin	Trans-2-decenoic acid	0.000234	0.002441	10	0.16
12	Pyraclostrobin	3-Decenoic acid	0.000234	0.004882	21	0.19
13	Pyraclostrobin	9-Decenoic acid	0.000234	0.002441	10	0.16
14	Pyraclostrobin	Trans-2-undecenoic acid	0.000234	0.002441	10	0.16

TABLE 45
Growth inhibition of Botrytis cinerea by azoxystrobin, in combination
with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Azoxystrobin		0.075
		Trans-2-hexenoic acid		0.15625
		Trans-3-hexenoic acid		0.3125
		4-Hexenoic acid		0.3125
		5-Hexenoic acid		0.3125
		Trans-2-octenoic acid		0.078125
		3-Octenoic acid		0.078125
		Trans-3-octenoic acid		0.15625
		7-Octenoic acid		0.15625
		Trans-2-nonenoic acid		0.039062
		3-Nonenoic acid		0.078125
		Trans-2-decenoic acid		0.039062
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.078125
		Trans-2-undecenoic acid		0.078125
1	Azoxystrobin	Trans-2-hexenoic acid	0.0375	0.039062	1	0.75
3	Azoxystrobin	Trans-3-hexenoic acid	0.0375	0.078125	2	0.75
4	Azoxystrobin	4-Hexenoic acid	0.0375	0.078125	2	0.75
5	Azoxystrobin	5-Hexenoic acid	0.0375	0.078125	2	0.75
6	Azoxystrobin	Trans-2-octenoic acid	0.009375	0.009766	1	0.25
7	Azoxystrobin	3-Octenoic acid	0.01875	0.019531	1	0.50
8	Azoxystrobin	Trans-3-octenoic acid	0.01875	0.019531	1	0.38
9	Azoxystrobin	7-Octenoic acid	0.01875	0.019531	1	0.38
10	Azoxystrobin	Trans-2-nonenoic acid	0.01875	0.019531	1	0.75
11	Azoxystrobin	3-Nonenoic acid	0.01875	0.019531	1	0.50
12	Azoxystrobin	Trans-2-decenoic acid	0.009375	0.009766	1	0.38
13	Azoxystrobin	3-Decenoic acid	0.009375	0.019531	2	0.38
14	Azoxystrobin	9-Decenoic acid	0.01875	0.019531	1	0.50
15	Azoxystrobin	Trans-2-undecenoic acid	0.01875	0.019531	1	0.50

TABLE 46
Growth inhibition of Botrytis cinerea by chlorothalonil, in
combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Chlorothalonil		1.758 × 10−5
		Trans-2-nonenoic acid		0.019531
		9-Decenoic acid		0.039062
1	Chlorothalonil	Trans-2-nonenoic acid	4.395 × 10−6	0.004882	1111	0.50
2	Chlorothalonil	9-Decenoic acid	4.395 × 10−6	0.019531	4444	0.75

TABLE 47
Growth inhibition of Botrytis cinerea by cyprodinil, in combination
with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Cyprodinil		0.0045
		3-Heptenoic acid		0.078125
		Trans-2-octenoic acid		0.078125
		3-Octenoic acid		0.078125
		7-Octenoic acid		0.078125
		Trans-2-nonenoic acid		0.078125
		3-Nonenoic acid		0.078125
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.078125
		Trans-2-undecenoic acid		0.078125
1	Cyprodinil	3-Heptenoic acid	0.001125	0.039062	35	0.75
2	Cyprodinil	Trans-2-octenoic acid	0.001125	0.039062	35	0.75
3	Cyprodinil	3-Octenoic acid	0.001125	0.039062	35	0.75
4	Cyprodinil	7-Octenoic acid	0.000562	0.019531	35	0.38
5	Cyprodinil	Trans-2-nonenoic acid	0.001125	0.039062	35	0.75
6	Cyprodinil	3-Nonenoic acid	0.001125	0.039062	35	0.75
7	Cyprodinil	3-Decenoic acid	0.000562	0.039062	69	0.63
8	Cyprodinil	9-Decenoic acid	0.000562	0.019531	35	0.38
9	Cyprodinil	Trans-2-undecenoic acid	0.000562	0.019531	35	0.38

TABLE 48
Growth inhibition of Botrytis cinerea by metalaxyl, in combination
with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Metalaxyl		0.316
		3-Nonenoic acid		0.078125
		9-Decenoic acid		0.078125
		Trans-2-undecenoic acid		0.078125
1	Metalaxyl	3-Nonenoic acid	0.079	0.039062	0.5	0.75
2	Metalaxyl	9-Decenoic acid	0.079	0.039062	0.5	0.75
3	Metalaxyl	Trans-2-undecenoic acid	0.079	0.039062	0.5	0.75

TABLE 49
Growth inhibition of Botrytis cinerea by epoxiconazole, in
combination with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Epoxiconazole		0.03
		3-Heptenoic acid		0.078125
		Trans-2-octenoic acid		0.15625
		3-Octenoic acid		0.078125
		Trans-3-octenoic acid		0.078125
		Trans-2-nonenoic acid		0.15625
		3-Nonenoic acid		0.078125
		Trans-2-decenoic acid		0.078125
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.15625
		Trans-2-undecenoic acid		0.078125
		(9Z)-octadecenoic acid		5.0
1	Epoxiconazole	3-Heptenoic acid	0.0075	0.039062	5	0.75
2	Epoxiconazole	Trans-2-octenoic acid	0.0075	0.039062	5	0.50
3	Epoxiconazole	3-Octenoic acid	0.0075	0.039062	5	0.75
4	Epoxiconazole	Trans-3-octenoic acid	0.0075	0.039062	5	0.75
5	Epoxiconazole	Trans-2-nonenoic acid	0.00375	0.019531	5	0.25
6	Epoxiconazole	3-Nonenoic acid	0.00375	0.019531	5	0.38
7	Epoxiconazole	Trans-2-decenoic acid	0.00375	0.019531	5	0.38
8	Epoxiconazole	3-Decenoic acid	0.001875	0.019531	10	0.31
9	Epoxiconazole	9-Decenoic acid	0.00375	0.019531	5	0.25
10	Epoxiconazole	Trans-2-undecenoic acid	0.0075	0.039062	5	0.75
11	Epoxiconazole	(9Z)-octadecenoic acid	0.015	2.5	167	1.00

TABLE 50
Growth inhibition of Botrytis cinerea by tebuconazole, in combination
with various exemplary unsaturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Tebuconazole		0.1125
		5-Hexenoic acid		0.15625
		Trans-2-octenoic acid		0.039062
		Trans-2-decenoic acid		0.039062
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.039062
		Trans-2-undecenoic acid		0.039062
		(9Z)-octadecenoic acid		5.0
1	Tebuconazole	5-Hexenoic acid	0.028125	0.039062	1.4	0.50
2	Tebuconazole	Trans-2-octenoic acid	0.014062	0.009766	0.7	0.38
3	Tebuconazole	Trans-2-decenoic acid	0.028125	0.019531	0.7	0.75
4	Tebuconazole	3-Decenoic acid	0.028125	0.019531	0.7	0.50
5	Tebuconazole	9-Decenoic acid	0.014062	0.019531	1.4	0.63
6	Tebuconazole	Trans-2-undecenoic acid	0.028125	0.019531	0.7	0.75
7	Tebuconazole	(9Z)-octadecenoic acid	0.015	2.5	44	1.00

Example 15: Growth Inhibition of Botrytis cinerea by Pyraclostrobin, Azoxystrobin, Cyprodinil, Difenoconazole, Epoxiconazole and Tebuconazole, in Combination with Various Exemplary Hydroxy-Substituted Saturated Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, cyprodinil, difenoconazole, epoxiconazole and tebuconazole, were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Table 51 below. Working solutions of 3-hydroxybutyric acid, 3-hydroxyhexanoic acid and 3-hydroxydecanoic acid (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Table 51 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the growth inhibition assay, observed following an incubation period of 48 hours, and the FIC Index for each combination calculated, as shown in Table 51 below.

TABLE 51
Growth inhibition of Botrytis cinerea by various synthetic fungicides
in combination with various exemplary saturated aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.015
	Azoxystrobin		0.15
	Cyprodinil		0.009
	Difenoconazole		0.0255
	Epoxiconazole		0.03
	Tebuconazole		0.1125
		3-hydroxybutyric acid		10
		3-hydroxyhexanoic acid		2.5
		3-hydroxydecanoic acid		0.125
1	Pyraclostrobin	3-hydroxybutyric acid	0.00375	2.5	667	0.50
2	Azoxystrobin	3-hydroxybutyric acid	0.0375	5	133	0.75
3	Cyprodinil	3-hydroxybutyric acid	0.00225	5	2222	0.75
4	Cyprodinil	3-hydroxyhexanoic acid	0.00225	1.25	556	0.75
5	Cyprodinil	3-hydroxydecanoic acid	0.00225	0.0625	28	0.75
6	Difenoconazole	3-hydroxybutyric acid	0.01275	2.5	196	0.75
7	Difenoconazole	3-hydroxyhexanoic acid	0.01275	0.625	49	0.75
8	Difenoconazole	3-hydroxydecanoic acid	0.01275	0.03125	2	0.75
9	Epoxiconazole	3-hydroxybutyric acid	0.0075	2.5	333	0.50
10	Tebuconazole	3-hydroxybutyric acid	0.01406	1.25	89	0.25

Example 16: Growth Inhibition of Fusarium oxysporum by Pyraclostrobin, Azoxystrobin, Fludioxonil, and Tebuconazole, in Combination with Various Exemplary Hydroxy-Substituted Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, fludioxonil, and tebuconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 52-54 below. Working solutions of 2-hydroxybutyric acid, 2-hydroxyhexanoic acid, 2-hydroxyoctanoic acid, 3-hydroxyoctanoic acid, 8-hydroxyoctanoic acid, and 10-hydroxydecanoic acid, (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 52-54 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 48 hours, and the FIC Index for each combination calculated, as shown in Tables 52-54 below.

TABLE 52
Growth inhibition of Fusarium oxysporum by various synthetic fungicides
in combination with exemplary hydroxy-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.015
	Azoxystrobin		0.15
	Tebuconazole		0.1125
		3-Hydroxyoctanoic acid		1.25
		8-Hydroxyoctanoic acid		5
1	Pyraclostrobin	3-Hydroxyoctanoic acid	0.0075	0.3125	42	0.75
2	Pyraclostrobin	8-Hydroxyoctanoic acid	0.0075	1.25	167	0.75
3	Azoxystrobin	3-Hydroxyoctanoic acid	0.075	0.3125	4	0.75
4	Azoxystrobin	8-Hydroxyoctanoic acid	0.075	1.25	17	0.75
7	Tebuconazole	8-Hydroxyoctanoic acid	0.05625	0.625	11	0.63

TABLE 53
Growth inhibition of Fusarium oxysporum by pyraclostrobin in
combination with an exemplary hydroxy-substituted aliphatic acid
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.015
		10-Hydroxydecanoic		1
		acid
1	Pyraclostrobin	10-Hydroxydecanoic	0.00375	0.25	67	0.50
		acid

TABLE 54
Growth inhibition of Fusarium oxysporum by various synthetic fungicides
in combination with various exemplary hydroxy-substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.015
	Fludioxonil		0.021
	Azoxystrobin		0.15
	Tebuconazole		0.225
		2-Hydroxybutyric acid		5
		2-Hydroxyhexanoic acid		2.5
		2-Hydroxyoctanoic acid		0.625
1	Pyraclostrobin	2-Hydroxybutyric acid	0.00375	1.25	333	0.50
2	Pyraclostrobin	2-Hydroxyhexanoic acid	0.00375	0.625	167	0.50
3	Fludioxonil	2-Hydroxybutyric acid	0.00525	1.25	238	0.50
4	Fludioxonil	2-Hydroxyhexanoic acid	0.00525	0.625	119	0.50
5	Fludioxonil	2-Hydroxyoctanoic acid	0.00525	0.15625	30	0.50
6	Azoxystrobin	2-Hydroxybutyric acid	0.0375	1.25	33	0.50
7	Azoxystrobin	2-Hydroxyhexanoic acid	0.0375	0.625	17	0.50
8	Tebuconazole	2-Hydroxyhexanoic acid	0.05625	0.625	11	0.50

Example 17: Growth Inhibition of Sclerotinia sclerotiorum by Pyraclostrobin, Azoxystrobin, Fludioxonil, Difenoconazole, and Tebuconazole, in Combination with Various Exemplary Hydroxy-Substituted Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, fludioxonil, difenoconazole, and tebuconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 55-57 below. Working solutions of 2-hydroxybutyric acid, 2-hydroxyhexanoic acid, 2-hydroxyoctanoic acid, 3-hydroxyoctanoic acid, 8-hydroxyoctanoic acid, 10-hydroxydecanoic acid, and 12-hydroxydodecanoic acid (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 55-57 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 7 days, and the FIC Index for each combination calculated, as shown in Tables 55-57 below.

TABLE 55
Growth inhibition of Sclerotinia sclerotiorum by by various synthetic fungicides
in combination with various exemplary hydroxy-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0075
	Azoxystrobin		0.15
	Fludioxonil		3.28125 × 10−4
	Tebuconazole		0.05625
		3-hydroxyoctanoic acid		0.625
		8-hydroxyoctanoic acid		5
1	Pyraclostrobin	3-hydroxyoctanoic acid	0.001875	0.15625	83	0.50
2	Pyraclostrobin	8-hydroxyoctanoic acid	9.375 × 10−4	0.3125	333	0.19
3	Azoxystrobin	3-hydroxyoctanoic acid	0.0375	0.15625	4	0.50
4	Azoxystrobin	8-hydroxyoctanoic acid	0.0375	0.625	17	0.38
5	Fludioxonil	8-hydroxyoctanoic acid	8.20315 × 10−5	1.25	15238	0.50
6	Tebuconazole	3-hydroxyoctanoic acid	0.028125	0.15625	6	0.75
7	Tebuconazole	8-hydroxyoctanoic acid	0.028125	0.625	22	0.63

TABLE 56
Growth inhibition of Sclerotinia sclerotiorum by various synthetic fungicides
in combination with various exemplary hydroxy-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0075
	Azoxystrobin		0.15
	Fludioxonil		3.28125 × 10−4
	Difenoconazole		0.0255
		10-hydroxydecanoic acid		0.5
		12-hydroxydodecanoic		0.1
		acid
1	Pyraclostrobin	10-hydroxydecanoic acid	0.001875	0.125	67	0.50
2	Pyraclostrobin	12-hydroxydodecanoic	0.001875	0.025	13	0.50
		acid
3	Azoxystrobin	10-hydroxydecanoic acid	0.0375	0.125	3	0.50
4	Fludioxonil	10-hydroxydecanoic acid	8.20315 × 10−5	0.25	3048	0.75
5	Difenoconazole	12-hydroxydodecanoic	0.006375	0.025	4	0.50
		acid

TABLE 57
Growth inhibition of Sclerotinia sclerotiorum by various synthetic fungicides
in combination with various exemplary hydroxy-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0075
	Fludioxonil		3.281 × 10−4
	Difenoconazole		0.0255
	Azoxystrobin		0.15
	Tebuconazole		0.1125
		2-Hydroxybutyric acid		2.5
		2-Hydroxyhexanoic acid		2.5
		2-Hydroxyoctanoic acid		0.3125
1	Pyraclostrobin	2-Hydroxybutyric acid	0.001875	1.25	667	0.75
2	Pyraclostrobin	2-Hydroxyhexanoic acid	0.001875	0.625	333	0.50
3	Pyraclostrobin	2-Hydroxyoctanoic acid	0.001875	0.15625	83	0.75
4	Fludioxonil	2-Hydroxybutyric acid	4.101 × 10−5	1.25	30476	0.63
5	Fludioxonil	2-Hydroxyhexanoic acid	4.101 × 10−5	0.625	15238	0.38
6	Fludioxonil	2-Hydroxyoctanoic acid	4.101 × 10−5	0.15625	3810	0.63
7	Difenoconazole	2-Hydroxybutyric acid	0.006375	1.25	196	0.75
8	Difenoconazole	2-Hydroxyhexanoic acid	0.006375	0.625	98	0.50
9	Azoxystrobin	2-Hydroxybutyric acid	0.0375	1.25	33	0.75
10	Azoxystrobin	2-Hydroxyhexanoic acid	0.0375	0.625	17	0.50
11	Azoxystrobin	2-Hydroxyoctanoic acid	0.0375	0.15625	4	0.75
12	Tebuconazole	2-Hydroxybutyric acid	0.01406	0.625	44	0.38
13	Tebuconazole	2-Hydroxyhexanoic acid	0.028125	0.625	22	0.50
14	Tebuconazole	2-Hydroxyoctanoic acid	0.028125	0.15625	6	0.75

Example 18: Growth Inhibition of Botryrtis cinerea by Various Exemplary Synthetic Fungicides, in Combination with Various Exemplary Hydroxy-Substituted Saturated Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, fludioxonil, tebuconazole, and difenoconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 58-61 below. Working solutions of 2-hydroxybutyric, 2-hydroxyhexanoic, 2-hydroxyoctanoic, 10-hydroxydecanoic, 12-hydroxydodecanoic, 3-hydroxyoctanoic, 8-hydroxyoctanoic acids, (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 58-61 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 2 days, and the FIC Index for each combination calculated, as shown in Tables 58-61 below.

TABLE 58
Growth inhibition of Botrytis cinerea by various exemplary synthetic fungicides
in combination with various exemplary hydroxy-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.015
	Azoxystrobin		0.15
	Difenoconazole		0.051
	Tebuconazole		0.1125
		3-hydroxyoctanoic acid		0.625
		8-hydroxyoctanoic acid		2.5
1	Pyraclostrobin	3-hydroxyoctanoic acid	0.00375	0.15625	42	0.50
2	Pyraclostrobin	8-hydroxyoctanoic acid	0.00375	0.625	167	0.50
3	Azoxystrobin	3-hydroxyoctanoic acid	0.0375	0.3125	8	0.75
4	Azoxystrobin	8-hydroxyoctanoic acid	0.0375	1.25	33	0.75
5	Difenoconazole	8-hydroxyoctanoic acid	0.006375	0.3125	49	0.25
6	Tebuconazole	3-hydroxyoctanoic acid	0.003516	0.01953	6	0.06
7	Tebuconazole	8-hydroxyoctanoic acid	0.001758	0.03906	22	0.03

TABLE 59
Growth inhibition of Botrytis cinerea by various exemplary synthetic fungicides
in combination with various exemplary hydroxy-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.015
	Fludioxonil		1.641 × 10−4
	Tebuconazole		0.1125
		3-Hydroxyoctanoic acid		0.625
		8-Hydroxyoctanoic acid		2.5
		10-Hydroxydecanoic		0.5
		acid
		12-Hydroxydodecanoic		0.05
		acid
1	Pyraclostrobin	12-Hydroxydodecanoic	0.00375	0.025	7	0.75
		acid
2	Fludioxonil	3-Hydroxyoctanoic acid	4.103 × 10−5	0.019531	476	0.28
3	Fludioxonil	8-Hydroxyoctanoic acid	4.103 × 10−5	0.078125	1904	0.28
4	Tebuconazole	10-Hydroxydecanoic	0.003516	0.015625	4	0.06
		acid

TABLE 60
Growth inhibition of Botrytis cinerea by various exemplary synthetic fungicides
in combination with various exemplary hydroxy-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Comp	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Comp A	Index
	Azoxystrobin		0.15
		12-Hydroxydodecanoic acid		0.1
1	Azoxystrobin	12-Hydroxydodecanoic acid	0.0375	0.05	1.33	0.75

TABLE 61
Growth inhibition of Botrytis cinerea by various exemplary synthetic fungicides
in combination with various exemplary hydroxy-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Comp	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Comp A	Index
	Pyraclostrobin		0.015
	Azoxystrobin		0.15
	Difenoconazole		0.051
		2-hydroxybutyric acid		5
		2-hydroxyhexanoic acid		2.5
		2-hydroxyoctanoic acid		0.625
1	Pyraclostrobin	2-hydroxyoctanoic acid	0.00375	0.15625	42	0.50
2	Azoxystrobin	2-hydroxybutyric acid	0.0375	2.5	67	0.75
3	Azoxystrobin	2-hydroxyhexanoic acid	0.0375	1.25	33	0.75
4	Azoxystrobin	2-hydroxyoctanoic acid	0.0375	0.3125	8	0.75
5	Difenoconazole	2-hydroxybutyric acid	0.01275	1.25	98	0.50

Example 19: Growth Inhibition of Sclerotinta Sclerotiorum by Pyraclostrobin, Azoxystrobin, Fludioxonil, and Tebuconazole, in Combination with Various Exemplary Alkyl-Substituted Aliphatic Acids

Working solutions ofpyraclostrobin, azoxystrobin, fludioxonil, and tebuconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 62-66 below. Working solutions of2,2-diethylbutanoic acid, 3-methylbutyric acid, 2-ethylhexanoic acid, 3-methylhexanoic acid, 4-methylhexanoc acid, and 2-methyloctanoic acid, (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 62-66 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 7 days, and the FIC Index for each combination calculated, as shown in Tables 62-66 below.

TABLE 62
Growth inhibition of Sclerotinia sclerotiorum by various exemplary synthetic fungicides
in combination with various exemplary alkyl-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0075
	Fludioxonil		3.281 × 10−4
	Azoxystrobin		0.15
	Tebuconazole		0.1125
		2,2-Diethylbutanoic acid		0.25
		3-Methylbutyric acid		0.625
	Pyraclostrobin	2,2-Diethylbutanoic acid	0.001875	0.0625	33	0.50
	Pyraclostrobin	3-Methylbutyric acid	9.375 × 10−4	0.078125	83	0.25
	Fludioxonil	2,2-Diethylbutanoic acid	4.101 × 10−5	0.0625	1524	0.38
	Fludioxonil	3-Methylbutyric acid	4.101 × 10−5	0.15625	3810	0.38
	Azoxystrobin	3-Methylbutyric acid	0.0375	0.15625	4	0.50
	Tebuconazole	2,2-Diethylbutanoic acid	0.028125	0.0625	2	0.50
	Tebuconazole	3-Methylbutyric acid	0.028125	0.15625	6	0.50

TABLE 63
Growth inhibition of Sclerotinia sclerotiorum by various exemplary synthetic
fungicides in combination with an exemplary alkyl-substituted aliphatic acid
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0075
	Azoxystrobin		0.15
	Fludioxonil		3.28125 × 10−4
	Difenoconazole		0.01275
	Tebuconazole		0.05625
		2-Ethylhexanoic acid		0.625
1	Pyraclostrobin	2-Ethylhexanoic acid	2.34375 × 10−4	0.009766	42	0.05
2	Azoxystrobin	2-Ethylhexanoic acid	0.01875	0.039062	2	0.19
3	Fludioxonil	2-Ethylhexanoic acid	4.10158 × 10−5	0.078125	1905	0.25
4	Difenoconazole	2-Ethylhexanoic acid	0.006375	0.078125	12	0.63
5	Tebuconazole	2-Ethylhexanoic acid	0.028125	0.078125	3	0.63

TABLE 64
Growth inhibition of Sclerotinia sclerotiorum by various exemplary synthetic
fungicides in combination with an exemplary alkyl-substituted aliphatic acid
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0075
	Azoxystrobin		0.15
	Fludioxonil		3.2813 × 10−4
		2-Methyloctanoic acid		0.078125
1	Pyraclostrobin	2-Methyloctanoic acid	9.375 × 10−4	0.009766	10	0.25
2	Azoxystrobin	2-Methyloctanoic acid	0.0375	0.019531	0.5	0.50
3	Fludioxonil	2-Methyloctanoic acid	4.10158 × 10−5	0.019531	476	0.38

TABLE 65
Growth inhibition of Sclerotinia sclerotiorum by various exemplary synthetic
fungicides in combination with an exemplary alkyl-substituted aliphatic acid
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.0075
	Fludioxonil		3.28125 × 10−4
		3-Methylhexanoic acid		0.125
1	Pyraclostrobin	3-Methylhexanoic acid	9.375 × 10−4	0.015625	17	0.25
2	Fludioxonil	3-Methylhexanoic acid	8.20315 × 10−5	0.0625	762	0.75

TABLE 66
Growth inhibition of Sclerotinia sclerotiorum by pyraclostrobin
in combination with an exemplary alkyl-substituted aliphatic acid
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Pyraclostrobin		0.00375
		4-Methylhexanoic acid		0.078125
1	Pyraclostrobin	4-Methylhexanoic acid	9.375 × 10−4	0.009766	10	0.38

Example 20: Growth Inhibition of Botrytis cinerea by Pyraclostrobin, Azoxystrobin, Difenoconazole, and Tebuconazole, in Combination with Various Exemplary Alkyl-Substituted Aliphatic Acids

Working solutions of pyraclostrobin, azoxystrobin, difenoconazole, and tebuconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 67-70 below. Working solutions of 2,2-diethylbutanoic acid, 3-methylbutyric acid, 2-ethylhexanoic acid, 3-methylhexanoic acid, 4-methylhexanoic acid, and 2-methyloctanoic acid, and 2-methyldecanoic acid (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 67-70 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 48 hours, and the FIC Index for each combination calculated, as shown in Tables 67-70 below.

TABLE 67
Growth inhibition of Botrytis cinerea by various exemplary synthetic fungicides
in combination with various exemplary alkyl-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio Comp	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Comp A	Index
	Pyraclostrobin		0.0015
	Difenoconazole		0.051
	Azoxystrobin		0.15
	Tebuconazole		0.1125
		2,2-Diethylbutanoic acid		0.25
		4-Methylhexanoic acid		0.15625
		2-Methyloctanoic acid		0.078125
1	Pyraclostrobin	4-Methylhexanoic acid	0.00375	0.03906	10	0.50
2	Difenoconazole	2,2-Diethylbutanoic acid	0.01275	0.0625	5	0.50
3	Difenoconazole	4-Methylhexanoic acid	0.01275	0.03906	3	0.50
4	Difenoconazole	2-Methyloctanoic acid	0.01275	0.019531	2	0.50
5	Azoxystrobin	4-Methylhexanoic acid	0.01875	0.039062	2	0.38
6	Tebuconazole	2,2-Diethylbutanoic acid	0.001758	0.003906	2	0.03
7	Tebuconazole	4-Methylhexanoic acid	0.003516	0.004883	1.4	0.06
8	Tebuconazole	2-Methyloctanoic acid	0.001758	0.001221	0.7	0.03

TABLE 68
Growth inhibition of Botrytis cinerea by various exemplary synthetic fungicides
in combination with an exemplary alkyl-substituted aliphatic acid
			MIC (A)	MIC (B)	Ratio Comp	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Comp A	Index
	Pyraclostrobin		0.015
	Difenoconazole		0.051
	Tebuconazole		0.1125
		2-Ethylhexanoic acid		0.3125
1	Pyraclostrobin	2-Ethylhexanoic acid	0.0075	0.078125	10	0.75
2	Difenoconazole	2-Ethylhexanoic acid	0.0255	0.078125	3	0.75
3	Tebuconazole	2-Ethylhexanoic acid	0.003516	0.004883	1	0.05

TABLE 69
Growth inhibition of Botrytis cinerea by various exemplary synthetic fungicides
in combination with an exemplary alkyl-substituted aliphatic acid
			MIC (A)	MIC (B)	Ratio Comp	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Comp A	Index
	Pyraclostrobin		0.015
	Azoxystrobin		0.15
	Tebuconazole		0.1125
		3-Methylhexanoic acid		0.125
1	Pyraclostrobin	3-Methylhexanoic acid	0.00375	0.03125	8	0.50
2	Azoxystrobin	3-Methylhexanoic acid	0.0375	0.0625	2	0.75
3	Tebuconazole	3-Methylhexanoic acid	0.001758	0.001953	1	0.03

TABLE 70
Growth inhibition of Botrytis cinerea by various exemplary synthetic fungicides
in combination with various exemplary alkyl-substituted aliphatic acids
			MIC (A)	MIC (B)	Ratio CompB/	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	Comp A	Index
	Pyraclostrobin		0.015
	Difenoconazole		0.051
		2-Methyldecanoic acid	0.015625
		3-Methylbutyric acid	0.3125
	Pyraclostrobin	2-Methyldecanoic acid	0.00375	0.0078125	2	0.75
1	Pyraclostrobin	3-Methylbutyric acid	0.00375	0.15625	42	0.75
2	Difenoconazole	3-Methylbutyric acid	0.006375	0.078125	12	0.38

Example 21: Growth Inhibition of Botrytis cinerea by Picoxystrobin, Mancozeb, Isopyrazam, Oxathiapiprolin, Penthiopyrad, Prothioconazole and Trifloxystrobin, in Combination with Various Exemplary C4-C10 Saturated, Unsaturated, Hydroxy-, Methyl-, Ethyl-, and Diethyl-Substituted Aliphatic Acids

Working solutions of picoxystrobin, mancozeb, isopyrazam, oxathiapiprolin, penthiopyrad, prothioconazole, and trifloxystrobin, were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 71-79 below. Working solutions of 2-hydroxybutyric acid, 2-hydroxyhexanoic acid, 2-hydroxyoctanoic acid, 3-hydroxybutyric acid, 3-hydroxyhexanoic acid, 3-hydroxyoctanoic acid, 3-hydroxydecanoic acid, 8-hydroxyoctanoic acid, 10-hydroxydecanoic acid, 12-hydroxydodecanoic acid, 2,2-diethylbutanoic acid, 2-ethylhexanoic acid, 2-methyloctanoic acid, 2-methyldecanoic acid, 3-methylbutyric acid, 3-methylhexanoic acid, 3-methylnonanoic acid, 4-methylhexanoic acid, hexanoic acid, octanoic acid, nonanoic acid, decanoic acid, dodecanoic acid, 2,4-hexedienoic acid, trans-2-hexenoic acid, trans-2-octenoic acid, trans-3-octenoic acid, 7-octenoic acid, trans-2-nonenoic acid, trans-2-decenoic acid, 3-decenoic acid, 9-decenoic acid, trans-2-undecenoic acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, 3-hydroxyhexanoic acid, 3-hydroxyoctanoic acid, 3-hydroxydecanoic acid, 8-hydroxyoctanoic acid, 12-hydroxydodecanoic acid, 2-methyloctanoic acid, 2-methyldecanoic acid, and oleic acid (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 71-79 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 48 hours, and the FIC Index for each combination calculated, as shown in Tables 71-79 below.

TABLE 71
Growth inhibition of Botrytis cinerea by picoxystrobin, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Picoxystrobin		0.25
		Trans-2-decenoic acid		0.019531
		2-Hydroxybutyric acid		5
		2-Hydroxyhexanoic acid		1.25
		2-Hydroxyoctanoic acid		0.625
		3-Hydroxybutyric acid		10
		3-Hydroxyhexanoic acid		2.5
		3-Hydroxyoctanoic acid		0.625
		3-Hydroxydecanoic acid		0.0625
		8-Hydroxyoctanoic acid		1.25
		10-Hydroxydecanoic acid		0.25
		12-Hydroxydodecanoic		0.1
		acid
		2,2-Diethylbutanoic acid		0.25
		2-Ethylhexanoic acid		0.15625
		2-Methyloctanoic acid		0.039062
		2-Methyldecanoic acid		0.0078125
		3-Methylbutyric acid		0.3125
		3-Methylhexanoic acid		0.125
		3-Methylnonanoic acid		0.015625
		4-Methylhexanoic acid		0.078125
1	Picoxystrobin	Trans-2-decenoic acid	0.015625	0.004883	0.31	0.31
2	Picoxystrobin	2-Hydroxybutyric acid	0.015625	0.625	40	0.19
3	Picoxystrobin	2-Hydroxyhexanoic acid	0.015625	0.3125	20	0.31
4	Picoxystrobin	2-Hydroxyoctanoic acid	0.015625	0.078125	5	0.19
5	Picoxystrobin	3-Hydroxybutyric acid	0.015625	1.25	80	0.19
6	Picoxystrobin	3-Hydroxyhexanoic acid	0.015625	0.3125	20	0.19
7	Picoxystrobin	3-Hydroxyoctanoic acid	0.03125	0.15625	5	0.38
8	Picoxystrobin	3-Hydroxydecanoic acid	0.015625	0.015625	1	0.31
9	Picoxystrobin	8-Hydroxyoctanoic acid	0.015625	0.3125	20	0.31
10	Picoxystrobin	10-Hydroxydecanoic acid	0.015625	0.0625	4	0.31
11	Picoxystrobin	12-Hydroxydodecanoic	0.03125	0.025	0.8	0.38
		acid
12	Picoxystrobin	2,2-Diethylbutanoic acid	0.015625	0.03125	2	0.19
13	Picoxystrobin	2-Ethylhexanoic acid	0.015625	0.019531	1.25	0.19
14	Picoxystrobin	2-Methyloctanoic acid	0.0078125	0.004883	0.6	0.16
15	Picoxystrobin	2-Methyldecanoic acid	0.015625	0.003906	0.25	0.56
16	Picoxystrobin	3-Methylbutyric acid	0.015625	0.078125	5	0.31
17	Picoxystrobin	3-Methylhexanoic acid	0.015625	0.015625	1	0.19
18	Picoxystrobin	3-Methylnonanoic acid	0.015625	0.001953	0.13	0.19
19	Picoxystrobin	4-Methylhexanoic acid	0.015625	0.019531	1.25	0.31

TABLE 72
Growth inhibition of Botrytis cinerea by picoxystrobin, in
combination with various exemplary unsaturated aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Picoxystrobin		0.25
		Decanoic acid		0.015625
		Trans-2-hexenoic		0.15625
		acid
	Picoxystrobin	Decanoic acid	0.03125	0.0078125	0.25	0.63
	Picoxystrobin	Trans-2-hexenoic	0.0625	0.019531	0.3	0.38
		acid

TABLE 73
Growth inhibition of Botrytis cinerea by mancozeb, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Mancozeb		0.03125
		Trans-2-octenoic acid		0.039062
		3-Decenoic acid		0.039062
1	Mancozeb	Trans-2-octenoic acid	0.003906	0.019531	5	0.63
2	Mancozeb	3-Decenoic acid	0.003906	0.019531	5	0.63

TABLE 74
Growth inhibition of Botrytis cinerea by isopyrazam, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Isopyrazam		0.03125
		Hexanoic acid		0.15625
		Octanoic acid		0.3125
		Decanoic acid		0.015625
		Dodecanoic acid		0.05
		2,4-Dihexenoic acid		0.125
		5-Hexenoic acid		0.3125
		7-Octenoic acid		0.3125
		3-Nonenoic acid		0.078125
		Trans-3-octenoic acid		0.039062
		3-Decenoic acid		0.039062
		9-Decenoic acid		0.078125
		Oleic acid		5
1	Isopyrazam	Hexanoic acid	0.0078125	0.03906	5	0.50
2	Isopyrazam	Octanoic acid	0.0078125	0.019531	2.5	0.31
3	Isopyrazam	Decanoic acid	0.0039062	0.0078125	2	0.63
4	Isopyrazam	Dodecanoic acid	0.0078125	0.0125	1.6	0.50
5	Isopyrazam	2,4-Dihexenoic acid	0.0078125	0.0625	8	0.75
6	Isopyrazam	5-Hexenoic acid	0.0078125	0.039062	5	0.38
7	Isopyrazam	7-Octenoic acid	0.0078125	0.019531	2.5	0.31
8	Isopyrazam	3-Nonenoic acid	0.0078125	0.019531	2.5	0.50
9	Isopyrazam	Trans-3-octenoic acid	0.0078125	0.019531	2.5	0.75
10	Isopyrazam	3-Decenoic acid	0.0078125	0.019531	2.5	0.75
11	Isopyrazam	9-Decenoic acid	0.0078125	0.019531	2.5	0.50
12	Isopyrazam	Oleic acid	0.03125	5	160	2.0

TABLE 75
Growth inhibition of Botrytis cinerea by oxathiapiprolin, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Oxathiapiprolin		0.5
		12-Hydroxydodecanoic		0.1
		acid
		2-Hydroxybutyric acid
1	Oxathiapiprolin	12-Hydroxydodecanoic	0.125	0.025	0.2	0.50
		acid
2	Oxathiapiprolin	2-Hydroxybutyric acid	0.125	1.25	10	0.75

TABLE 76
Growth inhibition of Botrytis cinerea by penthiopyrad, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Penthiopyrad		0.25
		Hexanoic acid		0.15625
		Octanoic acid		0.3125
		Nonanoic acid		0.078125
		Decanoic acid		0.03125
		Dodecanoic acid		0.05
		(2E,4E)-2,4-Hexadienoic		0.125
		acid
		Trans-2-hexenoic acid		0.3125
		Trans-2-octenoic acid		0.078125
		Trans-3-octenoic acid		0.078125
		7-Octenoic acid		0.3125
		Trans-2-nonenoic acid		0.15625
		Trans-2-decenoic acid		0.078125
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.078125
		Trans-2-undecenoic acid		0.039062
		2-Hydroxybutyric acid		2.5
		3-Hydroxybutyric acid		10
		3-Hydroxyhexanoic acid		5
		3-Hydroxyoctanoic acid		0.625
		3-Hydroxydecanoic acid		0.125
		8-Hydroxyoctanoic acid		2.5
		12-Hydroxydodecanoic		0.1
		acid
		2-Methyloctanoic acid		0.3125
		2-Methyldecanoic acid		0.125
		Oleic acid		5
1	Penthiopyrad	Hexanoic acid	0.0625	0.039062	0.6	0.50
2	Penthiopyrad	Octanoic acid	0.0625	0.019531	0.3	0.31
3	Penthiopyrad	Nonanoic acid	0.0625	0.019531	0.3	0.50
4	Penthiopyrad	Decanoic acid	0.03125	0.0078125	0.25	0.38
5	Penthiopyrad	Dodecanoic acid	0.0625	0.0125	0.2	0.50
6	Penthiopyrad	(2E,4E)-2,4-Hexadienoic	0.0625	0.0625	1	0.75
		acid
7	Penthiopyrad	Trans-2-hexenoic acid	0.0625	0.019531	0.3	0.31
8	Penthiopyrad	Trans-2-octenoic acid	0.0625	0.019531	0.3	0.50
9	Penthiopyrad	Trans-3-octenoic acid	0.0625	0.019531	0.3	0.50
10	Penthiopyrad	7-Octenoic acid	0.0625	0.019531	0.3	0.31
11	Penthiopyrad	Trans-2-nonenoic acid	0.0625	0.009766	0.16	0.31
12	Penthiopyrad	Trans-2-decenoic acid	0.03125	0.004883	0.16	0.19
13	Penthiopyrad	3-Decenoic acid	0.0625	0.019531	0.3	0.50
14	Penthiopyrad	9-Decenoic acid	0.0625	0.019531	0.3	0.50
15	Penthiopyrad	Trans-2-undecenoic acid	0.0625	0.019531	0.3	0.63
16	Penthiopyrad	2-Hydroxybutyric acid	0.0625	1.25	20	0.75
17	Penthiopyrad	3-Hydroxybutyric acid	0.0625	2.5	40	0.50
18	Penthiopyrad	3-Hydroxyhexanoic acid	0.0625	0.625	10	0.38
19	Penthiopyrad	3-Hydroxyoctanoic acid	0.0625	0.15625	2.5	0.50
20	Penthiopyrad	3-Hydroxydecanoic acid	0.0625	0.03125	0.5	0.50
21	Penthiopyrad	8-Hydroxyoctanoic acid	0.03125	0.3125	10	0.25
22	Penthiopyrad	12-Hydroxydodecanoic	0.0625	0.025	0.4	0.50
		acid
23	Penthiopyrad	2-Methyloctanoic acid	0.0625	0.019531	0.3	0.31
24	Penthiopyrad	2-Methyldecanoic acid	0.03125	0.0039062	0.13	0.16
25	Penthiopyrad	Oleic acid	0.125	2.5	20	1.0

TABLE 77
Growth inhibition of Botrytis cinerea by prothioconazole, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Prothioconazole		0.03125
		2-Hydroxybutyric		2.5
		acid
1	Prothioconazole	2-Hydroxybutyric	0.0078125	1.25	160	0.75
		acid

TABLE 78
Growth inhibition of Botrytis cinerea by trifloxystrobin, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Trifloxystrobin		0.25
		Hexanoic acid		0.3125
		Octanoic acid		0.625
		Decanoic acid		0.03125
		(2E,4E)-2,4-Hexadienoic		0.25
		acid
		Trans-2-octenoic acid		0.078125
		Trans-2-decenoic acid		0.15625
		3-Decenoic acid		0.15625
		9-Decenoic acid		0.15625
		Trans-2-undecenoic acid		0.15625
1	Trifloxystrobin	Hexanoic acid	0.03125	0.039062	1.25	0.25
2	Trifloxystrobin	Octanoic acid	0.03125	0.019531	0.6	0.16
3	Trifloxystrobin	Decanoic acid	0.03125	0.015625	0.5	0.63
4	Trifloxystrobin	(2E,4E)-2,4-Hexadienoic	0.03125	0.0625	2	0.38
		acid
5	Trifloxystrobin	Trans-2-octenoic acid	0.03125	0.019531	0.6	0.38
6	Trifloxystrobin	Trans-2-decenoic acid	0.03125	0.009766	0.3	0.19
7	Trifloxystrobin	3-Decenoic acid	0.03125	0.019531	0.6	0.25
8	Trifloxystrobin	9-Decenoic acid	0.03125	0.019531	0.6	0.25
9	Trifloxystrobin	Trans-2-undecenoic acid	0.03125	0.019531	0.6	0.25

TABLE 79
Growth inhibition of Botrytis cinerea by trifloxystrobin, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Trifloxystrobin		0.25
		Heptanoic acid		0.078125
		Nonanoic acid		0.078125
		2-Hydroxybutyric acid		2.5
		2-hydroxyhexanoic acid		1.25
		2-Hydroxydecanoic acid		0.3125
		3-Hydroxybutyric acid		5
		3-Hydroxyhexanoic acid		2.5
		3-Hydroxyoctanoic acid		0.625
		3-Hydroxydecanoic acid		0.125
		8-Hydroxyoctanoic acid		1.25
		10-Hydroxydecanoic acid		0.25
		12-Hydroxydodecanoic		0.05
		acid
		2,2-Diethylbutanoic acid		0.25
		2-Ethylhexanoic acid		0.15625
		2-Methyloctanoic acid		0.078125
		2-Methyldecanoic acid		0.125
		3-Methylbutyric acid		0.3125
		3-Methylhexanoic acid		0.125
		4-Methylhexanoic acid		0.078125
1	Trifloxystrobin	Heptanoic acid	0.03125	0.019531	0.6	0.38
2	Trifloxystrobin	Nonanoic acid	0.015625	0.009766	0.6	0.19
3	Trifloxystrobin	2-Hydroxybutyric acid	0.03125	1.25	40	0.63
4	Trifloxystrobin	2-hydroxyhexanoic acid	0.03125	0.625	20	0.63
5	Trifloxystrobin	2-Hydroxydecanoic acid	0.03125	0.15625	5	0.63
6	Trifloxystrobin	3-Hydroxybutyric acid	0.03125	2.5	80	0.63
7	Trifloxystrobin	3-Hydroxyhexanoic acid	0.03125	0.625	20	0.38
8	Trifloxystrobin	3-Hydroxyoctanoic acid	0.03125	0.15625	5	0.38
9	Trifloxystrobin	3-Hydroxydecanoic acid	0.03125	0.03125	1	0.38
10	Trifloxystrobin	8-Hydroxyoctanoic acid	0.03125	0.625	20	0.63
11	Trifloxystrobin	10-Hydroxydecanoic acid	0.03125	0.125	4	0.63
12	Trifloxystrobin	12-Hydroxydodecanoic	0.03125	0.025	0.8	0.63
		acid
13	Trifloxystrobin	2,2-Diethylbutanoic acid	0.03125	0.0625	2	0.38
14	Trifloxystrobin	2-Ethylhexanoic acid	0.015625	0.019531	1.25	0.19
15	Trifloxystrobin	2-Methyloctanoic acid	0.015625	0.009766	0.6	0.19
16	Trifloxystrobin	2-Methyldecanoic acid	0.015625	0.0039062	0.25	0.09
17	Trifloxystrobin	3-Methylbutyric acid	0.03125	0.15625	5	0.63
18	Trifloxystrobin	3-Methylhexanoic acid	0.03125	0.03125	1	0.38
19	Trifloxystrobin	4-Methylhexanoic acid	0.015625	0.019531	1.25	0.31

Example 22: Growth Inhibition of Alternaria Solani by Picoxystrobin, Mancozeb, Penthiopyrad, and Prothioconazole, in Combination with Various Exemplary C4-C10 Saturated, Unsaturated, Hydroxy-, Methyl-, Ethyl-, and Diethyl-Substituted Aliphatic Acids

Working solutions of picoxystrobin, mancozeb, penthiopyrad, and prothioconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 80-84 below. Working solutions of 2-hydroxybutyric acid, 2-hydroxyoctanoi c acid, 2-ethylhexanoi c acid, 2-methyloctanoic acid, 2-methyldecanoic acid, 3-methylhexanoic acid, 3-methylnonanoic acid, 4-methylhexanoic acid, hexanoic acid, heptanoic, octanoic acid, nonanoic acid, decanoic acid, dodecanoic acid, 2,4-hexedienoic acid, trans-3-hexenoic acid, 5-hexenoic acid, 3-heptenoic acid, trans-2-octenoic acid, 3-octenoic acid, trans-3-octenoic acid, trans-2-nonenoic acid, 3-nonenoic acid, trans-2-decenoic acid, cis-3-hexenoic acid, 7-octenoic acid, 3-decenoic acid, 9-decenoic acid, trans-2-undecenoic acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, 3-hydroxyhexanoic acid, 3-hydroxyoctanoic acid, 3-hydroxydecanoic acid, 8-hydroxyoctanoic acid, 12-hydroxydodecanoic acid, 2-methyloctanoic acid, 2-methyldecanoic acid, and oleic acid (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 80-84 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 7 days, and the FIC Index for each combination calculated, as shown in Tables 80-84 below.

TABLE 80
Growth inhibition of Alternaria solani by picoxystrobin, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Picoxystrobin		0.5
		Hexanoic acid		0.15625
		Heptanoic acid		0.15625
		Octanoic acid		0.15625
		Nonanoic acid		0.15625
		Decanoic acid		0.03125
		Dodecanoic acid		0.1
		(2E,4E)-2,4-Hexadienoic		0.125
		acid
		Trans-3-hexenoic acid		0.3125
		5-Hexenoic acid		0.3125
		3-Heptenoic acid		0.3125
		Trans-2-octenoic acid		0.078125
		3-Octenoic acid		0.15625
		Trans-3-octenoic acid		0.15625
		Trans-2-nonenoic acid		0.078125
		3-Nonenoic acid		0.078125
		Trans-2-decenoic acid		0.078125
		3-Decenoic acid		0.078125
		9-Decenoic acid		0.03906
		Trans-2-undecenoic acid		0.15625
1	Picoxystrobin	Hexanoic acid	0.125	0.039062	0.3	0.50
2	Picoxystrobin	Heptanoic acid	0.0625	0.019531	0.3	0.25
3	Picoxystrobin	Octanoic acid	0.03125	0.019531	0.6	0.19
4	Picoxystrobin	Nonanoic acid	0.0625	0.009766	0.16	0.19
5	Picoxystrobin	Decanoic acid	0.0625	0.0078125	0.13	0.38
6	Picoxystrobin	Dodecanoic acid	0.0625	0.0125	0.2	0.25
7	Picoxystrobin	(2E,4E)-2,4-Hexadienoic	0.0625	0.03125	0.5	0.38
		acid
8	Picoxystrobin	Trans-3-hexenoic acid	0.125	0.078125	0.6	0.50
9	Picoxystrobin	5-Hexenoic acid	0.125	0.078125	0.6	0.50
10	Picoxystrobin	3-Heptenoic acid	0.125	0.039062	0.3	0.38
11	Picoxystrobin	Trans-2-octenoic acid	0.125	0.019531	0.16	0.50
12	Picoxystrobin	3-Octenoic acid	0.125	0.039062	0.3	0.50
13	Picoxystrobin	Trans-3-octenoic acid	0.0625	0.019531	0.3	0.25
14	Picoxystrobin	Trans-2-nonenoic acid	0.03125	0.019531	0.6	0.31
15	Picoxystrobin	3-Nonenoic acid	0.0625	0.019531	0.3	0.38
16	Picoxystrobin	Trans-2-decenoic acid	0.125	0.039062	0.3	0.75
17	Picoxystrobin	3-Decenoic acid	0.0625	0.019531	0.3	0.38
18	Picoxystrobin	9-Decenoic acid	0.0625	0.019531	0.3	0.63
19	Picoxystrobin	Trans-2-undecenoic acid	0.0625	0.019531	0.3	0.25

TABLE 81
Growth inhibition of Alternaria solani by picoxystrobin, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Picoxystrobin		0.5
		Trans-2-decenoic acid		0.039062
		Cis-3-hexenoic acid		0.3125
		7-Octenoic acid		0.15625
		3-Hydroxyoctanoic acid		1.25
		8-Hydroxyoctanoic acid		2.5
		10-Hydroxydecanoic acid		1
		12-Hydroxydodecanoic		0.1
		acid
		2-Hydroxybutyric acid		2.5
		2-Hydroxyoctanoic acid		0.625
		2-Ethylhexanoic acid		0.15625
		2-Methyloctanoic acid		0.15625
		3-Methylhexanoic acid		0.25
		3-Methylnonanoic acid		0.0625
		4-Methylhexanoic acid		0.3125
		2-Methyldecanoic acid		0.125
1	Picoxystrobin	Trans-2-decenoic acid	0.0625	0.019531	0.3	0.63
2	Picoxystrobin	Cis-3-hexenoic acid	0.125	0.078125	0.6	0.50
3	Picoxystrobin	7-Octenoic acid	0.0625	0.019531	0.3	0.25
4	Picoxystrobin	3-Hydroxyoctanoic acid	0.125	0.15625	1.25	0.38
5	Picoxystrobin	8-Hydroxyoctanoic acid	0.125	0.625	5	0.50
6	Picoxystrobin	10-Hydroxydecanoic acid	0.125	0.125	1	0.38
7	Picoxystrobin	12-Hydroxydodecanoic	0.125	0.025	0.2	0.50
		acid
8	Picoxystrobin	2-Hydroxybutyric acid	0.125	0.625	5	0.50
9	Picoxystrobin	2-Hydroxyoctanoic acid	0.125	0.15625	1.25	0.50
10	Picoxystrobin	2-Ethylhexanoic acid	0.125	0.039062	0.3	0.50
11	Picoxystrobin	2-Methyloctanoic acid	0.0625	0.019531	0.3	0.25
12	Picoxystrobin	3-Methylhexanoic acid	0.125	0.03125	0.25	0.38
13	Picoxystrobin	3-Methylnonanoic acid	0.125	0.015625	0.13	0.50
14	Picoxystrobin	4-Methylhexanoic acid	0.125	0.039062	0.3	0.38
15	Picoxystrobin	2-Methyldecanoic acid	0.125	0.03125	0.25	0.50

TABLE 82
Growth inhibition of Alternaria solani by penthiopyrad, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Penthiopyrad		0.5
		Octanoic acid		0.3125
		Trans-2-nonenoic acid		0.15625
		Trans-3-octenoic acid		0.15625
1	Penthiopyrad	Octanoic acid	0.0625	0.039062	0.6	0.25
2	Penthiopyrad	Trans-2-nonenoic acid	0.125	0.078125	0.6	0.75
3	Penthiopyrad	Trans-3-octenoic acid	0.125	0.039062	0.3	0.50

TABLE 83
Growth inhibition of Alternaria solani by prothioconazole, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Prothioconazole		0.5
		2-Hydroxybutyric acid		2.5
		2-Hydroxyhexanoic		2.5
		acid
		3-Hydroxybutyric acid		5
		3-Hydroxyhexanoic		2.5
		acid
		8-Hydroxyoctanoic acid		2.5
		2-Ethylhexanoic acid		0.3125
		3-Methylnonanoic acid		0.0625
		2-Methyldecanoic acid		1
		3-Methylbutyric acid		0.3125
1	Prothioconazole	2-Hydroxybutyric acid	0.125	0.625	5	0.50
2	Prothioconazole	2-Hydroxyhexanoic	0.125	0.625	5	0.50
		acid
3	Prothioconazole	3-Hydroxybutyric acid	0.125	1.25	10	0.50
4	Prothioconazole	3-Hydroxyhexanoic	0.125	0.625	5	0.50
		acid
5	Prothioconazole	8-Hydroxyoctanoic acid	0.125	0.625	5	0.50
6	Prothioconazole	2-Ethylhexanoic acid	0.125	0.039062	0.3	0.38
7	Prothioconazole	3-Methylnonanoic acid	0.125	0.015625	0.13	0.50
8	Prothioconazole	2-Methyldecanoic acid	0.125	0.03125	0.25	0.28
9	Prothioconazole	3-Methylbutyric acid	0.125	0.078125	0.6	0.50

TABLE 84
Growth inhibition of Alternaria solani by mancozeb, in combination with
various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Mancozeb		0.5
		Heptanoic acid		0.15625
		2-Methyloctanoic acid		0.625
		2-Methyldecanoic acid		1
1	Mancozeb	Heptanoic acid	0.125	0.039062	0.3	0.50
2	Mancozeb	2-Methyloctanoic acid	0.125	0.039062	0.3	0.31
3	Mancozeb	2-Methyldecanoic acid	0.125	0.03125	0.25	0.28

Example 23: Growth Inhibition of Sclerotinia sclerotiorum by Picoxystrobin, Penthiopyrad, and Prothioconazole, in Combination with Various Exemplary C4-C10 Saturated, Unsaturated, Hydroxy-, Methyl-, and Ethyl-Substituted Aliphatic Acids

Working solutions of picoxystrobin, penthiopyrad, and prothioconazole were each prepared as described above (as Compound A) and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 85-88 below. Working solutions of 2-hydroxybutyric acid, 2-hydroxyoctanoic acid, 2-ethylhexanoic acid, 3-methylbutyric acid, nonanoic acid, trans-3-hexenoic acid, 3-heptenoic acid, trans-2-nonenoic acid, trans-2-decenoic acid, 3-decenoic acid, 9-decenoic acid, and 10-hydroxydecanoic acid (as Compound B), were each prepared as described above, and were serially diluted in PDB to the individual required concentrations for MIC testing as shown in Tables 85-88 below.

Each individual compound and combination was tested over a range of 2-fold dilutions in the synergistic growth inhibition assay, observed following an incubation period of 7 days, and the FIC Index for each combination calculated, as shown in Tables 85-88 below.

TABLE 85
Growth inhibition of Sclerotinia sclerotiorum by picoxystrobin, in combination
with various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Picoxystrobin		0.5
		Nonanoic acid		0.039062
		Trans-2-octenoic acid		0.039062
		3-Nonenoic acid		0.078125
		3-Decenoic acid		0.15625
1	Picoxystrobin	Nonanoic acid	0.125	0.019531	0.16	0.75
2	Picoxystrobin	Trans-2-octenoic acid	0.125	0.009766	0.08	0.50
3	Picoxystrobin	3-Nonenoic acid	0.125	0.019531	0.16	0.50
4	Picoxystrobin	3-Decenoic acid	0.125	0.019531	0.16	0.38

TABLE 86
Growth inhibition of Sclerotinia sclerotiorum by picoxystrobin, in combination
with various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Picoxystrobin		0.5
		Trans-2-decenoic acid		0.019531
		10-Hydroxydecanoic acid		0.5
		2-Hydroxybutyric acid		5
		2-Hydroxyoctanoic acid		0.625
		2-Ethylhexanoic acid		0.15625
		3-Methylbutyric acid		0.625
1	Picoxystrobin	Trans-2-decenoic acid	0.125	0.004883	0.04	0.5
2	Picoxystrobin	10-Hydroxydecanoic acid	0.125	0.125	1	0.50
3	Picoxystrobin	2-Hydroxybutyric acid	0.125	1.25	10	0.50
4	Picoxystrobin	2-Hydroxyoctanoic acid	0.125	0.15625	1.25	0.50
5	Picoxystrobin	2-Ethylhexanoic acid	0.125	0.078125	0.625	0.75
6	Picoxystrobin	3-Methylbutyric acid	0.125	0.15625	1.25	0.50

TABLE 87
Growth inhibition of Sclerotinia sclerotiorum by penthiopyrad, in combination
with various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Penthiopyrad		0.5
		Trans-3-hexenoic acid		0.3125
		3-Heptenoic acid		0.15625
		Trans-2-nonenoic acid		0.078125
		3-Decenoic acid		0.15625
		9-Decenoic acid		0.078125
1	Penthiopyrad	Trans-3-hexenoic acid	0.125	0.039062	0.3	0.38
2	Penthiopyrad	3-Heptenoic acid	0.125	0.019531	0.16	0.38
3	Penthiopyrad	Trans-2-nonenoic acid	0.125	0.019531	0.16	0.50
4	Penthiopyrad	3-Decenoic acid	0.125	0.019531	0.16	0.38
5	Penthiopyrad	9-Decenoic acid	0.125	0.019531	0.16	0.50

TABLE 88
Growth inhibition of Sclerotinia sclerotiorum by prothioconazole, in combination
with various exemplary saturated, unsaturated, and substituted aliphatic acids.
			MIC (A)	MIC (B)	Ratio Compound	FIC
Combination	Compound A	Compound B	(mg/mL)	(mg/mL)	B/Compound A	Index
	Prothioconazole		0.0625
		2-Hydroxybutyric acid		5
1	Prothioconazole	2-Hydroxybutyric acid	0.015625	1.25	80	0.50

Predictive Methods

In the experimental methods and results listed above, synergistic efficacy is shown for many exemplary synergistic pesticidal compositions according to some embodiments of the present disclosure, such synergistic pesticidal compositions comprising at least a pesticidal active ingredient and a C4-C10 (or in alternative embodiments, alternatively C11 or C12) saturated or unsaturated aliphatic acid or salt thereof. In addition to the above listed experimental methods, it is desirable to additionally employ predictive methods for predicting synergistic efficacy of a pesticidal composition comprising at least a pesticidal active ingredient and a C4-C10 (or in alternative embodiments, alternatively C11 or C12) saturated or unsaturated aliphatic acid or salt thereof. Accordingly, a synergistic composition predictive model was constructed using neural network machine learning computational techniques, to provide a synergistic compound screening system that is trained using experimentally determined in vitro results showing synergistic and non-synergistic pesticidal efficacy of pesticidal compositions comprising a pesticidal active ingredient and a C4-C10 (or in alternative embodiments, alternatively C11 or C12) saturated or unsaturated aliphatic acid or salt thereof, and which determines a probability of synergistic efficacy of a specific such pesticidal composition.

In one embodiment of the present disclosure, a synergistic composition predictive system was constructed using an ensemble of machine learning models, and which provides a predicted probability that a candidate pesticidal composition comprising a pesticidal active ingredient and a C4-C10 (or in alternative embodiments, alternatively C11 or C12) saturated or unsaturated aliphatic acid or salt thereof will exhibit synergistic pesticidal efficacy in vitro against a target pathogen or pest. Each individual predictive model within the ensemble was initialized differently and each such model was trained using a selected portion of an in vitro synergistic pesticidal composition training dataset, leaving a remaining portion of the dataset for validation of each individual predictive model. This approach allows for a diversity between the individual predictive models in the ensemble, resulting in improved average predictive accuracy of the combined predictions of synergy across the ensemble of models, for a particular candidate pesticidal composition comprising a pesticidal active ingredient and a C4-C10 (or in alternative embodiments, alternatively C11 or C12) saturated or unsaturated aliphatic acid or salt. In the present predictive method, a separate synergistic composition predictive model was constructed for predicting probability of synergy of a candidate pesticidal composition for each of three exemplary target pathogens or pests, including Fusarium oxysporum, Botrytis cinerea, and Sclerotinia sclerotiorum, and each such model was trained using an experimentally obtained dataset of in vitro synergistic efficacy results for a multiplicity of in vitro screened pesticidal compositions comprising a pesticidal active ingredient and a C4-C10 (or in alternative embodiments, alternatively C11 or C12). Each such model was validated using non-training portions of the in vitro experimental synergistic pesticidal composition dataset for the relevant pathogen, to determine and optimize its predictive performance in predicting in vitro synergy.

In some embodiments, Fusarium oxysporum was used as a representative pest organism or pathogen to determine a predicted probability of synergy for pesticidal compositions comprising a pesticidal active ingredient agent (compound A) and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agent or salt thereof (compound B). In other embodiments, Botrytis cinerea was used as a representative pest organism or pathogen to determine a predicted probability of synergy for pesticidal compositions comprising a pesticidal active ingredient (compound A) and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agent or salt thereof (compound B). In further embodiments, Sclerotinia sclerotiorum was used as a representative pest organism or pathogen to determine a predicted probability of synergy for pesticidal compositions comprising a pesticidal active ingredient (compound A) and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agent or salt thereof (compound B). In some embodiments, an exemplary threshold of predicted probability of synergy greater than 55% (or 0.55) was applied to determine exemplary predictions of in vitro synergistic interaction between a pesticidal active ingredient (compound A) and one or more C4-C10 (or alternatively C11 or C12) saturated or unsaturated aliphatic acid agent or salt thereof (compound B) in a synergistic pesticidal composition. Results of exemplary predictions of in vitro synergistic pesticidal efficacy against an exemplary pathogen or pest made using a synergistic composition predictive system as described above are shown in the following Tables 89-91.

PREDICTED EXAMPLES

Example 24: Predicted synergistic efficacy for in vitro growth inhibition of Fusarium oxysporum by benzovindiflupyr, bixafen, boscalid, cyproconazole, fenpicoxamid, fenpyrazimine, florylpicoxamid, flutriafol, fluxapyroxad, isopyrazam, isotianil, kresoxim-methyl, metrafenone, oxathiapiprolin, penflufen, penthiopyrad, picoxystrobin, prothioconazole, pydiflumetofen, revysol, sedaxane, trifloxystrobin, and valifenalate, in combination with various exemplary saturated and unsaturated C4-C12 aliphatic acids, according to an embodiment of the present disclosure.

A prediction of probability of synergistic efficacy for each combination of benzovindiflupyr, bixafen, boscalid, cyproconazole, fenpicoxamid, fenpyrazimine, florylpicoxamid, flutriafol, fluxapyroxad, isopyrazam, isotianil, kresoxim-methyl, metrafenone, oxathiapiprolin, penflufen, penthiopyrad, picoxystrobin, prothioconazole, pydiflumetofen, revysol, sedaxane, trifloxystrobin, and valifenalate (Compound A) and a saturated or unsaturated aliphatic acid (Compound B) compound was determined using a synergistic composition predictive model trained using an experimental in vitro synergistic efficacy dataset for in vitro growth inhibition of Fusarium oxysporum. The resulting synergistic efficacy predictions are shown in Table 89 below.

TABLE 89
Predicted synergistic efficacy for in vitro growth inhibition of Fusarium oxysporum
by benzovindiflupyr, bixafen, boscalid, cyproconazole, fenpicoxamid, fenpyrazimine,
florylpicoxamid, flutriafol, fluxapyroxad, isopyrazam, isotianil, kresoxim-methyl,
metrafenone, oxathiapiprolin, penflufen, penthiopyrad, picoxystrobin, prothioconazole,
pydiflumetofen, revysol, sedaxane, trifloxystrobin, and valifenalate, in combination
with various exemplary saturated and unsaturated C4-C12 aliphatic acids according
to an embodiment of the present disclosure
			Predicted
			Probability of	Synergistic
			Synergistic	Efficacy
Combination	Compound A	Compound B	Efficacy	Prediction
1	Benzovindiflupyr	2-aminohexanoic acid	0.5767963	Likely
2	Benzovindiflupyr	2-hydroxyoctanoic acid	0.55433092	Likely
3	Benzovindiflupyr	3-hydroxydecanoic acid	0.55428505	Likely
4	Benzovindiflupyr	2-hydroxybutyric acid	0.55139626	Likely
5	Benzovindiflupyr	2-hydroxyhexanoic acid	0.55136665	Likely
6	Benzovindiflupyr	2-aminobutyric acid	0.55121322	Likely
7	Bixafen	2-aminohexanoic acid	0.5986134	Likely
8	Bixafen	3-hydroxydecanoic acid	0.59260478	Likely
9	Bixafen	2-hydroxyoctanoic acid	0.59127055	Likely
10	Bixafen	2-hydroxyhexanoic acid	0.58412244	Likely
11	Bixafen	3-hydroxyoctanoic acid	0.58250974	Likely
12	Bixafen	2-hydroxybutyric acid	0.58020663	Likely
13	Bixafen	2-aminobutyric acid	0.57291304	Likely
14	Bixafen	8-hydroxyoctanoic acid	0.55678314	Likely
15	Bixafen	3-hydroxyhexanoic acid	0.55412076	Likely
16	Boscalid	2-aminohexanoic acid	0.56465167	Likely
17	Boscalid	2-hydroxybutyric acid	0.55472363	Likely
18	Boscalid	2-hydroxyoctanoic acid	0.55112691	Likely
19	Cyproconazole	2-aminohexanoic acid	0.57628425	Likely
20	Fenpicoxamid	2-aminohexanoic acid	0.58695443	Likely
21	Fenpicoxamid	2-aminobutyric acid	0.56769621	Likely
22	Fenpicoxamid	2-hydroxybutyric acid	0.56525598	Likely
23	Fenpicoxamid	2-hydroxyhexanoic acid	0.55343788	Likely
24	Fenpyrazamine	2-aminohexanoic acid	0.59352859	Likely
25	Fenpyrazamine	3-hydroxydecanoic acid	0.58132785	Likely
26	Fenpyrazamine	2-aminobutyric acid	0.5700103	Likely
27	Fenpyrazamine	2-hydroxyoctanoic acid	0.55568954	Likely
28	Fenpyrazamine	8-hydroxyoctanoic acid	0.55427292	Likely
29	Fenpyrazamine	3-aminobutyric acid	0.55375423	Likely
30	Fenpyrazamine	3-hydroxyoctanoic acid	0.5508373	Likely
31	Florylpicoxamid	2-aminohexanoic acid	0.63476055	Likely
32	Florylpicoxamid	2-hydroxybutyric acid	0.61054637	Likely
33	Florylpicoxamid	2-aminobutyric acid	0.60774106	Likely
34	Florylpicoxamid	2-hydroxyhexanoic acid	0.60711867	Likely
35	Florylpicoxamid	2-hydroxyoctanoic acid	0.60666923	Likely
36	Florylpicoxamid	3-hydroxyoctanoic acid	0.59813283	Likely
37	Florylpicoxamid	3-hydroxydecanoic acid	0.58653796	Likely
38	Florylpicoxamid	3-hydroxyhexanoic acid	0.58024375	Likely
39	Florylpicoxamid	octanoic acid	0.57787609	Likely
40	Florylpicoxamid	heptanoic acid	0.57581491	Likely
41	Florylpicoxamid	hexanoic acid	0.57327745	Likely
42	Florylpicoxamid	decanoic acid	0.56412624	Likely
43	Florylpicoxamid	3-aminobutyric acid	0.56136031	Likely
44	Florylpicoxamid	3-hydroxybutyric acid	0.56075103	Likely
45	Florylpicoxamid	nonanoic acid	0.55557516	Likely
46	Florylpicoxamid	dodecanoic acid	0.55174383	Likely
47	Flutriafol	2-aminohexanoic acid	0.64187107	Likely
48	Flutriafol	2-aminobutyric acid	0.61206777	Likely
49	Flutriafol	2-hydroxybutyric acid	0.61086082	Likely
50	Flutriafol	2-hydroxyhexanoic acid	0.60704852	Likely
51	Flutriafol	2-hydroxyoctanoic acid	0.60100349	Likely
52	Flutriafol	3-hydroxydecanoic acid	0.59106896	Likely
53	Flutriafol	3-hydroxyoctanoic acid	0.58686044	Likely
54	Flutriafol	3-hydroxyhexanoic acid	0.56472518	Likely
55	Flutriafol	3-aminobutyric acid	0.55888988	Likely
56	Fluxapyroxad	2-aminohexanoic acid	0.65365264	Likely
57	Fluxapyroxad	2-hydroxyoctanoic acid	0.63406985	Likely
58	Fluxapyroxad	3-hydroxydecanoic acid	0.63228451	Likely
59	Fluxapyroxad	2-aminobutyric acid	0.63064658	Likely
60	Fluxapyroxad	2-hydroxybutyric acid	0.62910696	Likely
61	Fluxapyroxad	2-hydroxyhexanoic acid	0.62872769	Likely
62	Fluxapyroxad	3-hydroxyoctanoic acid	0.62480617	Likely
63	Fluxapyroxad	3-hydroxyhexanoic acid	0.59925105	Likely
64	Fluxapyroxad	3-aminobutyric acid	0.59057821	Likely
65	Fluxapyroxad	8-hydroxyoctanoic acid	0.58737963	Likely
66	Fluxapyroxad	octanoic acid	0.58452264	Likely
67	Fluxapyroxad	3-hydroxybutyric acid	0.5824682	Likely
68	Fluxapyroxad	heptanoic acid	0.58077161	Likely
69	Fluxapyroxad	10-hydroxydecanoic acid	0.57686063	Likely
70	Fluxapyroxad	nonanoic acid	0.57673815	Likely
71	Fluxapyroxad	hexanoic acid	0.57447241	Likely
72	Fluxapyroxad	decanoic acid	0.5742406	Likely
73	Fluxapyroxad	dodecanoic acid	0.56431965	Likely
74	Isopyrazam	2-aminohexanoic acid	0.59632861	Likely
75	Isopyrazam	3-hydroxydecanoic acid	0.58139259	Likely
76	Isopyrazam	2-hydroxyoctanoic acid	0.58047971	Likely
77	Isopyrazam	2-aminobutyric acid	0.57527404	Likely
78	Isopyrazam	2-hydroxyhexanoic acid	0.57359112	Likely
79	Isopyrazam	2-hydroxybutyric acid	0.57283605	Likely
80	Isopyrazam	3-hydroxyoctanoic acid	0.56890551	Likely
81	Isotianil	2-aminohexanoic acid	0.55867075	Likely
82	Kresoxim-methyl	2-aminohexanoic acid	0.67504148	Likely
83	Kresoxim-methyl	2-aminobutyric acid	0.65768701	Likely
84	Kresoxim-methyl	2-hydroxyhexanoic acid	0.65029321	Likely
85	Kresoxim-methyl	2-hydroxyoctanoic acid	0.64980065	Likely
86	Kresoxim-methyl	2-hydroxybutyric acid	0.64942813	Likely
87	Kresoxim-methyl	3-hydroxydecanoic acid	0.6411885	Likely
88	Kresoxim-methyl	3-hydroxyoctanoic acid	0.63833933	Likely
89	Kresoxim-methyl	3-aminobutyric acid	0.62326319	Likely
90	Kresoxim-methyl	3-hydroxyhexanoic acid	0.62174223	Likely
91	Kresoxim-methyl	octanoic acid	0.61937875	Likely
92	Kresoxim-methyl	heptanoic acid	0.6178017	Likely
93	Kresoxim-methyl	hexanoic acid	0.6141121	Likely
94	Kresoxim-methyl	nonanoic acid	0.61324196	Likely
95	Kresoxim-methyl	decanoic acid	0.6072263	Likely
96	Kresoxim-methyl	3-hydroxybutyric acid	0.60505759	Likely
97	Kresoxim-methyl	8-hydroxyoctanoic acid	0.5980929	Likely
98	Kresoxim-methyl	dodecanoic acid	0.59499285	Likely
99	Kresoxim-methyl	10-hydroxydecanoic acid	0.58491864	Likely
100	Metrafenone	2-aminohexanoic acid	0.55733598	Likely
101	Oxathiapiprolin	2-aminohexanoic acid	0.60657606	Likely
102	Oxathiapiprolin	2-aminobutyric acid	0.57620296	Likely
103	Oxathiapiprolin	2-hydroxybutyric acid	0.57121888	Likely
104	Oxathiapiprolin	2-hydroxyhexanoic acid	0.56699662	Likely
105	Oxathiapiprolin	2-hydroxyoctanoic acid	0.56303861	Likely
106	Oxathiapiprolin	3-hydroxydecanoic acid	0.55268361	Likely
107	Penflufen	2-aminohexanoic acid	0.65852257	Likely
108	Penflufen	3-hydroxydecanoic acid	0.64106452	Likely
109	Penflufen	2-aminobutyric acid	0.63676316	Likely
110	Penflufen	2-hydroxyoctanoic acid	0.63645035	Likely
111	Penflufen	3-hydroxyoctanoic acid	0.63215253	Likely
112	Penflufen	2-hydroxyhexanoic acid	0.62836813	Likely
113	Penflufen	2-hydroxybutyric acid	0.62790927	Likely
114	Penflufen	8-hydroxyoctanoic acid	0.61006622	Likely
115	Penflufen	3-aminobutyric acid	0.60708461	Likely
116	Penflufen	3-hydroxyhexanoic acid	0.60651148	Likely
117	Penflufen	octanoic acid	0.60432406	Likely
118	Penflufen	nonanoic acid	0.59918836	Likely
119	Penflufen	heptanoic acid	0.59838795	Likely
120	Penflufen	10-hydroxydecanoic acid	0.59837799	Likely
121	Penflufen	decanoic acid	0.59424908	Likely
122	Penflufen	3-hydroxybutyric acid	0.59419846	Likely
123	Penflufen	hexanoic acid	0.59271353	Likely
124	Penflufen	dodecanoic acid	0.5846236	Likely
125	Penthiopyrad	2-aminohexanoic acid	0.60944926	Likely
126	Penthiopyrad	2-hydroxyoctanoic acid	0.59583883	Likely
127	Penthiopyrad	3-hydroxydecanoic acid	0.59161762	Likely
128	Penthiopyrad	2-hydroxyhexanoic acid	0.58502914	Likely
129	Penthiopyrad	2-aminobutyric acid	0.58086249	Likely
130	Penthiopyrad	3-hydroxyoctanoic acid	0.57843716	Likely
131	Penthiopyrad	2-hydroxybutyric acid	0.57289048	Likely
132	Penthiopyrad	octanoic acid	0.56894523	Likely
133	Penthiopyrad	nonanoic acid	0.56465257	Likely
134	Penthiopyrad	heptanoic acid	0.56091047	Likely
135	Penthiopyrad	8-hydroxyoctanoic acid	0.55971519	Likely
136	Penthiopyrad	decanoic acid	0.55588841	Likely
137	Picoxystrobin	2-aminohexanoic acid	0.67534766	Likely
138	Picoxystrobin	2-hydroxybutyric acid	0.6576197	Likely
139	Picoxystrobin	2-aminobutyric acid	0.65465706	Likely
140	Picoxystrobin	2-hydroxyhexanoic acid	0.65034573	Likely
141	Picoxystrobin	2-hydroxyoctanoic acid	0.64606039	Likely
142	Picoxystrobin	3-hydroxydecanoic acid	0.62761118	Likely
143	Picoxystrobin	3-hydroxyoctanoic acid	0.62541364	Likely
144	Picoxystrobin	3-hydroxyhexanoic acid	0.60288031	Likely
145	Picoxystrobin	3-aminobutyric acid	0.60074316	Likely
146	Picoxystrobin	octanoic acid	0.59284889	Likely
147	Picoxystrobin	heptanoic acid	0.59142244	Likely
148	Picoxystrobin	3-hydroxybutyric acid	0.5895552	Likely
149	Picoxystrobin	hexanoic acid	0.58764771	Likely
150	Picoxystrobin	nonanoic acid	0.58643743	Likely
151	Picoxystrobin	decanoic acid	0.58045772	Likely
152	Picoxystrobin	dodecanoic acid	0.56836147	Likely
153	Picoxystrobin	8-hydroxyoctanoic acid	0.55987424	Likely
154	Prothiaconazole	2-aminohexanoic acid	0.55020457	Likely
155	Pydiflumetofen	2-aminohexanoic acid	0.59467448	Likely
	(Adepidyn)
156	Pydiflumetofen	2-aminobutyric acid	0.56779618	Likely
	(Adepidyn)
157	Pydiflumetofen	3-hydroxydecanoic acid	0.55150402	Likely
	(Adepidyn)
158	Pydiflumetofen	2-hydroxyoctanoic acid	0.55106064	Likely
	(Adepidyn)
159	Revysol	2-aminohexanoic acid	0.63962624	Likely
160	Revysol	2-aminobutyric acid	0.6040647	Likely
161	Revysol	2-hydroxyhexanoic acid	0.57211448	Likely
162	Revysol	2-hydroxybutyric acid	0.57152455	Likely
163	Revysol	2-hydroxyoctanoic acid	0.5706463	Likely
164	Revysol	3-hydroxyoctanoic acid	0.5657302	Likely
165	Revysol	3-hydroxydecanoic acid	0.56351714	Likely
166	Revysol	3-aminobutyric acid	0.55580375	Likely
167	Revysol	octanoic acid	0.55272278	Likely
168	Revysol	decanoic acid	0.55074132	Likely
169	Sedaxane	2-aminohexanoic acid	0.61273053	Likely
170	Sedaxane	2-hydroxybutyric acid	0.60053037	Likely
171	Sedaxane	2-aminobutyric acid	0.59536255	Likely
172	Sedaxane	3-hydroxydecanoic acid	0.58749265	Likely
173	Sedaxane	2-hydroxyhexanoic acid	0.58642283	Likely
174	Sedaxane	2-hydroxyoctanoic acid	0.58351983	Likely
175	Sedaxane	3-hydroxyoctanoic acid	0.58184892	Likely
176	Sedaxane	3-aminobutyric acid	0.57278869	Likely
177	Sedaxane	3-hydroxyhexanoic acid	0.56216563	Likely
178	Sedaxane	3-hydroxybutyric acid	0.55541366	Likely
179	Trifloxystrobin	2-hydroxyoctanoic acid	0.65884011	Likely
180	Trifloxystrobin	2-hydroxyhexanoic acid	0.6587482	Likely
181	Trifloxystrobin	2-aminobutyric acid	0.65764501	Likely
182	Trifloxystrobin	2-hydroxybutyric acid	0.65679943	Likely
183	Trifloxystrobin	3-hydroxydecanoic acid	0.64921461	Likely
184	Trifloxystrobin	3-hydroxyoctanoic acid	0.64454011	Likely
185	Trifloxystrobin	3-hydroxyhexanoic acid	0.62748345	Likely
186	Trifloxystrobin	3-aminobutyric acid	0.62415011	Likely
187	Trifloxystrobin	octanoic acid	0.6218323	Likely
188	Trifloxystrobin	heptanoic acid	0.62072241	Likely
189	Trifloxystrobin	hexanoic acid	0.61619104	Likely
190	Trifloxystrobin	nonanoic acid	0.61475129	Likely
191	Trifloxystrobin	3-hydroxybutyric acid	0.61418406	Likely
192	Trifloxystrobin	decanoic acid	0.60804051	Likely
193	Trifloxystrobin	dodecanoic acid	0.59491928	Likely
194	Trifloxystrobin	8-hydroxyoctanoic acid	0.59290993	Likely
195	Trifloxystrobin	10-hydroxydecanoic acid	0.57914078	Likely
196	Valifenalate	2-aminohexanoic acid	0.5944192	Likely
197	Valifenalate	2-aminobutyric acid	0.56510459	Likely
198	Valifenalate	2-hydroxyoctanoic acid	0.55897016	Likely
199	Valifenalate	3-hydroxydecanoic acid	0.55603569	Likely

Example 25: Predicted synergistic efficacy for in vitro growth inhibition of Sclerotinia sclerotiorum by bixafen, boscalid, cyproconazole, fenpicoxamid, fenpyrazimine, florylpicoxamid, flutriafol, fluxapyroxad, isopyrazam, isotianil, kresoxim-methyl, metrafenone, penflufen, penthiopyrad, picoxystrobin, pydiflumetofen, revysol, trifloxystrobin, and valifenalate, in combination with various exemplary saturated and unsaturated C4-C12 aliphatic acids, according to an embodiment of the present disclosure.

A prediction of probability of synergistic efficacy for each combination of bixafen, boscalid, cyproconazole, fenpicoxamid, fenpyrazimine, florylpicoxamid, flutriafol, fluxapyroxad, isopyrazam, isotianil, kresoxim-methyl, metrafenone, penflufen, penthiopyrad, picoxystrobin, pydiflumetofen, revysol, trifloxystrobin, and valifenalate (Compound A) and saturated or unsaturated aliphatic acid (Compound B) compound was determined using a synergistic composition predictive model trained using an experimental in vitro synergistic efficacy dataset for in vitro growth inhibition of Sclerotinia sclerotiorum. The resulting synergistic efficacy predictions are shown in Table 90 below.

TABLE 90
Predicted synergistic efficacy for in vitro growth inhibition of Sclerotinia sclerotiorum
by bixafen, boscalid, fenpicoxamid, fenpyrazimine, florylpicoxamid, fluxapyroxad,
isotianil, kresoxim-methyl, metrafenone, oxathiapiprolin, penflufen, penthiopyrad,
picoxystrobin, prothioconazole, pydiflumetofen, revysol, sedaxane, trifloxystrobin,
and valifenalate, in combination with various exemplary C4-C12 saturated and unsaturated
aliphatic acids according to an embodiment of the present disclosure
			Predicted
			Probability of	Synergistic
			Synergistic	Efficacy
Combination	Compound A	Compound B	Efficacy	Prediction
1	Bixafen	trans-2-nonenoic acid	0.63422002	Likely
2	Bixafen	trans-2-undecenoic acid	0.61975961	Likely
3	Bixafen	trans-2-decenoic acid	0.61877499	Likely
4	Bixafen	trans-2-octenoic acid	0.59647564	Likely
5	Bixafen	3-decenoic acid	0.56026628	Likely
6	Boscalid	trans-2-undecenoic acid	0.64000795	Likely
7	Boscalid	trans-2-decenoic acid	0.63932319	Likely
8	Boscalid	trans-2-nonenoic acid	0.63189319	Likely
9	Boscalid	trans-2-octenoic acid	0.6128523	Likely
10	Boscalid	3-decenoic acid	0.56328052	Likely
11	Boscalid	dodecanoic acid	0.5582064	Likely
12	Boscalid	decanoic acid	0.5560983	Likely
13	Boscalid	nonanoic acid	0.55505839	Likely
14	Boscalid	octanoic acid	0.55438775	Likely
15	Boscalid	3-nonenoic acid	0.55383059	Likely
16	Fenpicoxamid	trans-2-undecenoic acid	0.64517585	Likely
17	Fenpicoxamid	trans-2-decenoic acid	0.64430379	Likely
18	Fenpicoxamid	trans-2-nonenoic acid	0.63685218	Likely
19	Fenpicoxamid	trans-2-octenoic acid	0.61571277	Likely
20	Fenpicoxamid	3-decenoic acid	0.5717719	Likely
21	Fenpicoxamid	dodecanoic acid	0.56812335	Likely
22	Fenpicoxamid	decanoic acid	0.56706998	Likely
23	Fenpicoxamid	nonanoic acid	0.5660589	Likely
24	Fenpicoxamid	octanoic acid	0.56546112	Likely
25	Fenpicoxamid	heptanoic acid	0.56213194	Likely
26	Fenpicoxamid	3-nonenoic acid	0.56106859	Likely
27	Fenpyrazamine	trans-2-undecenoic acid	0.64570129	Likely
28	Fenpyrazamine	trans-2-decenoic acid	0.64445113	Likely
29	Fenpyrazamine	trans-2-nonenoic acid	0.64373701	Likely
30	Fenpyrazamine	trans-2-octenoic acid	0.61870502	Likely
31	Fenpyrazamine	3-decenoic acid	0.57072864	Likely
32	Fenpyrazamine	dodecanoic acid	0.56926688	Likely
33	Fenpyrazamine	decanoic acid	0.56696534	Likely
34	Fenpyrazamine	nonanoic acid	0.56557274	Likely
35	Fenpyrazamine	octanoic acid	0.56470615	Likely
36	Fenpyrazamine	3-nonenoic acid	0.56308404	Likely
37	Fenpyrazamine	heptanoic acid	0.56026874	Likely
38	Fenpyrazamine	trans-2-hexenoic acid	0.55896424	Likely
39	Fenpyrazamine	9-decenoic acid	0.55287297	Likely
40	Florylpicoxamid	trans-2-undecenoic acid	0.66003401	Likely
41	Florylpicoxamid	trans-2-decenoic acid	0.65861813	Likely
42	Florylpicoxamid	trans-2-nonenoic acid	0.65382792	Likely
43	Florylpicoxamid	trans-2-octenoic acid	0.63490106	Likely
44	Florylpicoxamid	3-decenoic acid	0.58621619	Likely
45	Florylpicoxamid	dodecanoic acid	0.5781119	Likely
46	Florylpicoxamid	3-nonenoic acid	0.57620949	Likely
47	Florylpicoxamid	trans-2-hexenoic acid	0.57501872	Likely
48	Florylpicoxamid	nonanoic acid	0.57407232	Likely
49	Florylpicoxamid	decanoic acid	0.5728504	Likely
50	Florylpicoxamid	octanoic acid	0.5696201	Likely
51	Florylpicoxamid	heptanoic acid	0.56792373	Likely
52	Florylpicoxamid	3-octenoic acid	0.55302533	Likely
53	Florylpicoxamid	hexanoic acid	0.55097026	Likely
54	Fluxapyroxad	trans-2-undecenoic acid	0.66353832	Likely
55	Fluxapyroxad	trans-2-decenoic acid	0.66228828	Likely
56	Fluxapyroxad	trans-2-nonenoic acid	0.65719566	Likely
57	Fluxapyroxad	trans-2-octenoic acid	0.63807777	Likely
58	Fluxapyroxad	3-decenoic acid	0.58704056	Likely
59	Fluxapyroxad	3-nonenoic acid	0.57704323	Likely
60	Fluxapyroxad	trans-2-hexenoic acid	0.56795649	Likely
61	Fluxapyroxad	dodecanoic acid	0.56294662	Likely
62	Fluxapyroxad	decanoic acid	0.56026234	Likely
63	Fluxapyroxad	nonanoic acid	0.55851251	Likely
64	Fluxapyroxad	octanoic acid	0.55714217	Likely
65	Fluxapyroxad	3-octenoic acid	0.55502918	Likely
66	Fluxapyroxad	trans-3-octenoic acid	0.55502918	Likely
67	Fluxapyroxad	heptanoic acid	0.5533742	Likely
68	Isotianil	trans-2-undecenoic acid	0.58734897	Likely
69	Isotianil	trans-2-decenoic acid	0.5861208	Likely
70	Isotianil	trans-2-nonenoic acid	0.57581536	Likely
71	Isotianil	trans-2-octenoic acid	0.55436011	Likely
72	Kresoxim-methyl	trans-2-undecenoic acid	0.69437059	Likely
73	Kresoxim-methyl	trans-2-nonenoic acid	0.68996981	Likely
74	Kresoxim-methyl	trans-2-decenoic acid	0.68445944	Likely
75	Kresoxim-methyl	trans-2-octenoic acid	0.67452894	Likely
76	Kresoxim-methyl	dodecanoic acid	0.63170701	Likely
77	Kresoxim-methyl	3-decenoic acid	0.62730097	Likely
78	Kresoxim-methyl	nonanoic acid	0.62720372	Likely
79	Kresoxim-methyl	decanoic acid	0.62517832	Likely
80	Kresoxim-methyl	octanoic acid	0.62229298	Likely
81	Kresoxim-methyl	heptanoic acid	0.61779979	Likely
82	Kresoxim-methyl	3-nonenoic acid	0.61715368	Likely
83	Kresoxim-methyl	trans-2-hexenoic acid	0.616918	Likely
84	Kresoxim-methyl	hexanoic acid	0.59974539	Likely
85	Kresoxim-methyl	3-octenoic acid	0.59338092	Likely
86	Kresoxim-methyl	9-decenoic acid	0.58882145	Likely
87	Kresoxim-methyl	3-heptenoic acid	0.5842284	Likely
88	Kresoxim-methyl	trans-3-octenoic acid	0.58338154	Likely
89	Kresoxim-methyl	2-ethylhexanoic acid	0.58021401	Likely
90	Kresoxim-methyl	3-methylnonanoic acid	0.57904676	Likely
91	Kresoxim-methyl	2-methyloctanoic acid	0.57545126	Likely
92	Kresoxim-methyl	2-methyldecanoic acid	0.57396175	Likely
93	Kresoxim-methyl	7-octenoic acid	0.56941623	Likely
94	Kresoxim-methyl	2-hydroxyoctanoic acid	0.56689941	Likely
95	Kresoxim-methyl	2-aminohexanoic acid	0.56447951	Likely
96	Metrafenone	trans-2-undecenoic acid	0.64443278	Likely
97	Metrafenone	trans-2-decenoic acid	0.64366354	Likely
98	Metrafenone	trans-2-nonenoic acid	0.63731814	Likely
99	Metrafenone	trans-2-octenoic acid	0.61913326	Likely
100	Metrafenone	3-decenoic acid	0.56409456	Likely
101	Metrafenone	dodecanoic acid	0.55737829	Likely
102	Metrafenone	trans-2-hexenoic acid	0.55535108	Likely
103	Metrafenone	3-nonenoic acid	0.55484796	Likely
104	Metrafenone	decanoic acid	0.55289211	Likely
105	Metrafenone	nonanoic acid	0.55017602	Likely
106	Penflufen	trans-2-undecenoic acid	0.64399335	Likely
107	Penflufen	trans-2-decenoic acid	0.64252008	Likely
108	Penflufen	trans-2-nonenoic acid	0.62746654	Likely
109	Penflufen	trans-2-octenoic acid	0.61407125	Likely
110	Penflufen	dodecanoic acid	0.57058068	Likely
111	Penflufen	decanoic acid	0.56765798	Likely
112	Penflufen	nonanoic acid	0.56592093	Likely
113	Penflufen	octanoic acid	0.56437438	Likely
114	Penflufen	3-decenoic acid	0.56411505	Likely
115	Penflufen	3-nonenoic acid	0.56120105	Likely
116	Penflufen	heptanoic acid	0.55998814	Likely
117	Penthiopyrad	trans-2-decenoic acid	0.60351946	Likely
118	Penthiopyrad	trans-2-octenoic acid	0.57867577	Likely
119	Picoxystrobin	trans-2-decenoic acid	0.6041138	Likely
120	Picoxystrobin	trans-2-undecenoic acid	0.60380391	Likely
121	Picoxystrobin	trans-2-nonenoic acid	0.60102845	Likely
122	Picoxystrobin	trans-2-octenoic acid	0.58557471	Likely
123	Pydiflumetofen (Adepidyn)	trans-2-undecenoic acid	0.62980278	Likely
124	Pydiflumetofen (Adepidyn)	trans-2-decenoic acid	0.62913683	Likely
125	Pydiflumetofen (Adepidyn)	trans-2-nonenoic acid	0.6215863	Likely
126	Pydiflumetofen (Adepidyn)	trans-2-octenoic acid	0.59947248	Likely
127	Pydiflumetofen (Adepidyn)	dodecanoic acid	0.55658742	Likely
128	Pydiflumetofen (Adepidyn)	decanoic acid	0.55425756	Likely
129	Pydiflumetofen (Adepidyn)	nonanoic acid	0.55224037	Likely
130	Pydiflumetofen (Adepidyn)	octanoic acid	0.55034847	Likely
131	Revysol	trans-2-undecenoic acid	0.57872331	Likely
132	Revysol	trans-2-decenoic acid	0.57789835	Likely
133	Revysol	trans-2-nonenoic acid	0.57143113	Likely
134	Revysol	trans-2-octenoic acid	0.55187153	Likely
135	Trifloxystrobin	trans-2-octenoic acid	0.65344118	Likely
136	Trifloxystrobin	dodecanoic acid	0.60296979	Likely
137	Trifloxystrobin	3-decenoic acid	0.60065202	Likely
138	Trifloxystrobin	decanoic acid	0.59917673	Likely
139	Trifloxystrobin	nonanoic acid	0.59665176	Likely
140	Trifloxystrobin	octanoic acid	0.59411821	Likely
141	Trifloxystrobin	trans-2-hexenoic acid	0.58938381	Likely
142	Trifloxystrobin	3-nonenoic acid	0.58652177	Likely
143	Trifloxystrobin	heptanoic acid	0.58451477	Likely
144	Trifloxystrobin	3-octenoic acid	0.56976633	Likely
145	Trifloxystrobin	9-decenoic acid	0.56827708	Likely
146	Trifloxystrobin	trans-3-octenoic acid	0.56589124	Likely
147	Trifloxystrobin	hexanoic acid	0.56398016	Likely
148	Trifloxystrobin	3-heptenoic acid	0.56110153	Likely
149	Trifloxystrobin	3-methylnonanoic acid	0.55144026	Likely
150	Valifenalate	trans-2-octenoic acid	0.62518207	Likely
151	Valifenalate	3-decenoic acid	0.57403389	Likely
152	Valifenalate	trans-2-hexenoic acid	0.57030915	Likely
153	Valifenalate	nonanoic acid	0.5635556	Likely
154	Valifenalate	dodecanoic acid	0.56304971	Likely
155	Valifenalate	decanoic acid	0.55918886	Likely
156	Valifenalate	octanoic acid	0.55868943	Likely
157	Valifenalate	heptanoic acid	0.55620831	Likely
158	Valifenalate	3-nonenoic acid	0.55386801	Likely

Example 26: Predicted synergistic efficacy for in vitro growth inhibition of Botritis cinerea by bixafen, fenpicoxamid, florylpicoxamid, fluxapyroxad, kresoxim-methyl, picoxystrobin, pydiflumetofen, revysol, trifloxystrobin, and valifenalate, in combination with various exemplary saturated and unsaturated C4-C12 aliphatic acids, according to an embodiment of the present disclosure.

A prediction of probability of synergistic efficacy for each combination of bixafen, fenpicoxamid, florylpicoxamid, fluxapyroxad, kresoxim-methyl, picoxystrobin, pydiflumetofen, revysol, trifloxystrobin, and valifenalate (Compound A) and a saturated or unsaturated C4-C12 aliphatic acid (Compound B) compound was determined using a synergistic composition predictive model trained using an experimental in vitro synergistic efficacy dataset for in vitro growth inhibition ofBotritis cinerea. The resulting synergistic efficacy predictions are shown in Table 91 below.

TABLE 91
Predicted synergistic efficacy for in vitro growth inhibition of Botritis cinerea
by bixafen, fenpicoxamid, florylpicoxamid, fluxapyroxad, kresoxim-methyl, picoxystrobin,
pydiflumetofen, revysol, trifloxystrobin, and valifenalate, in combination with
various exemplary saturated and unsaturated C4-C12 aliphatic acids
			Predicted
			Probability of	Synergistic
			Synergistic	Efficacy
Combination	Compound A	Compound B	Efficacy	Prediction
1	Bixafen	9-decenoic acid	0.55622956	Likely
2	Bixafen	decanoic acid	0.55589771	Likely
3	Bixafen	octanoic acid	0.55586089	Likely
4	Bixafen	nonanoic acid	0.55584134	Likely
5	Bixafen	dodecanoic acid	0.55552297	Likely
6	Fenpicoxamid	nonanoic acid	0.62459222	Likely
7	Fenpicoxamid	octanoic acid	0.61360456	Likely
8	Fenpicoxamid	decanoic acid	0.61240222	Likely
9	Fenpicoxamid	dodecanoic acid	0.61135991	Likely
10	Fenpicoxamid	heptanoic acid	0.61086404	Likely
11	Fenpicoxamid	9-decenoic acid	0.60419807	Likely
12	Fenpicoxamid	7-octenoic acid	0.58622763	Likely
13	Fenpicoxamid	hexanoic acid	0.58429749	Likely
14	Fenpicoxamid	8-hydroxyoctanoic acid	0.57570006	Likely
15	Fenpicoxamid	10-hydroxydecanoic acid	0.57503872	Likely
16	Fenpicoxamid	12-hydroxydodecanoic acid	0.57498789	Likely
17	Fenpicoxamid	3-methylnonanoic acid	0.55528876	Likely
18	Fenpicoxamid	5-hexenoic acid	0.55508957	Likely
19	Florylpicoxamid	decanoic acid	0.71071466	Likely
20	Florylpicoxamid	nonanoic acid	0.71019579	Likely
21	Florylpicoxamid	dodecanoic acid	0.70658516	Likely
22	Florylpicoxamid	octanoic acid	0.70647826	Likely
23	Florylpicoxamid	heptanoic acid	0.6966848	Likely
24	Florylpicoxamid	9-decenoic acid	0.69075607	Likely
25	Florylpicoxamid	8-hydroxyoctanoic acid	0.68890783	Likely
26	Florylpicoxamid	12-hydroxydodecanoic acid	0.68347669	Likely
27	Florylpicoxamid	10-hydroxydecanoic acid	0.6833026	Likely
28	Florylpicoxamid	7-octenoic acid	0.68061823	Likely
29	Florylpicoxamid	hexanoic acid	0.68034807	Likely
30	Florylpicoxamid	5-hexenoic acid	0.63863994	Likely
31	Florylpicoxamid	3-methylnonanoic acid	0.63745326	Likely
32	Florylpicoxamid	trans-2-undecenoic acid	0.63357106	Likely
33	Florylpicoxamid	trans-2-decenoic acid	0.62787411	Likely
34	Florylpicoxamid	3-decenoic acid	0.61742779	Likely
35	Florylpicoxamid	trans-2-nonenoic acid	0.61304636	Likely
36	Florylpicoxamid	3-nonenoic acid	0.6103797	Likely
37	Florylpicoxamid	3-methylhexanoic acid	0.60093858	Likely
38	Florylpicoxamid	3-heptenoic acid	0.5967274	Likely
39	Florylpicoxamid	trans-2-octenoic acid	0.59637633	Likely
40	Florylpicoxamid	3-octenoic acid	0.59633581	Likely
41	Florylpicoxamid	trans-3-octenoic acid	0.59633581	Likely
42	Florylpicoxamid	trans-2-hexenoic acid	0.57528369	Likely
43	Florylpicoxamid	trans-3-hexenoic acid	0.56214715	Likely
44	Florylpicoxamid	cis-3-hexenoic acid	0.56185557	Likely
45	Florylpicoxamid	4-hexenoic acid	0.55965197	Likely
46	Florylpicoxamid	2-methyloctanoic acid	0.55344194	Likely
47	Florylpicoxamid	2-methyldecanoic acid	0.55045301	Likely
48	Florylpicoxamid	3-methylbutyric acid	0.55003294	Likely
49	Fluxapyroxad	9-decenoic acid	0.57082343	Likely
50	Fluxapyroxad	decanoic acid	0.5582246	Likely
51	Fluxapyroxad	dodecanoic acid	0.55812293	Likely
52	Fluxapyroxad	octanoic acid	0.55790607	Likely
53	Kresoxim-methyl	9-decenoic acid	0.65007721	Likely
54	Kresoxim-methyl	dodecanoic acid	0.64561872	Likely
55	Kresoxim-methyl	decanoic acid	0.64533766	Likely
56	Kresoxim-methyl	octanoic acid	0.64519368	Likely
57	Kresoxim-methyl	nonanoic acid	0.64517309	Likely
58	Kresoxim-methyl	heptanoic acid	0.63135262	Likely
59	Kresoxim-methyl	7-octenoic acid	0.63015161	Likely
60	Kresoxim-methyl	8-hydroxyoctanoic acid	0.62234793	Likely
61	Kresoxim-methyl	12-hydroxydodecanoic acid	0.62204227	Likely
62	Kresoxim-methyl	10-hydroxydecanoic acid	0.62185931	Likely
63	Kresoxim-methyl	hexanoic acid	0.61156485	Likely
64	Kresoxim-methyl	5-hexenoic acid	0.58608413	Likely
65	Kresoxim-methyl	3-methylnonanoic acid	0.58495826	Likely
66	Kresoxim-methyl	trans-2-decenoic acid	0.5617413	Likely
67	Kresoxim-methyl	trans-2-undecenoic acid	0.5611554	Likely
68	Kresoxim-methyl	3-decenoic acid	0.55813311	Likely
69	Picoxystrobin	9-decenoic acid	0.64360938	Likely
70	Picoxystrobin	decanoic acid	0.63400232	Likely
71	Picoxystrobin	nonanoic acid	0.6337739	Likely
72	Picoxystrobin	octanoic acid	0.63365494	Likely
73	Picoxystrobin	dodecanoic acid	0.63256371	Likely
74	Picoxystrobin	7-octenoic acid	0.62759129	Likely
75	Picoxystrobin	heptanoic acid	0.62253746	Likely
76	Picoxystrobin	12-hydroxydodecanoic acid	0.61545208	Likely
77	Picoxystrobin	8-hydroxyoctanoic acid	0.61335731	Likely
78	Picoxystrobin	10-hydroxydecanoic acid	0.60911996	Likely
79	Picoxystrobin	hexanoic acid	0.60391683	Likely
80	Picoxystrobin	5-hexenoic acid	0.58423756	Likely
81	Picoxystrobin	trans-2-decenoic acid	0.57715665	Likely
82	Picoxystrobin	trans-2-undecenoic acid	0.57706139	Likely
83	Picoxystrobin	3-decenoic acid	0.56894624	Likely
84	Picoxystrobin	trans-2-nonenoic acid	0.56590575	Likely
85	Picoxystrobin	3-nonenoic acid	0.56021643	Likely
86	Picoxystrobin	3-methylnonanoic acid	0.55981524	Likely
87	Picoxystrobin	trans-2-octenoic acid	0.55049884	Likely
88	Pydiflumetofen (Adepidyn)	octanoic acid	0.58507421	Likely
89	Pydiflumetofen (Adepidyn)	nonanoic acid	0.58455386	Likely
90	Pydiflumetofen (Adepidyn)	decanoic acid	0.58388714	Likely
91	Pydiflumetofen (Adepidyn)	dodecanoic acid	0.58166713	Likely
92	Pydiflumetofen (Adepidyn)	heptanoic acid	0.57342989	Likely
93	Pydiflumetofen (Adepidyn)	9-decenoic acid	0.57237365	Likely
94	Pydiflumetofen (Adepidyn)	hexanoic acid	0.55570532	Likely
95	Pydiflumetofen (Adepidyn)	7-octenoic acid	0.55530685	Likely
96	Revysol	dodecanoic acid	0.6001254	Likely
97	Revysol	decanoic acid	0.59978312	Likely
98	Revysol	nonanoic acid	0.59915221	Likely
99	Revysol	octanoic acid	0.59870726	Likely
100	Revysol	heptanoic acid	0.5884472	Likely
101	Revysol	9-decenoic acid	0.58379308	Likely
102	Revysol	hexanoic acid	0.56996538	Likely
103	Revysol	7-octenoic acid	0.56562299	Likely
104	Revysol	12-hydroxydodecanoic acid	0.56383193	Likely
105	Revysol	10-hydroxydecanoic acid	0.56139958	Likely
106	Revysol	8-hydroxyoctanoic acid	0.55953437	Likely
107	Revysol	3-methylnonanoic acid	0.5520322	Likely
108	Trifloxystrobin	9-decenoic acid	0.6725654	Likely
109	Trifloxystrobin	dodecanoic acid	0.66157781	Likely
110	Trifloxystrobin	decanoic acid	0.66133578	Likely
111	Trifloxystrobin	nonanoic acid	0.66097871	Likely
112	Trifloxystrobin	octanoic acid	0.66093915	Likely
113	Trifloxystrobin	7-octenoic acid	0.65512001	Likely
114	Trifloxystrobin	heptanoic acid	0.65001921	Likely
115	Trifloxystrobin	12-hydroxydodecanoic acid	0.64941725	Likely
116	Trifloxystrobin	10-hydroxydecanoic acid	0.64885914	Likely
117	Trifloxystrobin	8-hydroxyoctanoic acid	0.64848276	Likely
118	Trifloxystrobin	hexanoic acid	0.63310591	Likely
119	Trifloxystrobin	3-methylnonanoic acid	0.61211242	Likely
120	Trifloxystrobin	5-hexenoic acid	0.60404247	Likely
121	Trifloxystrobin	trans-2-decenoic acid	0.59111476	Likely
122	Trifloxystrobin	trans-2-undecenoic acid	0.59108112	Likely
123	Trifloxystrobin	3-decenoic acid	0.58504908	Likely
124	Trifloxystrobin	trans-2-nonenoic acid	0.57766945	Likely
125	Trifloxystrobin	3-nonenoic acid	0.57481307	Likely
126	Trifloxystrobin	3-methylhexanoic acid	0.57295034	Likely
127	Trifloxystrobin	trans-2-octenoic acid	0.56120624	Likely
128	Trifloxystrobin	3-octenoic acid	0.56061667	Likely
129	Trifloxystrobin	3-heptenoic acid	0.5584203	Likely
130	Valifenalate	dodecanoic acid	0.59915539	Likely
131	Valifenalate	decanoic acid	0.5985593	Likely
132	Valifenalate	nonanoic acid	0.59810962	Likely
133	Valifenalate	octanoic acid	0.59787693	Likely
134	Valifenalate	heptanoic acid	0.58391599	Likely
135	Valifenalate	9-decenoic acid	0.58095987	Likely
136	Valifenalate	hexanoic acid	0.56507724	Likely
137	Valifenalate	12-hydroxydodecanoic acid	0.5648372	Likely
138	Valifenalate	10-hydroxydecanoic acid	0.56308371	Likely
139	Valifenalate	8-hydroxyoctanoic acid	0.56188978	Likely
140	Valifenalate	7-octenoic acid	0.56071382	Likely

In some embodiments according to the present disclosure, and as illustrated in some exemplary embodiments in the above-described experimental examples, the combination of a C4-C10 unsaturated aliphatic acid (and agriculturally acceptable salts thereof in some particular embodiments) and a pesticidal active ingredient produces a synergistic pesticidal composition demonstrating or reasonably predicted to demonstrate a synergistic effect. That is, when used in combination, the C4-C10 unsaturated aliphatic acid and the pesticidal active ingredient have or are reasonably predicted to have an efficacy that is greater than would be expected by simply adding the efficacy of the pesticidal active ingredient and the C4-C10 unsaturated aliphatic acid when used alone. In some alternative embodiments, the unsaturated aliphatic acid or agriculturally acceptable salt thereof may comprise a C11 unsaturated aliphatic acid or agriculturally acceptable salt thereof. In some further alternative embodiments, the unsaturated aliphatic acid or agriculturally acceptable salt thereof may comprise a C12 unsaturated aliphatic acid or agriculturally acceptable salt thereof.

In some embodiments according to the present disclosure, and as illustrated in some exemplary embodiments in the above-described experimental examples, the combination of a C4-C10 saturated aliphatic acid (and agriculturally acceptable salts thereof in some particular embodiments) and a pesticidal active ingredient produces a synergistic pesticidal composition demonstrating a synergistic effect or reasonably predicted to demonstrate a synergistic effect. That is, when used in combination, the C4-C10 saturated aliphatic acid and the pesticidal active ingredient have or are predicted to have an efficacy that is greater than would be expected by simply adding the efficacy of the pesticidal active ingredient and the C4-C10 saturated aliphatic acid when used alone. In some particular embodiments, the combination of a C4-C10 saturated aliphatic acid and a neem seed, kernel, oil, extract or derivative pesticidal active ingredient produces a synergistic pesticidal composition demonstrating a synergistic pesticidal effect. In some further embodiments, the combination of a C11 or C12 saturated aliphatic acid and a neem seed, kernel, oil, extract or derivative pesticidal active ingredient produces a synergistic pesticidal composition demonstrating or reasonably predicted to demonstrate a synergistic pesticidal effect. In some alternative embodiments according to the present disclosure, the combination of a C11 or C12 saturated aliphatic acid (and agriculturally acceptable salts thereof in some particular embodiments) and a pesticidal active ingredient produces a synergistic pesticidal composition demonstrating a synergistic effect.

While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced are to be given the broadest interpretation consistent with the disclosure as a whole.

Claims

1. A synergistic pesticidal composition comprising

a pesticidal active ingredient selected from the list comprising: benzovindiflupyr, bixafen, boscalid, cyproconazole, fenpicoxamid, fenpyrazimine, florylpicoxamid, flutriafol, fluxapyroxad, isopyrazam, isotianil, kresoxim-methyl, metrafenone, oxathiapiprolin, penflufen, penthiopyrad, picoxystrobin, prothioconazole, pydiflumetofen, revysol, sedaxane, trifloxystrobin, pyraclostrobin, azoxystrobin, chlorothalonil, cyprodinil, metalaxyl, epoxiconazole, propiconazole, difenoconazole, fludioxonil, mancozeb, tebuconazole, valifenalate, and combinations thereof; and

a C4-C10 saturated or unsaturated aliphatic acid or an agriculturally compatible salt thereof;

wherein a ratio of the concentrations of said pesticidal active ingredient and said C4-C10 saturated or unsaturated aliphatic acid or an agriculturally compatible salt thereof is between about 1:15000 and 15000:1.

2. The synergistic pesticidal composition according to claim 1, wherein said C4-C10 saturated or unsaturated aliphatic acid comprises a C4-C10 unsaturated aliphatic acid;

wherein the C4-C10 unsaturated aliphatic acid comprises at least one unsaturated C—C bond; and

wherein a ratio of the concentrations of said pesticidal active ingredient and said C4-C10 unsaturated aliphatic acid is between about 1:15,000 and 15,000:1.

3. (canceled)

4. The synergistic pesticidal composition according to claim 1, wherein the C4-C10 saturated or unsaturated aliphatic acid or salt thereof comprises a methyl-, ethyl-, hydroxy-, or amino-substituent.

5. The synergistic pesticidal composition according to claim 2, wherein the C4-C10 unsaturated aliphatic acid comprises at least one of:

a trans-butanoic acid, a cis-butanoic acid, a butynoic acid, a buta-dienoic acid, a trans-hexenoic acid, a cis-hexenoic acid, a hexa-dienoic acid, a hexynoic acid, a trans-heptenoic acid, a cis-heptenoic acid, a hepta-dienoic acid, a heptynoic acid, a trans-octenoic acid, a cis-octenoic acid, an octa-dienoic acid, an octynoic acid, a trans-nonenoic acid, a cis-nonenoic acid, a nona-dienoic acid, a nonynoic acid, a trans-decenoic acid, a cis-decenoic acid, a deca-dienoic acid, and a decynoic acid.

6. (canceled)

7. (canceled)

8. The synergistic pesticidal composition according to claim 1, wherein the synergistic pesticidal composition has a predicted probability of synergy of greater than 0.55.

9.-11. (canceled)

12. The synergistic pesticidal composition according to claim 1, wherein said pesticidal active ingredient comprises at least one pesticidal active ingredient selected from the list comprising:

A) Respiration inhibitors selected from: inhibitors of complex III at Qo site: azoxystrobin (II-1), coumethoxy-strobin, coumoxystrobin, dimoxystrobin (II-2), enestroburin, fenamin-strobin, fenoxystrobin/flufenoxystrobin, fluoxastrobin (II-3), kresoxim-methyl (II-4), metominostrobin, orysastrobin (II-5), picoxystrobin (II-6), pyraclostrobin (II-7), pyrametostrobin, pyraoxystrobin, trifloxystrobin (II-8), 2-[2-(2,5-dimethyl-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester and 2-(2-(3-(2,6-dichlorophenyl)-1-methyl-allylideneamino-oxymethyl)-phenyl)-2-methoxyimino-N-methyl-acetamide, pyribencarb, triclopyricarb/chlorodincarb, famoxadone, fenamidone; Inhibitors of complex III at Qi site: cyazofamid, amisulbrom, [(3S,6S,7R,8R)-8-benzyl-3-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)-amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[[3-(acetoxymethoxy)-4-methoxy-pyridine-2-carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[(3-isobutoxycarbony-loxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[[3-(1,3-benzodioxol5-ylmethoxy)-4-methoxy-pyridine-2-carbon-yl]amino]-6-methyl-4,9-dioxol,5-dioxonan-7-yl] 2-methylpropanoate; (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenyl-methyl)-1,5-dioxonan-7-yl 2-methylpropanoate; Inhibitors of complex II: benodanil, benzovindiflupyr (II-9), bixafen (II-10), boscalid (II-11), carboxin, fenfuram, fluopyram (II-12), flutolanil, fluxapyroxad (II-13), furametpyr, isofetamid, isopyrazam (II-14), mepronil, oxycarboxin, penflufen (II-15), penthiopyrad (II-16), sedaxane (II-17), tecloftalam, thifluzamide, N-(4′-trifluoromethylthiobiphenyl-2-yl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(2-(1,3,3-trimethyl-butyl)-phenyl)-1,3-dimethyl-5-fluoro-1H-pyrazole-4-carboxamide, 3-(difluorome-thyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1,5-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3,5-trimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, N-(7-fluoro-1,1,3-trime-thyl-indan-4-yl)-1,3-dimethyl-pyrazole-4-carboxamide, N-[2-(2,4-dichlorophenyl)-2-methoxy-1-methyl-ethyl]-3-(difluoromethyl)-1-methyl-pyrazole-4-carboxamide; Other respiration inhibitors: diflumetorim, (5,8-difluoroquinazolin-4-yl)-{2-[2-fluoro-4-(4-trifluorometh-ylpyridin-2-yloxy)-phenyl]-ethyl}-amine; binapacryl, dinobuton, dinocap, fluazinam (II-18); ferimzone; fentin salts such as fentin-acetate, fentin chloride or fentin hydroxide; ametoctradin (II-19); and silthiofam; B) Sterol biosynthesis inhibitors (SBI fungicides) selected from: C14 demethylase inhibitors (DMI fungicides): azaconazole, bitertanol, bromuconazole, cyproconazole (II-20), difenoconazole (II-21), diniconazole, diniconazole-M, epoxiconazole (II-22), fenbuconazole, fluquinconazole (II-23), flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole (II-24), myclobutanil, oxpoconazole, paclobutrazole, penconazole, propiconazole (II-25), prothioconazole (II-26), simeconazole, tebuconazole (II-27), tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole; imazalil, pefurazoate, prochloraz, triflumizol; fenarimol, nuarimol, pyrifenox, triforine, [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)isoxazol-4-yl]-(3-pyridyl)methanol; Delta14-reductase inhibitors: aldimorph, dodemorph, dodemorphacetate, fenpropimorph, tridemorph, fenpropidin, piperalin, spiroxamine; Inhibitors of 3-keto reductase: fenhexamid;

C) Nucleic acid synthesis inhibitors selected from: phenylamides or acyl amino acid fungicides: benalaxyl, benalaxyl-M, kiralaxyl, metalaxyl, metalaxyl-M (mefenoxam) (II-38), ofurace, oxadixyl; others nucleic acid inhibitors: hymexazole, octhilinone, oxolinic acid, bupirimate, 5-fluorocytosine, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine, 5-fluoro-2-(4-fluorophenylmethoxy)pyrimidin-4-amine;

D) Inhibitors of cell division and cytoskeleton selected from: tubulin inhibitors: benomyl, carbendazim, fuberidazole, thiabendazole, thiophanate-methyl (II-39); 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine other cell division inhibitors: diethofencarb, ethaboxam, pencycuron, fluopicolide, zoxamide, metrafenone (II-40), pyriofenone;

E) Inhibitors of amino acid and protein synthesis selected from: methionine synthesis inhibitors (anilino-pyrimidines): cyprodinil, mepanipyrim, Pyrimethanil (II-41); protein synthesis inhibitors: blasticidin-S, kasugamycin, kasugamycin hydrochloride-hydrate, mildiomycin, streptomycin, oxytetracyclin, polyoxine, validamycin A;

F) Signal transduction inhibitors selected from: MAP/histidine kinase inhibitors: fluoroimid, iprodione, procymidone, vinclozolin, fenpiclonil, fludioxonil; G protein inhibitors: quinoxyfen;

G) Lipid and membrane synthesis inhibitors selected from: Phospholipid biosynthesis inhibitors: edifenphos, iprobenfos, pyrazophos, isoprothiolane; propamocarb, propamocarb-hydrochloride; lipid peroxidation inhibitors: dicloran, quintozene, tecnazene, tolclofos-methyl, biphenyl, chloroneb, etridiazole; phospholipid biosynthesis and cell wall deposition: dimethomorph (II-42), flumorph, mandipropamid (II-43), pyrimorph, benthiavalicarb, iprovalicarb, valifenalate, N-(1-(1-(4-cyano-phenyl)ethanesulfonyl)-but-2-yl) carbamic acid-(4-fluorophenyl) ester; acid amide hydrolase inhibitors: oxathiapiprolin;

H) Inhibitors with Multi Site Action selected from:

 inorganic active substances: Bordeaux mixture, copper acetate, copper hydroxide, copper oxychloride (II-44), basic copper sulfate, sulfur; thio- and dithiocarbamates: ferbam, mancozeb (II-45), maneb, metam, metiram (II-46), propineb, thiram, zineb, ziram; organochlorine compounds: anilazine, Chlorothalonil (II-47), captafol, captan, folpet, dichlofluanid, dichlorophen, hexachlorobenzene, pentachlorophenole and its salts, phthalide, tolylfluanid, N-(4-chlo-ro-2-nitro-phenyl)-N-ethyl-4-methyl-benzenesulfonamide; guanidines and others: guanidine, dodine, dodine free base, guazatine, guazatine-acetate, iminoc-tadine, iminoctadine-triacetate, iminoctadine-tris(albesilate), dithianon, 2,6-dimethyl-1H,5H-[1,4]dithii-no[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetraone (II-48);

I) Cell wall synthesis inhibitors selected from: inhibitors of glucan synthesis: validamycin, polyoxin B; melanin synthesis inhibitors: pyroquilon, tricyclazole, carpropamid, dicyclomet, fenoxanil;

J) Plant defence inducers selected from: acibenzolar-S-methyl, probenazole, isotianil, tiadinil, prohexadione-calcium; fosetyl, fosetyl-aluminum, phosphorous acid and its salts (II-49);

K) Unknown mode of action selected from: bronopol, chinomethionat, cyflufenamid, cymoxanil, dazomet, debacarb, diclomezine, difenzoquat, difenzoquat-methylsulfate, diphenylamin, fenpyrazamine, flumetover, flusulfamide, flutianil, methasulfocarb, nitrapyrin, nitrothal-isopropyl, oxathiapiprolin, tolprocarb, 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, 2-[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-fluoro-6-(prop-2-yn-1-yl-oxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]-ethanone, 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, oxin-copper, proquinazid, tebufloquin, tecloftalam, triazoxide, 2-butoxy-6-iodo-3-propylchromen-4-one, N-(cyclo-propylmethoxyimino-(6-difluoro-methoxy-2,3-difluoro-phenyl)-methyl)-2-phenyl acetamide, N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethylphenyl)-N-ethyl-N-methyl formamidine, N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(2-methyl-5-trifluoromethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine, N′-(5-difluoromethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine, methoxyacetic acid 6-tert-butyl-8-fluoro-2,3-dimethyl-quinolin-4-yl ester, 3-[5-(4-meth-ylphenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine, 3-[5-(4-chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine (pyrisoxazole), N-(6-methoxy-pyridin-3-yl) cyclopropanecarboxylic acid amide, 5-chloro-1-(4,6-dimethoxy-pyrimidin-2-yl)-2-methyl-1H-benzoimidazole, 2-(4-chloro-phenyl)-N-[4-(3,4-dimethoxy-phe-nyl)-isoxazol-5-yl]-2-prop2-ynyloxy-acetamide, ethyl (Z)-3-amino-2-cyano-3-phenyl-prop-2-enoate, tertbutyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]-amino]oxymethyl]-2-pyridyl]carbamate, pentyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate, 2-[2-[(7,8-dif-luoro-2-methyl-3-quinolyl)oxy]-6-fluoro-phenyl]propan-2-ol, 2-[2-fluoro-6-[(8-fluoro-2-methyl-3-qui-nolyl)oxy]phenyl]propan-2-ol, 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline, 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroiso-quinolin-1-yl)quinoline;

L) Antifungal biopesticides selected from: Ampelomyces quisqualis, Aspergillus flavus, Aureobasidium pullulans, Bacillus pumilus (II-50), Bacillus subtilis (II-51), Bacillus subtilis var. amyloliquefaciens (II-52), Candida oleophila I-82, Candida saitoana, Clonostachys rosea f. catenulata, also named Gliocladium catenulatum, Coniothyrium minitans, Cryphonectria parasitica, Cryptococcus albidus, Metschnikowia fructicola, Microdochium dimerum, Phlebiopsis gigantea, Pseudozyma flocculosa, Pythium oligandrum DV74, Reynoutria sachlinensis, Talaromyces flavus V117b, Trichoderma asperellum SKT-1, T. atroviride LC52, T. harzianum T-22, T. harzianum TH 35, T. harzianum T-39; T. harzianum and T. viride, T. harzianum ICCO12 and T. viride ICC080; T. polysporum and T. harzianum; T. stromaticum, T. virens GL-21, T. viride, T. viride TV1, Ulocladium oudemansii HRU3;

M) Growth regulators selected from: abscisic acid, amidochlor, ancymidol, 6-benzylaminopurine, brassino-lide, butralin, chlormequat (chlormequat chloride), choline chloride, cyclanilide, daminozide, dikegulac, dimethipin, 2,6-dimethylpuridine, ethephon, flumetralin, flurprimidol, fluthiacet, forchlorfenuron, gibberellic acid, inabenfide, indole-3-acetic acid, maleic hydrazide, mefluidide, mepiquat (mepiquat chloride) (II-54), naphthaleneacetic acid, N-6-benzyladenine, paclobutrazol, prohexadione (prohexadione-calcium, II-55), prohydrojasmon, thidiazuron, triapenthenol, tributyl phosphorotrithioate, 2,3,5-tri-iodobenzoic acid, trinex-apac-ethyl and uniconazole;

N) Herbicides selected from: acetamides: acetochlor, alachlor, butachlor, dimethachlor, dimethenamid, flufenacet, mefenacet, me-tolachlor, metazachlor, napropamide, naproanilide, pethoxamid, pretilachlor, propachlor, thenylchlor; amino acid derivatives: bilanafos, glyphosate, glufosinate, sulfosate; aryloxyphenoxypropionates: clodinafop, cyhalofop-butyl, fenoxaprop, fluazifop, haloxyfop, metamifop, propaquizafop, quizalofop, quizalofop-P-tefuryl; Bipyridyls: diquat, paraquat; (thio)carbamates: asulam, butylate, carbetamide, desmedipham, dimepiperate, eptam (EPTC), esprocarb, molinate, orbencarb, phenmedipham, prosulfocarb, pyributicarb, thiobencarb, triallate; cyclohexanediones: butroxydim, clethodim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, tralkoxydim; dinitroanilines: benfluralin, ethalfluralin, oryzalin, pendimethalin, prodiamine, trifluralin; diphenyl ethers: acifluorfen, aclonifen, bifenox, diclofop, ethoxyfen, fomesafen, lactofen, oxyfluorfen; —hydroxybenzonitriles: bomoxynil, dichlobenil, ioxynil; imidazolinones: imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr; phenoxy acetic acids: clomeprop, 2,4-dichlorophenoxyacetic acid (2,4-D), 2,4-DB, dichlorprop, MCPA, MCPA-thioethyl, MCPB, Mecoprop; pyrazines: chloridazon, flufenpyr-ethyl, fluthiacet, norflurazon, pyridate; pyridines: aminopyralid, clopyralid, diflufenican, dithiopyr, fluridone, fluroxypyr, picloram, picolinafen, thiazopyr; sulfonyl ureas: amidosulfuron, azimsulfuron, bensulfuron, chlorimuronethyl, chlorsulfuron, cinosul-furon, cyclosulfamuron, ethoxysulfuron, flazasulfuron, flucetosulfuron, flupyrsulfuron, foramsulfuron, halosulfuron, imazosulfuron, iodosulfuron, mesosulfuron, metazosulfuron, metsulfuron-methyl, nico-sulfuron, oxasulfuron, primisulfuron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosul-furon, thifensulfuron, triasulfuron, tribenuron, trifloxysulfuron, triflusulfuron, tritosulfuron, 1-((2-chloro-6-propyl-imidazo[1,2-b]pyridazin-3-yl)sulfonyl)-3-(4,6-dimethoxy-pyrimidin-2-yl)urea; triazines: ametryn, atrazine, cyanazine, dimethametryn, ethiozin, hexazinone, metamitron, metribuzin, prometryn, simazine, terbuthylazine, terbutryn, triaziflam; ureas: chlorotoluron, daimuron, diuron, fluometuron, isoproturon, linuron, methabenzthiazuron, tebuthiuron; other acetolactate synthase inhibitors: bispyribac-sodium, cloransulammethyl, diclosulam, florasulam, flucarbazone, flumetsulam, metosulam, ortho-sulfamuron, penoxsulam, propoxycarbazone, pyribam-benz-propyl, pyribenzoxim, pyriftalid, pyriminobac-methyl, pyrimisulfan, pyrithiobac, pyroxasulfone, py-roxsulam; other herbicides: amicarbazone, aminotriazole, anilofos, beflubutamid, benazolin, bencarbazone, benfluresate, benzofenap, bentazone, benzobicyclon, bicyclopyrone, bromacil, bromobutide, butafenacil, butamifos, cafenstrole, carfentrazone, cinidon-ethyl, chlorthal, cinmethylin, clomazone, cumyluron, cyprosulfa-mide, dicamba, difenzoquat, diflufenzopyr, Drechslera monoceras, endothal, ethofumesate, etobenzanid, fenoxasulfone, fentrazamide, flumiclorac-pentyl, flumioxazin, flupoxam, flurochloridone, flurtamone, indanofan, isoxaben, isoxaflutole, lenacil, propanil, propyzamide, quinclorac, quinmerac, mesotrione, methyl arsonic acid, naptalam, oxadiargyl, oxadiazon, oxaziclomefone, pentoxazone, pinoxaden, pyraclonil, pyraflufen-ethyl, pyrasulfotole, pyrazoxyfen, pyrazolynate, quinoclamine, saflufenacil, sulcotrione, sulfentrazone, terbacil, tefuryltrione, tembotrione, thiencarbazone, topramezone, (3-[2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydro-2H-pyrimidin-1-yl)-phenoxy]-pyri-din-2-yloxy)-acetic acid ethyl ester, 6-amino-5-chloro-2-cyclopropyl-pyrimidine-4-carboxylic acid methyl ester, 6-chloro-3-(2-cyclopropyl-6-methyl-phenoxy)-pyridazin-4-ol, 4-amino-3-chloro-6-(4-chloro-phenyl)-5-fluoro-pyridine-2-carboxylic acid, 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxy-phenyl)-pyridine-2-carboxylic acid methyl ester, and 4-amino-3-chloro-6-(4-chloro-3-dimethylamino-2-fluoro-phenyl)-pyridine-2-carboxylic acid methyl ester;

O) Insecticides selected from: organo(thio)phosphates: acephate, azamethiphos, azinphos-methyl, chlorpyrifos, chlorpyrifos-methyl, chlorfenvinphos, diazinon, dichlorvos, dicrotophos, dimethoate, disulfoton, ethion, fenitrothion, fenthion, isoxathion, malathion, methamidophos, methidathion, methyl-parathion, mevinphos, monocrotophos, oxydemeton-methyl, paraoxon, parathion, phenthoate, phosalone, phosmet, phos-phamidon, phorate, phoxim, pirimiphos-methyl, profenofos, prothiofos, sulprophos, tetrachlorvinphos, terbufos, triazophos, trichlorfon; carbamates: alanycarb, aldicarb, bendiocarb, benfuracarb, carbaryl, carbofuran, carbosulfan, fenox-ycarb, furathiocarb, methiocarb, methomyl, oxamyl, pirimicarb, propoxur, thiodicarb, triazamate; pyrethroids: allethrin, bifenthrin, cyfluthrin, cyhalothrin, cyphenothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, zetacypermethrin, deltamethrin, esfenvalerate, etofenprox, fenpropathrin, fen-valerate, imiprothrin, lambda-cyhalothrin, permethrin, prallethrin, pyrethrin I and II, resmethrin, silafluofen, tau-fluvalinate, tefluthrin, tetramethrin, tralomethrin, transfluthrin, profluthrin, dimefluthrin; insect growth regulators: a) chitin synthesis inhibitors: benzoylureas: chlorfluazuron, cyramazin, dif-lubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, teflubenzuron, triflumuron; buprofezin, diofenolan, hexythiazox, etoxazole, clofentazine; b) ecdysone antagonists: halofenozide, methoxyfenozide, tebufenozide, azadirachtin; c) juvenoids: pyriproxyfen, methoprene, fenoxycarb; d) lipid biosynthesis inhibitors: spirodiclofen, spiromesifen, spirotetramat; nicotinic receptor agonists/antagonists compounds: clothianidin, dinotefuran, flupyradifurone, imidacloprid, thiamethoxam, nitenpyram, acetamiprid, thiacloprid, 1-2-chloro-thiazol-5-ylmethyl)-2-nitrimino-3,5-dimethyl-[1,3,5]triazinane; nicotinic acetylcholine receptor disruptors or allosteric modulators (IRAC Goup 5):

spinosyn (including but not limited to spinosyns A, D, B, C, E, F, G, H, J, and other spinosyn isolates from Saccharopolyspora spinosa culture), spinosad (comprising primarily spinsyns A and D), and derivatives or substituents thereof (including but not limited to tetracyclic and pentacyclic spinosyn derivatives, aziridine spinosyn derivatives, C-5,6 and/or C-13,14 substituted spinosyn derivatives); spinetoram (including but not limited to XDE-175-J, XDE-175-L or other O-ethyl substituted spinosyn derivatives); butenyl-spinosyn and derivatives or substituents thereof (such as isolates from Saccharopolyspora pogona culture); bioinsecticides including but not limited to Bacillus thuriengiensis, Burkholderia spp, Beauveria bassiana, Metarhizium anisoptiae, Paecilomyces fumosoroseus, and baculoviruses (including but not limited to granuloviruses and nucleopolyhedroviruses); GABA antagonist compounds: endosulfan, ethiprole, fipronil, vaniliprole, pyrafluprole, pyriprole, 5-amino-1-(2,6-dichloro-4-methyl-phenyl)-4-sulfinamoyl-1H-pyrazole-3-carbothioic acid amide; mitochondrial electron transport inhibitor (METI) I acaricides: fenazaquin, pyridaben, tebufenpyrad, tolfenpyrad, flufenerim; METI II and III compounds: acequinocyl, fluacyprim, hydramethylnon; Uncouplers: chlorfenapyr; oxidative phosphorylation inhibitors: cyhexatin, diafenthiuron, fenbutatin oxide, propargite; moulting disruptor compounds: cryomazine; mixed function oxidase inhibitors: piperonyl butoxide; sodium channel blockers: indoxacarb, metaflumizone; ryanodine receptor inhibitors: chlorantraniliprole, cyantraniliprole, fluben-diamide, N-[4,6-dichloro-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyra-zole-3-carboxamide; N-[4-chloro-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-6-methyl-phenyl]-2-(3-chloro-2-pyridyl)-5-trifluoromethyl)pyrazole-3-carboxamide; N-[4-chloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-6-methyl-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-car-boxamide; N-[4,6-dichloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; N-[4,6-dichloro-2-[(diethyl-lambda-4-sulfanyli-dene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(difluoromethyl)pyrazole-3-carboxamide; N-[4,6-di-bromo-2-[(di-2-propyl-lambda-4-sulfanyl-idene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluor-omethyl)pyrazole-3-carboxamide; N-[4-chloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-6-cyano-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; N-[4,6-dibromo-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; others: benclothiaz, bifenazate, cartap, flonicamid, pyridalyl, pymetrozine, sulfur, thiocyclam, cy-enopyrafen, flupyrazofos, cyflumetofen, amidoflumet, imicyafos, bistrifluron, pyrifluquinazon, 1,1′-[(3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-[[(2-cyclopropylacetyl)oxy]-methyl]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-12-hydroxy-4,6a,12b-trimethyl-11-oxo-9-(3-pyridinyl)-2H,11H-naphtho[2,1-b]pyrano[3,4-e]pyran-3,6-diyl] cyclopropaneacetic acid ester; fluensulfone, fluoroalkenyl thioethers; and

P) ribonucleic acid (RNA) and associated compounds including double-stranded RNA (dsRNA), microRNA (miRNA) and small interfering RNA (siRNA); bacteriophages.

13. The synergistic pesticidal composition according to claim 1, wherein a ratio of the concentrations of said pesticidal active ingredient and said C4-C10 saturated or unsaturated aliphatic acid or an agriculturally compatible salt thereof is between about at least one of: 1:15,000 and 15,000:1; 1:10,000 and 10,000:1, 1:5000 and 5000:1, 1:2500 and 2500:1, 1:1500 and 1500:1, 1:1000 and 1000, 1:750 and 750:1, 1:500 and 500:1, 1:400 and 400:1, 1:300 and 300:1, 1:250 and 250:1, 1:200 and 200:1, 1:150 and 150:1, 1:100 and 100:1, 1:90 and 90:1, 1:80 and 80:1, 1:70 and 70:1, 1:60 and 60:1, 1:50 and 50:1, 1:40 and 40:1, 1:30 and 30:1, 1:25 and 25:1, 1:20 and 20:1, 1:15 and 15:1, 1:10 and 10:1, 1:9 and 9:1. 1:8 and 8:1, 1:7 and 7:1, 1:6 and 6:1, 1:5 and 5:1, 1: and 4:1, 1:3 and 3:1, 1:2 and 2:1, 1:1.5 and 1.5:1, and 1.25 and 1.25:1.

14. A method of synergistically enhancing the pesticidal activity of at least one pesticidal active ingredient adapted to control at least one target pest organism comprising:

providing at least one pesticidal active ingredient active for said at least one target pest organism, wherein said pesticidal active ingredient is selected from the list comprising: benzovindiflupyr, bixafen, boscalid, cyproconazole, fenpicoxamid, fenpyrazimine, florylpicoxamid, flutriafol, fluxapyroxad, isopyrazam, isotianil, kresoxim-methyl, metrafenone, oxathiapiprolin, penflufen, penthiopyrad, picoxystrobin, prothioconazole, pydiflumetofen, revysol, sedaxane, trifloxystrobin, pyraclostrobin, azoxystrobin, chlorothalonil, cyprodinil, metalaxyl, epoxiconazole, propiconazole, difenoconazole, fludioxonil, mancozeb, tebuconazole, valifenalate, and combinations thereof;

adding a synergistically effective concentration of at least one C4-C10 saturated or unsaturated aliphatic acid, or an agriculturally acceptable salt thereof, to said pesticidal active ingredient to provide a synergistic pesticidal composition; and

applying said synergistic pesticidal composition in a pesticidally effective concentration to control said at least one target pest organism.

15.-17. (canceled)

18. The method according to claim 14, wherein a ratio of said synergistically effective concentration of said C4-C10 saturated or unsaturated aliphatic acid or an agriculturally compatible salt thereof and said pesticidal active ingredient is between about at least one of: 1:15,000 and 15,000:1; 1:10,000 and 10,000:1, 1:5000 and 5000:1, 1:2500 and 2500:1, 1:1500 and 1500:1, 1:1000 and 1000, 1:750 and 750:1, 1:500 and 500:1, 1:400 and 400:1, 1:300 and 300:1, 1:250 and 250:1, 1:200 and 200:1, 1:150 and 150:1, 1:100 and 100:1, 1:90 and 90:1, 1:80 and 80:1, 1:70 and 70:1, 1:60 and 60:1, 1:50 and 50:1, 1:40 and 40:1, 1:30 and 30:1, 1:25 and 25:1, 1:20 and 20:1, 1:15 and 15:1, 1:10 and 10:1, 1:9 and 9:1. 1:8 and 8:1, 1:7 and 7:1, 1:6 and 6:1, 1:5 and 5:1, 1: and 4:1, 1:3 and 3:1, 1:2 and 2:1, 1:1.5 and 1.5:1, and 1.25 and 1.25:1.

19. The method according to claim 14, wherein the synergistic pesticidal composition has an FIC Index value of less than 1; or preferably less than 0.75, or more preferably less than 0.5.

20. The method according to claim 14, wherein the synergistic pesticidal composition has a predicted probability of synergy of greater than 0.55.

21. A pesticidal composition comprising:

one or more pesticidal agents selected from the list comprising: benzovindiflupyr, bixafen, boscalid, cyproconazole, fenpicoxamid, fenpyrazimine, florylpicoxamid, flutriafol, fluxapyroxad, isopyrazam, isotianil, kresoxim-methyl, metrafenone, oxathiapiprolin, penflufen, penthiopyrad, picoxystrobin, prothioconazole, pydiflumetofen, revysol, sedaxane, trifloxystrobin, pyraclostrobin, azoxystrobin, chlorothalonil, cyprodinil, metalaxyl, epoxiconazole, propiconazole, difenoconazole, fludioxonil, mancozeb, tebuconazole, valifenalate, and combinations thereof; and

one or more saturated or unsaturated C4-C10 aliphatic acids or agriculturally compatible salts thereof,

wherein said one or more saturated or unsaturated C4-C10 aliphatic acids produce a synergistic effect on the pesticidal activity of the pesticidal composition in comparison to the pesticidal activity of the pesticidal agent alone and are present in a respective synergistically active concentration ratio between about 1:15000 and 15000:1.

22. (canceled)

23. The pesticidal composition according to claim 21, wherein the C4-C10 saturated or unsaturated aliphatic acid comprises a C4-C10 unsaturated aliphatic acid, and wherein the unsaturated C4-C10 aliphatic acid comprises at least one of: a trans-2, trans-3, trans-4, trans-5, trans-6, trans-7, trans-8, and trans-9, cis-2, cis-3, cis-4, cis-5, cis-6, cis-7, cis-8, and cis-9 unsaturated bond.

24. (canceled)

25. The synergistic pesticidal composition according to claim 21, wherein the synergistic pesticidal composition has an FIC Index value of less than 1; or preferably less than 0.75, or more preferably less than 0.5.

26. The synergistic pesticidal composition according to claim 21, wherein the synergistic pesticidal composition has a predicted probability of synergy of greater than 0.55.

27. The pesticidal composition according to claim 21, wherein said pesticidal agent comprises at least one pesticidal active ingredient selected from the list comprising:

A) Respiration inhibitors selected from: inhibitors of complex III at Qo site: azoxystrobin (II-1), coumethoxy-strobin, coumoxystrobin, dimoxystrobin (II-2), enestroburin, fenamin-strobin, fenoxystrobin/flufenoxystrobin, fluoxastrobin (II-3), kresoxim-methyl (II-4), metominostrobin, orysastrobin (II-5), picoxystrobin (II-6), pyraclostrobin (II-7), pyrametostrobin, pyraoxystrobin, trifloxystrobin (II-8), 2-[2-(2,5-dimethyl-phenoxymethyl)-phenyl]-3-methoxy-acrylic acid methyl ester and 2-(2-(3-(2,6-dichlorophenyl)-1-methyl-allylideneamino-oxymethyl)-phe-nyl)-2-methoxyimino-N-methyl-acetamide, pyribencarb, triclopyricarb/chlorodincarb, famoxadone, fenamidone; Inhibitors of complex III at Qi site: cyazofamid, amisulbrom, [(3S,6S,7R,8R)-8-benzyl-3-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)-amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[[3-(acetoxymethoxy)-4-methoxy-pyridine-2-carbonyl]amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[(3-isobutoxycarbony-loxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl] 2-methylpropanoate, [(3S,6S,7R,8R)-8-benzyl-3-[[3-(1,3-benzodioxol5-ylmethoxy)-4-methoxy-pyridine-2-carbon-yl]amino]-6-methyl-4,9-dioxol,5-dioxonan-7-yl] 2-methylpropanoate; (3S,6S,7R,8R)-3-[[(3-hydroxy-4-methoxy-2-pyridinyl)carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenyl-methyl)-1,5-dioxonan-7-yl 2-methylpropanoate;

Inhibitors of complex II: benodanil, benzovindiflupyr (II-9), bixafen (II-10), boscalid (II-11), carboxin, fenfuram, fluopyram (II-12), flutolanil, fluxapyroxad (II-13), furametpyr, isofetamid, isopyrazam (II-14), mepronil, oxycarboxin, penflufen (II-15), penthiopyrad (II-16), sedaxane (II-17), tecloftalam, thifluzamide, N-(4′-trifluoromethylthiobiphenyl-2-yl)-3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N-(2-(1,3,3-trimethyl-butyl)-phenyl)-1,3-dimethyl-5-fluoro-1H-pyrazole-4-carboxamide, 3-(difluorome-thyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1-methyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 3-(trifluoromethyl)-1,5-dimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, 1,3,5-trimethyl-N-(1,1,3-trimethylindan-4-yl)pyrazole-4-carboxamide, N-(7-fluoro-1,1,3-trime-thyl-indan-4-yl)-1,3-dimethyl-pyrazole-4-carboxamide, N-[2-(2,4-dichlorophenyl)-2-methoxy-1-methyl-ethyl]-3-(difluoromethyl)-1-methyl-pyrazole-4-carboxamide;

Other respiration inhibitors: diflumetorim, (5,8-difluoroquinazolin-4-yl)-{2-[2-fluoro-4-(4-trifluorometh-ylpyridin-2-yloxy)-phenyl]-ethyl}-amine; binapacryl, dinobuton, dinocap, fluazinam (II-18); ferimzone; fentin salts such as fentin-acetate, fentin chloride or fentin hydroxide; ametoctradin (II-19); and silthiofam;

B) Sterol biosynthesis inhibitors (SBI fungicides) selected from: C14 demethylase inhibitors (DMI fungicides): azaconazole, bitertanol, bromuconazole, cyproconazole (II-20), difenoconazole (II-21), diniconazole, diniconazole-M, epoxiconazole (II-22), fenbuconazole, fluquinconazole (II-23), flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole (II-24), myclobutanil, oxpoconazole, paclobutrazole, penconazole, propiconazole (II-25), prothioconazole (II-26), simeconazole, tebuconazole (II-27), tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole; imazalil, pefurazoate, prochloraz, triflumizol; fenarimol, nuarimol, pyrifenox, triforine, [3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)isoxazol-4-yl]-(3-pyridyl)methanol; Delta14-reductase inhibitors: aldimorph, dodemorph, dodemorphacetate, fenpropimorph, tridemorph, fenpropidin, piperalin, spiroxamine; Inhibitors of 3-keto reductase: fenhexamid;

C) Nucleic acid synthesis inhibitors selected from: phenylamides or acyl amino acid fungicides: benalaxyl, benalaxyl-M, kiralaxyl, metalaxyl, metalaxyl-M (mefenoxam) (II-38), ofurace, oxadixyl; others nucleic acid inhibitors: hymexazole, octhilinone, oxolinic acid, bupirimate, 5-fluorocytosine, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine, 5-fluoro-2-(4-fluorophenylmethoxy)pyrimidin-4-amine;

D) Inhibitors of cell division and cytoskeleton selected from: tubulin inhibitors: benomyl, carbendazim, fuberidazole, thiabendazole, thiophanate-methyl (II-39); 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine other cell division inhibitors: diethofencarb, ethaboxam, pencycuron, fluopicolide, zoxamide, metrafenone (II-40), pyriofenone;

E) Inhibitors of amino acid and protein synthesis selected from: methionine synthesis inhibitors (anilino-pyrimidines): cyprodinil, mepanipyrim, Pyrimethanil (II-41); protein synthesis inhibitors: blasticidin-S, kasugamycin, kasugamycin hydrochloride-hydrate, mildiomycin, streptomycin, oxytetracyclin, polyoxine, validamycin A;

F) Signal transduction inhibitors selected from: MAP/histidine kinase inhibitors: fluoroimid, iprodione, procymidone, vinclozolin, fenpiclonil, fludioxonil; G protein inhibitors: quinoxyfen;

G) Lipid and membrane synthesis inhibitors selected from: Phospholipid biosynthesis inhibitors: edifenphos, iprobenfos, pyrazophos, isoprothiolane; propamocarb, propamocarb-hydrochloride; lipid peroxidation inhibitors: dicloran, quintozene, tecnazene, tolclofos-methyl, biphenyl, chloroneb, etridiazole; phospholipid biosynthesis and cell wall deposition: dimethomorph (II-42), flumorph, mandipropamid (II-43), pyrimorph, benthiavalicarb, iprovalicarb, valifenalate, N-(1-(1-(4-cyano-phenyl)ethanesulfonyl)-but-2-yl) carbamic acid-(4-fluorophenyl) ester; acid amide hydrolase inhibitors: oxathiapiprolin;

H) Inhibitors with Multi Site Action selected from: inorganic active substances: Bordeaux mixture, copper acetate, copper hydroxide, copper oxychloride (II-44), basic copper sulfate, sulfur; thio- and dithiocarbamates: ferbam, mancozeb (II-45), maneb, metam, metiram (II-46), propineb, thiram, zineb, ziram; organochlorine compounds: anilazine, Chlorothalonil (II-47), captafol, captan, folpet, dichlofluanid, dichlorophen, hexachlorobenzene, pentachlorophenole and its salts, phthalide, tolylfluanid, N-(4-chlo-ro-2-nitro-phenyl)-N-ethyl-4-methyl-benzenesulfonamide; guanidines and others: guanidine, dodine, dodine free base, guazatine, guazatine-acetate, iminoc-tadine, iminoctadine-triacetate, iminoctadine-tris(albesilate), dithianon, 2,6-dimethyl-1H,5H-[1,4]dithii-no[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetraone (II-48);

I) Cell wall synthesis inhibitors selected from: inhibitors of glucan synthesis: validamycin, polyoxin B; melanin synthesis inhibitors: pyroquilon, tricyclazole, carpropamid, dicyclomet, fenoxanil;

J) Plant defence inducers selected from: acibenzolar-S-methyl, probenazole, isotianil, tiadinil, prohexadione-calcium; fosetyl, fosetyl-aluminum, phosphorous acid and its salts (II-49);

K) Unknown mode of action selected from: bronopol, chinomethionat, cyflufenamid, cymoxanil, dazomet, debacarb, diclomezine, difenzoquat, difenzoquat-methylsulfate, diphenylamin, fenpyrazamine, flumetover, flusulfamide, flutianil, methasulfocarb, nitrapyrin, nitrothal-isopropyl, oxathiapiprolin, tolprocarb, 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl1-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, 2-[3,5-bis-(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-{5-[2-fluoro-6-(prop-2-yn-1-yl-oxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]-ethanone, 2-[3,5-bis(difluoromethyl)-1H-pyrazol-1-yl]-1-[4-(4-15-[2-chloro-6-(prop-2-yn-1-yloxy)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}-1,3-thiazol-2-yl)piperidin-1-yl]ethanone, oxin-copper, proquinazid, tebufloquin, tecloftalam, triazoxide, 2-butoxy-6-iodo-3-propylchromen-4-one, N-(cyclo-propylmethoxyimino-(6-difluoro-methoxy-2,3-difluoro-phenyl)-methyl)-2-phenyl acetamide, N′-(4-(4-chloro-3-trifluoromethyl-phenoxy)-2,5-dimethylphenyl)-N-ethyl-N-methyl formamidine, N′-(4-(4-fluoro-3-trifluoromethyl-phenoxy)-2,5-dimethyl-phenyl)-N-ethyl-N-methyl formamidine, N′-(2-methyl-5-trifluoromethyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine, N′-(5-difluoromethyl-2-methyl-4-(3-trimethylsilanyl-propoxy)-phenyl)-N-ethyl-N-methyl formamidine, methoxyacetic acid 6-tert-butyl-8-fluoro-2,3-dimethyl-quinolin-4-yl ester, 3-[5-(4-meth-ylphenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine, 3-[5-(4-chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine (pyrisoxazole), N-(6-methoxy-pyridin-3-yl) cyclopropanecarboxylic acid amide, 5-chloro-1-(4,6-dimethoxy-pyrimidin-2-yl)-2-methyl-1H-benzoimidazole, 2-(4-chloro-phenyl)-N-[4-(3,4-dimethoxy-phe-nyl)-isoxazol-5-yl]-2-prop2-ynyloxy-acetamide, ethyl (Z)-3-amino-2-cyano-3-phenyl-prop-2-enoate, tertbutyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]-amino]oxymethyl]-2-pyridyl]carbamate, pentyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate, 2-[2-[(7,8-dif-luoro-2-methyl-3-quinolyl)oxy]-6-fluoro-phenyl]propan-2-ol, 2-[2-fluoro-6-[(8-fluoro-2-methyl-3-qui-nolyl)oxy]phenyl]propan-2-ol, 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline, 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroiso-quinolin-1-yl)quinoline;

Fenpicoxamid, florylpicoxamid;

L) Antifungal biopesticides selected from: Ampelomyces quisqualis, Aspergillus flavus, Aureobasidium pullulans, Bacillus pumilus (II-50), Bacillus subtilis (II-51), Bacillus subtilis var. amyloliquefaciens (II-52), Candida oleophila I-82, Candida saitoana, Clonostachys rosea f. catenulata, also named Gliocladium catenulatum, Coniothyrium minitans, Cryphonectria parasitica, Cryptococcus albidus, Metschnikowia fructicola, Microdochium dimerum, Phlebiopsis gigantea, Pseudozyma flocculosa, Pythium oligandrum DV74, Reynoutria sachlinensis, Talaromyces flavus V117b, Trichoderma asperellum SKT-1, T. atroviride LC52, T. harzianum T-22, T. harzianum TH 35, T. harzianum T-39; T. harzianum and T. viride, T. harzianum ICCO12 and T. viride ICC080; T. polysporum and T. harzianum; T. stromaticum, T. virens GL-21, T. viride, T. viride TV1, Ulocladium oudemansii HRU3;

M) Growth regulators selected from: abscisic acid, amidochlor, ancymidol, 6-benzylaminopurine, brassino-lide, butralin, chlormequat (chlormequat chloride), choline chloride, cyclanilide, daminozide, dikegulac, dimethipin, 2,6-dimethylpuridine, ethephon, flumetralin, flurprimidol, fluthiacet, forchlorfenuron, gibberellic acid, inabenfide, indole-3-acetic acid, maleic hydrazide, mefluidide, mepiquat (mepiquat chloride) (II-54), naphthaleneacetic acid, N-6-benzyladenine, paclobutrazol, prohexadione (prohexadione-calcium, II-55), prohydrojasmon, thidiazuron, triapenthenol, tributyl phosphorotrithioate, 2,3,5-tri-iodobenzoic acid, trinex-apac-ethyl and uniconazole;

N) Herbicides selected from: acetamides: acetochlor, alachlor, butachlor, dimethachlor, dimethenamid, flufenacet, mefenacet, me-tolachlor, metazachlor, napropamide, naproanilide, pethoxamid, pretilachlor, propachlor, thenylchlor; amino acid derivatives: bilanafos, glyphosate, glufosinate, sulfosate; aryloxyphenoxypropionates: clodinafop, cyhalofop-butyl, fenoxaprop, fluazifop, haloxyfop, metamifop, propaquizafop, quizalofop, quizalofop-P-tefuryl; Bipyridyls: diquat, paraquat; (thio)carbamates: asulam, butylate, carbetamide, desmedipham, dimepiperate, eptam (EPTC), esprocarb, molinate, orbencarb, phenmedipham, prosulfocarb, pyributicarb, thiobencarb, triallate; cyclohexanediones: butroxydim, clethodim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, tralkoxydim; dinitroanilines: benfluralin, ethalfluralin, oryzalin, pendimethalin, prodiamine, trifluralin; diphenyl ethers: acifluorfen, aclonifen, bifenox, diclofop, ethoxyfen, fomesafen, lactofen, oxyfluorfen; —hydroxybenzonitriles: bomoxynil, dichlobenil, ioxynil; imidazolinones: imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr; phenoxy acetic acids: clomeprop, 2,4-dichlorophenoxyacetic acid (2,4-D), 2,4-DB, dichlorprop, MCPA, MCPA-thioethyl, MCPB, Mecoprop; pyrazines: chloridazon, flufenpyr-ethyl, fluthiacet, norflurazon, pyridate; pyridines: aminopyralid, clopyralid, diflufenican, dithiopyr, fluridone, fluroxypyr, picloram, picolinafen, thiazopyr; sulfonyl ureas: amidosulfuron, azimsulfuron, bensulfuron, chlorimuronethyl, chlorsulfuron, cinosul-furon, cyclosulfamuron, ethoxysulfuron, flazasulfuron, flucetosulfuron, flupyrsulfuron, foramsulfuron, halosulfuron, imazosulfuron, iodosulfuron, mesosulfuron, metazosulfuron, metsulfuron-methyl, nico-sulfuron, oxasulfuron, primisulfuron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosul-furon, thifensulfuron, triasulfuron, tribenuron, trifloxysulfuron, triflusulfuron, tritosulfuron, 1-((2-chloro-6-propyl-imidazo[1,2-b]pyridazin-3-yl)sulfonyl)-3-(4,6-dimethoxy-pyrimidin-2-yl)urea; triazines: ametryn, atrazine, cyanazine, dimethametryn, ethiozin, hexazinone, metamitron, metribuzin, prometryn, simazine, terbuthylazine, terbutryn, triaziflam; ureas: chlorotoluron, daimuron, diuron, fluometuron, isoproturon, linuron, methabenzthiazuron, tebuthiuron; other acetolactate synthase inhibitors: bispyribac-sodium, cloransulammethyl, diclosulam, florasulam, flucarbazone, flumetsulam, metosulam, ortho-sulfamuron, penoxsulam, propoxycarbazone, pyribam-benz-propyl, pyribenzoxim, pyriftalid, pyriminobac-methyl, pyrimisulfan, pyrithiobac, pyroxasulfone, py-roxsulam; other herbicides: amicarbazone, aminotriazole, anilofos, beflubutamid, benazolin, bencarbazone, benfluresate, benzofenap, bentazone, benzobicyclon, bicyclopyrone, bromacil, bromobutide, butafenacil, butamifos, cafenstrole, carfentrazone, cinidon-ethyl, chlorthal, cinmethylin, clomazone, cumyluron, cyprosulfa-mide, dicamba, difenzoquat, diflufenzopyr, Drechslera monoceras, endothal, ethofumesate, etobenzanid, fenoxasulfone, fentrazamide, flumiclorac-pentyl, flumioxazin, flupoxam, flurochloridone, flurtamone, indanofan, isoxaben, isoxaflutole, lenacil, propanil, propyzamide, quinclorac, quinmerac, mesotrione, methyl arsonic acid, naptalam, oxadiargyl, oxadiazon, oxaziclomefone, pentoxazone, pinoxaden, pyraclonil, pyraflufen-ethyl, pyrasulfotole, pyrazoxyfen, pyrazolynate, quinoclamine, saflufenacil, sulcotrione, sulfentrazone, terbacil, tefuryltrione, tembotrione, thiencarbazone, topramezone, (3-[2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydro-2H-pyrimidin-1-yl)-phenoxy]-pyri-din-2-yloxy)-acetic acid ethyl ester, 6-amino-5-chloro-2-cyclopropyl-pyrimidine-4-carboxylic acid methyl ester, 6-chloro-3-(2-cyclopropyl-6-methyl-phenoxy)-pyridazin-4-ol, 4-amino-3-chloro-6-(4-chloro-phenyl)-5-fluoro-pyridine-2-carboxylic acid, 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxy-phenyl)-pyridine-2-carboxylic acid methyl ester, and 4-amino-3-chloro-6-(4-chloro-3-dimethylamino-2-fluoro-phenyl)-pyridine-2-carboxylic acid methyl ester;

O) Insecticides selected from: organo(thio)phosphates: acephate, azamethiphos, azinphos-methyl, chlorpyrifos, chlorpyrifos-methyl, chlorfenvinphos, diazinon, dichlorvos, dicrotophos, dimethoate, disulfoton, ethion, fenitrothion, fenthion, isoxathion, malathion, methamidophos, methidathion, methyl-parathion, mevinphos, monocrotophos, oxydemeton-methyl, paraoxon, parathion, phenthoate, phosalone, phosmet, phos-phamidon, phorate, phoxim, pirimiphos-methyl, profenofos, prothiofos, sulprophos, tetrachlorvinphos, terbufos, triazophos, trichlorfon; carbamates: alanycarb, aldicarb, bendiocarb, benfuracarb, carbaryl, carbofuran, carbosulfan, fenox-ycarb, furathiocarb, methiocarb, methomyl, oxamyl, pirimicarb, propoxur, thiodicarb, triazamate; pyrethroids: allethrin, bifenthrin, cyfluthrin, cyhalothrin, cyphenothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, zetacypermethrin, deltamethrin, esfenvalerate, etofenprox, fenpropathrin, fen-valerate, imiprothrin, lambda-cyhalothrin, permethrin, prallethrin, pyrethrin I and II, resmethrin, silafluofen, tau-fluvalinate, tefluthrin, tetramethrin, tralomethrin, transfluthrin, profluthrin, dimefluthrin; insect growth regulators: a) chitin synthesis inhibitors: benzoylureas: chlorfluazuron, cyramazin, dif-lubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, teflubenzuron, triflumuron; buprofezin, diofenolan, hexythiazox, etoxazole, clofentazine; b) ecdysone antagonists: halofenozide, methoxyfenozide, tebufenozide, azadirachtin; c) juvenoids: pyriproxyfen, methoprene, fenoxycarb; d) lipid biosynthesis inhibitors: spirodiclofen, spiromesifen, spirotetramat; nicotinic receptor agonists/antagonists compounds: clothianidin, dinotefuran, flupyradifurone, imidacloprid, thiamethoxam, nitenpyram, acetamiprid, thiacloprid, 1-2-chloro-thiazol-5-ylmethyl)-2-nitrimino-3,5-dimethyl-[1,3,5]triazinane; nicotinic acetylcholine receptor disruptors or allosteric modulators (IRAC Goup 5): spinosyn (including but not limited to spinosyns A, D, B, C, E, F, G, H, J, and other spinosyn isolates from Saccharopolyspora spinosa culture), spinosad (comprising primarily spinsyns A and D), and derivatives or substituents thereof (including but not limited to tetracyclic and pentacyclic spinosyn derivatives, aziridine spinosyn derivatives, C-5,6 and/or C-13,14 substituted spinosyn derivatives); spinetoram (including but not limited to XDE-175-J, XDE-175-L or other O-ethyl substituted spinosyn derivatives); butenyl-spinosyn and derivatives or substituents thereof (such as isolates from Saccharopolyspora pogona culture); bioinsecticides including but not limited to Bacillus thuriengiensis, Burkholderia spp, Beauveria bassiana, Metarhizium anisoptiae, Paecilomyces fumosoroseus, and baculoviruses (including but not limited to granuloviruses and nucleopolyhedroviruses); GABA antagonist compounds: endosulfan, ethiprole, fipronil, vaniliprole, pyrafluprole, pyriprole, 5-amino-1-(2,6-dichloro-4-methyl-phenyl)-4-sulfinamoyl-1H-pyrazole-3-carbothioic acid amide; mitochondrial electron transport inhibitor (METI) I acaricides: fenazaquin, pyridaben, tebufenpyrad, tolfenpyrad, flufenerim; METI II and III compounds: acequinocyl, fluacyprim, hydramethylnon; Uncouplers: chlorfenapyr; oxidative phosphorylation inhibitors: cyhexatin, diafenthiuron, fenbutatin oxide, propargite; moulting disruptor compounds: cryomazine; mixed function oxidase inhibitors: piperonyl butoxide; sodium channel blockers: indoxacarb, metaflumizone; ryanodine receptor inhibitors: chlorantraniliprole, cyantraniliprole, fluben-diamide, N-[4,6-dichloro-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyra-zole-3-carboxamide; N-[4-chloro-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-6-methyl-phenyl]-2-(3-chloro-2-pyridyl)-5-trifluoromethyl)pyrazole-3-carboxamide; N-[4-chloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-6-methyl-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-car-boxamide; N-[4,6-dichloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; N-[4,6-dichloro-2-[(diethyl-lambda-4-sulfanyli-dene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(difluoromethyl)pyrazole-3-carboxamide; N-[4,6-di-bromo-2-[(di-2-propyl-lambda-4-sulfanyl-idene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluor-omethyl)pyrazole-3-carboxamide; N-[4-chloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-6-cyano-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; N-[4,6-dibromo-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; others: benclothiaz, bifenazate, cartap, flonicamid, pyridalyl, pymetrozine, sulfur, thiocyclam, cyenopyrafen, flupyrazofos, cyflumetofen, amidoflumet, imicyafos, bistrifluron, pyrifluquinazon, 1,1′-[(3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-[[(2-cyclopropylacetyl)oxy]-methyl]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-12-hydroxy-4,6a,12b-trimethyl-11-oxo-9-(3-pyridinyl)-2H,11H-naphtho[2,1-b]pyrano[3,4-e]pyran-3,6-diyl] cyclopropaneacetic acid ester; fluensulfone, fluoroalkenyl thioethers; and

P) ribonucleic acid (RNA) and associated compounds including double-stranded RNA (dsRNA), microRNA (miRNA) and small interfering RNA (siRNA); bacteriophages.

28. The pesticidal composition according to claim 21, wherein said pesticidal agent comprises at least one of: a fungicide, nematicide, insecticide, acaricide, herbicide, molluscicide, and a bactericide.

29.-33. (canceled)

34. The synergistic pesticidal composition according to claim 1, wherein said C4-C10 saturated or unsaturated aliphatic acid comprises at least one substituent selected from the list comprising: hydroxy-alkyl- and amino-substituents.

35. The synergistic pesticidal composition according to claim 1, wherein the pesticidal active ingredient is selected from at least one of: a fungicide having a fungicidal mode of action inhibiting a cellular membrane cytochrome bc1 complex, and a fungicide having a fungicidal mode of action inhibiting a cellular membrane cytochrome p450 complex.

36. The synergistic pesticidal composition according to claim 1, wherein the pesticidal active ingredient comprises at least one of a strobilurin fungicide, and a triazole fungicide.